AMINES FOR USE AS SIGMA RECEPTOR MODULATORS

Abstract
The present invention discloses a number of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.
Description
BACKGROUND

There is a continuing need for new opioid receptors modulators for the management of pain with reduced or fewer side effects. There is also a continuing need for new opioid receptors modulators for the treatment migraine, depression, cognitive disorders, Parkinson's disease, locomotor disfunction, pruritus, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, bladder dysfunctions, overactive bladder, urinary incontinence, neurogenic bladder, interstitial cystitis, drug addiction, alcohol addiction, drug overdose, premature ejaculation, cough, lung edema, cardiac disorders, cardioprotection, and respiratory depression, and as immunomodulatory and anti-tumor agents. A number of such opioid receptor modulators are disclosed in U.S. Pat. No. 10,676,456 (incorporated by reference). Some additional new compounds are shown below.


SUMMARY

The present invention provides polycyclic amines, prodrugs and pharmaceutically acceptable salts thereof (“compounds of the invention”), which are useful in the treatment of diseases through the modulation of opioid receptors; similar to the compounds and their uses disclosed in U.S. Pat. No. 10,676,456. The process of making the compounds listed below are disclosed in or similar to processes of making compounds disclosed in U.S. Pat. No. 10,676,456.


The compounds of the invention are useful for preventing or treating a disease or condition selected from the group consisting of cardioprotection, cardiac disorders, analgesia, functional pain, inflammatory pain, peripherally mediated and neuropathic pain, non-somatic pain, arthritis, mental illness, cognitive disorders, depression, Parkinson's disease, locomotor disfunction, urogenital tract disorders, bladder dysfunction, overactive bladder, urinary incontinence, neurogenic bladder, psoriasis, pruritus, emesis, acne, skin lesions, non-ulcerogenic dyspepisa, gastro-intestinal disorders, functional bowel disease, diarrhea, inflammatory bowel disease, irritable bowel syndrome, interstitial cystitis, sexual dysfunctions, drug addiction, alcohol addiction, drug overdose, premature ejaculation, asthma, cough, lung edema, disorders of respiratory function, respiratory depression, functional distension, and disorders of motility or secretion. These compounds are also useful for immunomodulation, inhibiting or preventing organ or skin graft rejection, or treating tumors or cancer. All such treatment involves administering, to a patient, an effective amount of one or more of the compounds of the invention.


The present invention also includes a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more of the compounds of the invention.


These and other aspects and embodiments of the invention will be apparent from the detailed description that follows.







DETAILED DESCRIPTION

Certain compounds of the invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.


The compounds of the invention, or their pharmaceutically acceptable salts, may have asymmetric carbon atoms or double bonds in their structure. The compounds of the invention and their pharmaceutical acceptable salts may therefore exit as single stereoisomers, racemates, and as mixtures of enantiomers, diastereomers and geometric isomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of the invention. Absolute configuration of certain carbon atoms within the compounds, if known, are indicated by the appropriate absolute descriptors R or S.


The compounds of the invention may be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedure. The racemic compounds of the invention may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of the invention involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.


The compounds of the invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (.sup.3H), iodine-125 (.sup. 1251) or carbon-14 (.sup.14C). All isotopic variations of the compounds of the invention, whether radioactive or not, are encompassed within the scope of the present invention.


“Therapeutic” as used herein, includes prevention, treatment and/or prophylaxis for humans as well as other animals.


“Pharmaceutically or therapeutically effective dose or amount” refers to a dosage level sufficient to induce a desired biological result. That result may be the alleviation of the signs, symptoms or causes of a disease or any other alteration of a biological system that is desired. The precise dosage will vary according to a variety of factors, including but not limited to the age and size of the subject, the disease and the treatment being effected.


A “host” or “patient” or “subject” is a living mammal, human or animal, for whom therapy is desired. The “host,” “patient” or “subject” generally refers to the recipient of the therapy to be practiced according to the method of the invention. It should be noted that the invention described herein may be used for veterinary as well as human applications and that the term “host” should not be construed in a limiting manner. In the case of veterinary applications, the dosage ranges can be determined as described below, taking into account the body weight of the animal.


As used herein, the term “pharmaceutically acceptable” means approved by a regulatory agency of a federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals and, more particularly, in humans. The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered and includes, but is not limited to such sterile liquids as water and oils.


The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydroiodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science 66:1-19 (1977)). Certain specific compounds of the invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.


Other examples of pharmaceutically acceptable salts of the invention include salts derived from an appropriate base, such as an alkali metal (for example, sodium, potassium), an alkaline earth metal (for example, calcium, magnesium), ammonium and NR′4 (wherein R′ is C1-C4 alkyl). Pharmaceutically acceptable salts of the invention having an amino group include salts of: organic carboxylic acids such as acetic, lactic, tartaric, malic, lactobionic, fumaric, and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, isethionic, benzenesulfonic and p-toluenesulfonic acids; and inorganic acids such as hydrochloric, hydrobromic, sulfuric, phosphoric and sulfamic acids. Pharmaceutically acceptable salts of the invention having a hydroxyl group consist of the anion of such compounds in combination with a suitable cation such as Na+, NH4+, or NR′4+, (wherein R′ is for example a C1-C4 group).


The neutral forms of the compounds of the invention are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents.


In addition to salt forms, the invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the invention.


Additionally, prodrugs can be converted to the compounds of the invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound of the invention. Certain compounds of the invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the invention. Certain compounds of the invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the invention and are intended to be within the scope of the invention.


A “pharmaceutical composition” is a formulation comprising the disclosed compounds in a form suitable for administration to a subject. A pharmaceutical composition of the invention is preferably formulated to be compatible with its intended route of administration. Examples of routes of administration include, but are not limited to, oral and parenteral, e.g., intravenous, intradermal, subcutaneous, inhalation, topical, transdermal, transmucosal, and rectal administration.


The compounds of the invention can combine with an exogenous receptor or be used as complexing compounds, and may be used for binding with an opioid receptor. Further, the compounds may be used as a conjugate in an agonist/antagonist pair that is employed for transductional assay of neurotransmitter function in appertaining cellular or differentiated tissue systems, as well as for receptor assay, differential binding, and specificity applications for cellular, histological, and corporeal monitoring and assessment purposes.


The compounds of the invention can be administered for therapeutic intervention in a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier. The invention contemplates the use of any means and/or of modality of administration of the compositions of the invention.


The compounds of the invention include their physiologically functional derivatives. “Physiologically functional derivative” includes a pharmaceutically acceptable salt, ether, ester or salt of an ether or ester of the compounds of the invention or any other compound which, upon administration to the recipient, is capable of providing (directly or indirectly) a compound of the invention or an active metabolite or residue thereof. Phenolic C1-C6 alkyl ethers are a sub-class of physiologically functional derivatives of the compounds of the invention.


The compounds of the invention when used in pharmaceutical or diagnostic applications preferably are prepared in a racemic mixture or an essentially pure enantiomer form, with an enantiopurity of at least 90% enantiomeric excess (EE), preferably at least 95% EE, more preferably at least 98% EE, and most preferably at least 99% EE. Enantiomeric excess values provide a quantitative measure of the excess of the percentage amount of a major isomer over the percentage amount of a minor isomer which is present therewith, and may be readily determined by suitable methods well-known and established in the art, as for example chiral high pressure liquid chromatography (HPLC), chiral gas chromatography (GC), nuclear magnetic resonance (NMR) using chiral shift reagents, etc.


Subjects to be treated by administration of the compounds of the invention are preferably human subjects, but also include non-human mammals and other animals (e.g., bird, dog, cat, cow, horse).


Depending on the specific condition to be treated, subjects may be administered compounds of the invention at any suitable therapeutically effective and safe dosage, as may readily be determined within the skill of the art, and without undue experimentation, with extrapolation from the animal dosages set forth herein in the examples. In in vitro tests for agonist/antagonist activity, such as receptor binding affinity tests, and inhibition of electrically stimulated muscle twitch tests, compounds of the invention exhibit potency.


In general, while the effective dosage of compounds of the invention for therapeutic use may be widely varied in the broad practice of the invention, depending on the specific application, condition, or disease state involved, as readily determinable within the skill of the art, suitable therapeutic doses of the compounds of the invention, for each of the appertaining compositions described herein, and for achievement of therapeutic benefit in treatment of each of the conditions described herein, will be in the range of 10 micrograms (μg) to 100 milligrams (mg) per kilogram body weight of the recipient per day, preferably in the range of 50 μg to 75 mg per kilogram body weight per day, and most preferably in the range of 100 μg to 50 mg per kilogram body weight per day. The desired dose is preferably presented as one, two, three, four, five, six, or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing from 10 μg to 1000 mg, preferably from 50 μg to 500 mg, more preferably from 50 μg to 250 mg, and most preferably from 50 μg to 10 mg of active ingredient per unit dosage form. Alternatively, if the condition of the recipient so requires, the doses may be administered as a continuous infusion.


The mode of administration and dosage forms will affect the therapeutic amounts of the compounds which are desirable and efficacious for the given treatment application.


For example, orally administered dosages typically are at least twice, e.g., 2-10 times, the dosage levels used in parenteral administration methods, for the same active ingredient. In oral administration, dosage levels for delta receptor binding compounds of the invention may be on the order of 5-200 mg/70 kg body weight/day. In tablet dosage forms, typical active agent dose levels are on the order of 10-100 mg per tablet.


The compounds of the invention may be administered per se as well as in the form of pharmaceutically acceptable esters, salts, and ethers, as well as other physiologically functional derivatives of such compounds.


The present invention also contemplates pharmaceutical compositions, both for veterinary and for human medical use, which comprise as the active agent one or more compound(s) of the invention.


In such pharmaceutical compositions, the active agent preferably is utilized together with one or more pharmaceutically acceptable carrier(s) therefor and optionally any other therapeutic ingredients. The carrier(s) preferably are compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof. The active agent is preferably in a pharmaceutically acceptable amount effective to achieve the desired pharmacological effect.


The formulations include those suitable for parenteral as well as non-parenteral administration, and specific administration modalities include oral, rectal, topical, sub-lingual, mucosal, transdermal, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdermal, spinal, intrathecal, intra-articular, intra-arterial, sub-arachnoid, bronchial, lymphatic, and intra-uterine administration. Formulations suitable for oral administration are preferred.


When the active agent is utilized in a formulation comprising a liquid solution, the formulation advantageously may be administered parenterally. When the active agent is employed in a liquid suspension formulation or as a powder in a biocompatible carrier formulation, the formulation may be advantageously administered orally, rectally, or bronchially.


When the active agent is utilized directly in the form of a powdered solid, the active agent may be advantageously administered orally. Alternatively, it may be administered bronchially, via nebulization of the powder in a carrier gas, to form a gaseous dispersion of the powder which is inspired by the patient from a breathing circuit comprising a suitable nebulizer device.


In some applications, it may be advantageous to utilize the active agent in a “vectorized” form, such as by encapsulation of the active agent in a liposome or other encapsulant medium, or by fixation of the active agent, e.g., by covalent bonding, chelation, or associative coordination, on a suitable biomolecule, such as those selected from proteins, lipoproteins, glycoproteins, and polysaccharides.


The formulations comprising the compounds of the invention may conveniently be presented in unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing the compound(s) into association with a carrier that constitutes one or more accessory ingredients. Typically, the formulations are prepared by uniformly and intimately bringing the active compound(s) into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into dosage forms of the desired formulation.


Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active ingredient as a powder or granules; or a suspension in an aqueous liquor or a non-aqueous liquid, such as a syrup, an elixir, an emulsion, or a draught.


A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, with the active compound being in a free-flowing form such as a powder or granules which optionally is mixed with a binder, disintegrant, lubricant, inert compound, surface active agent, or discharging agent. Molded tablets comprised of a mixture of the powdered active compound with a suitable carrier may be made by molding in a suitable machine.


A syrup may be made by adding the active compound to a concentrated aqueous solution of a sugar, for example sucrose, to which may also be added any accessory ingredient(s). Such accessory ingredient(s) may include flavorings, suitable preservative, agents to retard crystallization of the sugar, and agents to increase the solubility of any other ingredient, such as a polyhydroxy alcohol, for example glycerol or sorbitol.


Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound, which preferably is isotonic with the blood of the recipient (e.g., physiological saline solution). Such formulations may include suspending agents and thickening agents and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. The formulations may be presented in unit-dose or multi-dose form.


Nasal spray formulations comprise purified aqueous solutions of the active compounds with preservative agents and isotonic agents. Such formulations are preferably adjusted to a pH and isotonic state compatible with the nasal mucous membranes.


Formulations for rectal administration may be presented as a suppository with a suitable carrier such as cocoa butter, hydrogenated fats, or hydrogenated fatty carboxylic acids.


Ophthalmic formulations are prepared by a similar method to the nasal spray, except that the pH and isotonic factors are preferably adjusted to match that of the eye.


Topical formulations comprise the active compound dissolved or suspended in one or more media, such as mineral oil, petroleum, polyhydroxy alcohols, or other bases used for topical pharmaceutical formulations.


Transdermal formulations may be prepared by incorporating the active agent in a thixotropic or gelatinous carrier such as a cellulosic medium, e.g., methyl cellulose or hydroxyethyl cellulose, with the resulting formulation then being packed in a transdermal device adapted to be secured in dermal contact with the skin of a wearer.


In addition to the aforementioned ingredients, formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavoring agents, binders, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants), and the like.


The disease state or physiological condition involved in such therapeutic intervention may be of any type or kind noted above, e.g., centrally mediated disorders; pain, depression, drug addiction, and drug dependence, alcohol addiction; and peripherally mediated neuropathic pain, cough, lung edema, gastro-intestinal disorders, arthritis, psoriasis, asthma, inflammatory bowel disease, disorders of respiratory function, functional bowel disease, irritable bowel syndrome, diarrhea, functional distension, pain (e.g., functional pain, trauma pain, etc.), non-ulcerogenic dyspepsia, urogenital tract disorders, premature ejaculation, overactive bladder, urinary incontinence, organ transplant rejection, skin graft rejection, cardiac disorders, cardioprotection, emesis, acne and skin lesions.


The compounds of the present invention may be readily synthesized within the skill of the art and in view of the illustrative synthesis examples hereinafter set forth.


The invention is further illustrated by the following non-limiting preparation schemes and other examples.


Preparation of Opioid Receptor Modulators

The following exemplary schemes illustrate methods of preparing the compounds of the invention, wherein the compounds of the invention have a structure according to Formula I, and include pharmaceutically acceptable salts and other derivatives of this structure:




embedded image




    • wherein:

    • A includes substituted or unsubstituted: alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and arylalkyl;

    • Y includes substituted or unsubstituted: alkyl, heteroalkyl, cycloalkyl, and heterocycloalkyl;

    • Q includes: substituted or unsubstituted: aryl, heteroaryl, and null;

    • W includes substituted or unsubstituted, saturated or unsaturated: (i) 4- to 8-membered heterocyclic rings including an N-substituent as an atom of the ring; and (ii) bicyclic or heterobicyclic fused rings wherein each ring has 4- to 10-members, and wherein at least one of the rings includes an N-substituent as an atom of the ring;

    • G includes substituted or unsubstituted alkyl or an N atom;

    • Z includes substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and null;

    • If Z is null then T is null, but if Z is not null, T is selected from: (i) the moieties H, OH, NH2, NO2, —SO2NH2, halogen, (ii) substituted or unsubstituted: alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;

    • n is an integer from 1-4 when G is alkyl and is 1 when G is an N atom;

    • R1 and R3 are members independently selected from H and substituted or unsubstituted: alkyl, heteroalkyl, 3- to 7-membered cycloalkyl, 3- to 7-membered heterocycloalkyl, aryl, and heteroaryl;

    • m is an integer from 0-8 and can be same or different for each of R2, R4, R5 and R6, and wherein R2, R4, R5 and R6 are each independently selected from H and substituted or unsubstituted: alkyl, heteroalkyl, 3- to 7-membered cycloalkyl, 3- to 7-membered heterocycloalkyl, and where m is greater than 1 for any of R2, R4, R5 and R6, each member in such a multi-member R2, R4, R5 and R6 chain can be the same or different; and further provided that the total number of R2, R4, R5 and R6 having an m value greater than 0 is always less than or equal to the number of W ring positions available for covalent bonding; and

    • R1 and R3, or R1 or R3 and Z, or R2 and A, or R2 and Y together with groups to which they may be joined, optionally form a substituted or unsubstituted 3- to 7-membered ring.







text missing or illegible when filed


text missing or illegible when filed




    • wherein for Scheme I above, X is selected from: Cl, Br, I, p-toluenesulfonyl (Tos), methanesulfonyl (Ms) and trifluoromethanesulfonyl (Tf).





In Scheme I, a substituted cyclic ester 1-1 is deprotonated in the presence of a strong base, such as LDA, LHMDS, or the like, followed by alkylation to produce 1-2a. Reduction of 1-2a followed by alkylation gives the ether 1-4. Deprotection of the Boc group of 1-4 is carried out in the presence of an acid, such as TFA, HCl or the like. Reductive amination of 1-5 with a suitable aldehyde or ketone 1-5a or alkylation of 1-5 with 1-5b under basic conditions gives 1-6. The compounds with different moieties from R1 are exemplified by the synthesis of intermediates such as 1-2b, 1-2c, or 1-2d. Reaction of 1-1 with a suitable ketone or aldehyde 1-7 gives the intermediate 1-2b. Activation of the hydroxyl group of 1-2b using MsCl followed by the elimination in the presence of bases, such as DBU or the like, produces the unsaturated intermediates 1-2c. Hydrogenation of 1-2c gives the intermediate 1-2d.




embedded image


Oxidation of 1-3 to 2-1 is carried out by Swern oxidation or other oxidants, such as Dess-Martin Periodiane or the like. Grignard reaction of aldehyde 2-1 with an unsaturated or a saturated Grignard reagent, followed by alkylation with an unsaturated or a saturated alkylating reagent under basic condition gives 2-3. Ring-closing metathesis (RCM) of 2-3 with a catalyst, such as Grubbs ruthenium-carbene complexes or the like, yields an unsaturated oxygen-containing heterocyclic 2-4 or a saturated oxygen-containing heterocyclic 2-4 after hydrogenation. Alternatively, the synthesis of 2-4 is achieved by a Grignard reaction of 2-1 with 2-1a or 2-1b, followed by either deprotection of the intermediate 2-7 or hydroboration of double bond of the intermediate 2-9 to give the corresponding diol 2-8. The diol 2-8 is converted to 2-4 by intramolecular cyclization under Mitsunobu reaction condition or displacement of the corresponding mesylates, tosylates, or the like.


Finally, the synthesis of 2-6 from 2-4 is achieved using the same methodology as the conversion of 1-4 to 1-6 in Scheme 1.


Scheme 3

Compounds where “A” of Formula I is a heteroaryl moiety are synthesized as illustrated in Scheme 3 and exemplified by the synthesis of 3-8. text missing or illegible when filed


The cyano intermediate 3-3 and the ester intermediate 3-5 are prepared from substituted 3-2 by cyanidation and 3-4 by alkylation as described in Scheme 1. The cyano group of 3-3 and the ester group of 3-5 are converted to heterocyclic rings such as imidazole, thiazole, thiadiazole, oxadiazole 3-6 (3-6a, 3-6b, 3-6c and 3-6d), etc. through the corresponding intermediates such as amide, thioamide, hydrazide, thiohydrazide or N-hydroxy-imidamide using the common methods exemplified in the scheme 3. The conversion of 3-6 to 3-8 is achieved using the methodology illustrated in Scheme 1.




embedded image


A suitable substituted cyclic amide 4-3 is prepared from the corresponding ester 4-1 by hydrolysis using bases, such as NaOH, LiOH, KOH, or the like, followed by coupling with an amine in the presence of coupling reagents, such as EDCI/HOBt, DCC, HATU, or the like. Reduction of 4-3 using BH3 or LiAlH4, followed by deprotection of Boc group of 4-4 and alkylation of 4-5 as described in Scheme 1 yields compound 4-6.




embedded image


Reduction of CN group to aldehyde 5-1, followed by Wittig reaction with a quaternary phosphonium salt such as 5-1a produces compound 5-2. Hydrogenation of the double bond of 5-2 followed by deprotection or deprotection of 5-2 followed by the alkylation gives either an unsaturated or a saturated compound 5-8. The quaternary phosphonium salt 5-1a is prepared from a suitable bromide 5-9. Conversion of a suitable bromide 5-9 to the corresponding aldehyde 5-10, followed by reduction of the aldehyde with a suitable reducing agent, such as NaBH4 or the like, gives alcohol 5-11. Halogenation of alcohol 5-11, followed by the treatment with PPh3 gives a quaternary phosphonium salt 5-1a.




embedded image


Alcohol 2-2 is oxidized with oxidants such as Dess-Martin Periodiane, PCC, or the like to form ketone 6-1. Deprotection of the Boc group of 6-1, followed by alkylation generates 6-3.




embedded image


The starting 7-1 is a group of intermediates which are prepared according to the schemes 1 to 6. The aryl group of 7-1 is a substituted or an unsubstituted aryl group, such as benzene, thiazolyl, thiophenyl, furanyl, imidazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl. The R4 is a functional group such as Br, I, CN, COOH, COOEt, boric acid. The conversion of R4 to R6 is achieved via Suzuki coupling of boric acid with Br or I, or the cyclization of hydrazide of ester with acid or the cyclization of N-hydroxy-imidamide with an acyl chloride.




embedded image


embedded image


In scheme 8, ester 8-2, prepared according to scheme 1, is hydrolyzed to acid 8-3 using inorganic bases, such as LiOH, NaOH, KOH, or the like. Acid 8-3 is activated to its corresponding acid chloride or mixed anhydride, followed by reaction with lithiated chiral auxiliary salt provides a mixture of diastereomers 8-4 and 8-5. The separation of diastereomeric mixture provides the single enantiomers 8-4 and 8-5.


The enantiomerically pure intermediates such as 8-4 and 8-5 are further transformed into a variety of the key intermediates, such as 8-8 and 8-10, in enantiomerically pure form, using the methodologies illustrated in the schemes 1-7. Some examples are illustrated in Scheme 9 and Scheme 10 below.




embedded image


The enantiomerically pure intermediate 8-4 described in Scheme 8 is reduced using NaBH4 to a chiral alcohol 9-1. The transformation of alcohol 9-1 to 9-8 is carried out according to the methodologies described in schemes 1 to 5. Using the same methodology as demonstrated in Scheme 9, the enantiomer of 9-8 is synthesized starting from the enantiomerically pure intermediate 8-5.




embedded image


The enantiomerically pure compound 10-8 is synthesized starting from 8-5 according to the methodologies described in scheme 9. Using the same methodology as demonstrated in Scheme 10, the enantiomer of 10-8 is synthesized starting from the enantiomerically pure intermediate 8-4.




embedded image


embedded image


The enantiomerically intermediate 10-3 and 9-1 was synthesized starting from 8-3 according to the methodologies described in scheme 9 and 10. Using the same methodology as demonstrated in Scheme 11, the enantiomer of 10-3 and 9-1 is synthesized starting from the enantiomerically pure intermediate 11-2.


Formulation of the Compounds (Compositions)

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.


In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.


The powders and tablets preferably contain from 5% or 10% to 70% of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term “preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration. For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.


Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.


Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.


Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.


The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.


The quantity of active component in a unit dose preparation may be varied or adjusted to provide a pharmaceutically acceptable dosage of the active component.


The compounds of the invention and for some of them, their properties, are listed below in Tables I to VI.









TABLE I







Compounds with a pyrrolidine ring and a pyridine or pyridine-like


molecule bonded to the pyrrolidine N-constituent














MS



Compound


(ESI+):



No.
Structure
Name
[M + H]+
H-NMR














1


embedded image


5-((R or S)-3- (ethoxymethyl)- 3-(2-(5- methylthiophen- 2-yl)ethyl) pyrrolidin- 1-yl)-2- methyl-6,7- dihydro-5H- cyclopenta[b] pyridine
385

1H NMR (300 MHz, CDCl3): 7.52 (d, J = 7.5 Hz, 1H), 6.95 (d, J = 7.8 Hz, 1H), 6.53-6.51 (m, 2H), 4.25- 4.15 (m, 1H), 3.45 (q, J = 5.1 Hz, 2H),







3.31-3.23 (m,






2H), 3.15-






3.03 (m, 1H),






2.95-2.81 (m,






1H), 2.79-






2.60 (m, 3H),






2.60-2.55 (m,






1H), 2.52 (s,






3H), 2.42 (s,






3H), 2.39-






2.35 (m, 1H),






2.18-2.10 (m,






2H), 2.10-






1.98 (m, 1H),






1.90-1.75 (m,






2H), 1.65-






1.59 (m, 2H),






1.17 (t, J =






7.2 Hz, 3H).





2


embedded image


(S or R)-3-(2-(3- (ethoxymethyl)- 3-(2-(3- methylthiophen- 2-yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)pyridine
373

1H NMR (300 MHz, MeOD): δ 8.70 (s, 1H), 8.38-8.36 (m, 1H), 8.00- 7.97 (m, 1H), 7.41-7.37 (m, 1H), 7.01 (d, J = 5.1 Hz, 1H), 6.73 (d, J = 5.1 Hz, 1H), 3.48 (q, J = 6.9 Hz, 2H), 3.33-3.30 (m,







2H), 3.29-






3.27 (m, 2H),






2.68-2.55 (m,






4H), 2.53 (d,






J = 9.3 Hz, 1H),






2.32 (d, J =






9.3 Hz, 1H),






2.11 (s, 3H),






1.78-1.64 (m,






2H), 1.62-






1.55 (m, 2H),






1.44 (s, 6H),






1.17 (t, J =






6.9 Hz, 3H)





3


embedded image


(S or R)-3-(2-(3- (ethoxymethyl)- 3-(2-(thiophen- 2-yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)pyridine
359

1H NMR (300 MHz, MeOD): δ 8.70 (s, 1H), 8.37 (d, J = 3.9 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.38 (m, 1H), 7.13 (dd, J = 5.1, 1.2 Hz, 1H), 6.87 (dd, J = 5.1, 3.3 Hz, 1H), 6.76







(d, J = 2.4 Hz,






1H), 3.47 (q,






J = 6.9 Hz, 2H),






3.34-3.30 (m,






2H), 2.78 (t,






J = 8.4 Hz, 2H),






2.64-2.60 (m,






2H), 2.52 (d,






J = 9.3 Hz, 1H),






2.31 (d, J =






9.3 Hz, 1H),






1.82-1.77 (m,






2H), 1.59 (t,






J = 6.9 Hz, 2H),






1.43 (s, 6H),






1.16 (t, J =






6.9 Hz, 3H)





4


embedded image


(S or R)-5-(2-(3- (2-ethoxypropan- 2-yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
402
1H NMR (300 MHz, MeOD): δ 8.77 (s, 1H), 8.13 (dd, J = 8.4, 2.4 Hz, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.17-7.16 (m, 1H), 6.90- 6.87 (m, 1H), 6.80-6.79 (m, 1H), 3.50- 3.29 (m, 7H), 3.12-3.08 (m,






1H), 2.80 (q,






J = 15.6 Hz,






4H), 2.56 (s,






3H), 2.37-






2.25 (m, 1H),






1.92 (s, 6H),






1.87-1.78 (m,






3H), 1.13 (d,






J = 8.7 Hz, 6H),






1.02 (t, J =






6.9 Hz, 3H)


5


embedded image


5-(2-((S&R)-3- ((S or R)-1- ethoxyethyl)-3- (2-(thiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine citrate
388
1H NMR (300 MHz, MeOD): d 8.75-8.67 (m, 1H), 8.15- 8.03 (m, 1H), 7.45 (t, J = 6.6 Hz, 1H), 7.18-7.17 (m, 1H), 6.90- 6.88 (m, 1H), 6.81 (s, 1H), 3.56-3.50 (m, 2H), 3.40- 3.31 (m, 2H),






3.25-3.15 (m,






3H), 2.87-






2.75 (m, 6H),






2.58 (s, 3H),






2.33-2.08 (m,






2H), 1.90 (d,






J = 7.8 Hz, 6H),






1.87-1.62 (m,






2H), 1.36-






1.00 (m, 6H)





6


embedded image


2-methyl-5-(2- ((3R or S)-3- phenethyl-3- (tetrahydrofuran- 2-yl)pyrrolidin- 1-yl)propan-2- yl)pyridine citrate
379

1H NMR (300 MHz, MeOD): δ 8.73-8.71 (m, 1H), 8.07 (t, J = 8.4 Hz, 1H), 7.45 (dd, J = 8.4, 2.4 Hz, 1H), 7.27- 7.12 (m, 5H), 3.92-3.80 (m, 2H), 3.65- 3.26 (m, 2H),







3.47-3.38 (m,






2H), 3.31 (q,






J = 1.5 Hz, 1H),






2.80 (q, J =






15.3 Hz, 4H),






2.61-2.50 (m,






5H), 2.20 (m,






1H), 2.15-






1.95 (m, 3H),






1.87 (s, 3H),






1.85 (s, 3H),






1.77-1.72 (m,






3H), 1.28-






1.15 (m, 1H)





7


embedded image


5-(2-((3R or S)- 3- (tetrahydrofuran- 2-yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- (trifluoromethyl) pyridine
439

1H NMR (300 MHz, MeOD): δ 8.89 (s, 1H), 8.00 (d, J = 4.8 Hz, 1H), 7.62 (d, J = 8.1 Hz, 1H), 7.12-7.11 (m, 1H), 6.92- 6.91 (m, 1H),







6.80 (s, 1H),






3.86-3.82 (m,






2H), 3.74-






3.71 (m, 1H),






2.90-2.85 (m,






2H), 2.70-






2.51 (m, 3H),






2.47-2.36 (m,






2H), 1.96-






1.42 (m, 13H)





8


embedded image


2-methyl-5-(2- ((R or S)-3-((S or R)- tetrahydrofuran- 2-yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)pyridine
387

1H NMR (300 MHz,CDCl3): 88.60 (d, J = 1.5 Hz, 1H), 7.72 (dd, J = 6.0, 1.5 Hz, 1H), 7.11- 7.08 (m, 2H), 6.91 (dd, J = 2.4, 3.9 Hz, 1H), 6.79 (d, J = 1.8 Hz, 1H), 3.87-3.83 (m, 2H), 3.73- 3.71 (m, 1H),







3.00-2.88 (m,






1H), 2.87-






2.78 (m, 1H),






2.59-2.53 (m,






3H), 2.51 (s,






3H), 2.43 (d,






J = 6.9 Hz, 1H),






2.00-1.91 (m,






1H), 1.90-






1.85 (m, 3H),






1.78-1.71 (m,






3H), 1.61-






1.52 (m, 1H),






1.39 (d, J =






0.9 Hz, 6H)





9


embedded image


2-methyl-5-(2- ((3S or R)-3- (tetrahydrofuran- 2-yl)-3- (thiophen-2- ylmethyl) pyrrolidin-1-yl) propan- 2-yl)pyridine
371

1H NMR (300 MHz, CDCl3): δ 8.57 (s, 1H), 7.63 (d, J = 7.5 Hz, 1H), 7.12 (s, 1H), 7.07 (d, J = 8.1 Hz, 1H), 6.93 (s, 1H), 6.81 (s, 1H), 3.88-3.78 (m, 1H), 3.76- 3.69 (m, 3H), 3.15-3.10 (m,







1H), 2.95-






2.83 (m, 1H),






2.52 (s, 3H),






2.48-2.36 (m,






3H), 1.76-






1.60 (m, 6H),






1.36 (s, 3H),






1.35 (s, 3H)





10


embedded image


5-(2-((R or S)-3- ((S or R)- ethoxy(phenyl) methyl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine
449
1H NMR (300 MHz, MeOD): δ 8.68 (d, J = 2.1 Hz, 1H), 8.02 (dd, J = 8.3, 2.1 Hz, 1H), 7.43- 7.34 (m, 5H), 7.32-7.26 (m, 1H), 7.14 (d, J = 5.1 Hz, 1H), 6.88-6.85 (m, 1H), 6.74 (d, J = 2.4 Hz, 1H), 4.39 (s, 1H), 3.41-3.35 (m,






2H), 3.28-






3.25 (m, 2H),






3.16-3.06 (m,






2H), 2.92-






2.83 (m, 2H),






2.84-2.71 (m,






4H), 2.56 (s,






3H), 2.25-






2.13 (m, 1H),






2.90-2.81 (m,






1H), 1.77-






1.73 (m, 6H),






1.61-1.50 (m,






2H), 1.05 (t,






J = 6.9 Hz, 3H)





11


embedded image


5-(2-((R or S)-3- ((R or S)- ethoxy(phenyl) methyl)-3-(2- (thiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- N 2-yl)-2- methylpyridine
449

1H NMR (300 MHz, CDCl3): δ 8.53 (d, J = 2.4 Hz, 1H), 7.60 (dd, J = 8.1, 2.4, Hz 1H), 7.32- 7.28 (m, 5H), 7,10-7.04 (m, 2H), 6.90 (dd, J= 5.1, 3.6 Hz, 1H), 6.76 (d, J = 2.4 Hz, 1H), 4.20 (s, 1H), 3.41- 3.30 (m, 1H), 3.27-3.12 (m,







1H), 3.05-






2.92 (m, 1H),






2.91-2.82 (m,






1H), 2.74 (d,






J = 9.2 Hz, 1H),






2.52 (s, 3H),






2.51-2.45 (m,






1H), 2.41-






2.30 (m, 1H),






2.24 (d, J =






9.0 Hz, 1H),






2.02-1.88 (m,






2H), 1.71-






1.65 (m, 2H),






1.37 (s, 3H),






1.34 (s, 3H),






1.15 (t, J =






6.9 Hz, 3H)





12


embedded image


5-(2-((R or S)-3- ((R or S)-1- ethoxyethyl)-3- (2-(thiophen-2- yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
387

1H NMR (300 MHz, MeOD): δ 8.70 (d, J = 2.1 Hz, 1H), 8.05 (dd, J = 8.1, 2.4, Hz 1H), 7.41 (d, J = 8.1 Hz, 1H), 7.16 (dd, J = 5.1, 1.2 Hz, 1H), 6.88 (dd, J= 5.1, 3.3 Hz, 1H), 6.79 (d, J = 3.3 Hz, 1H), 3.61-







3.58 (m, 1H),






3.50-3.34 (m,






1H), 3.32-






3.30 (m, 2H),






3.25-3.22 (m,






2H), 3.21-






3.19 (m, 1H),






2.92-2.82 (m,






2H), 2.80-






2.70 (m, 4H),






2.56 (s, 3H),






2.09-1.95 (m,






1H), 1.94-






1.85 (m, 3H),






1.82 (s, 6H),






1.10-1.03 (m,






6H)





13


embedded image


5-(2-((R or S)-3- ((S or R)-1- ethoxyethyl)-3- (2-(thiophen-2- yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
387

1H NMR (300 MHz, MeOD): δ 8.69 (d, J = 2.1 Hz, 1H), 8.03 (d, J = 8.7 Hz, 1H), 7.42 (d, J = 7.2 Hz, 1H), 7.17 (dd, J = 4.8, 1.2, Hz, 1H), 6.88 (dd, J= 3.3, 5.1 Hz 1H), 6.79 (d, J = 3.0 Hz, 1H), 3.68-







3.60 (m, 1H),






3.49-3.43 (m,






1H), 3.30-






3.18 (m, 4H),






3.17-2.98 (m,






2H), 2.86-






2.71 (m, 4H),






2.56 (s, 3H),






2.25-2.12 (m,






1H), 2.10-






1.90 (m, 1H),






1.82 (s, 6H),






1.81-1.76 (m,






2H), 1.71-






1.60 (m, 1H),






1.13-1.03 (m,






6H)





14


embedded image


(R or S)-2- methyl-5-(2-(3- (propoxymethyl)- 3-(2- (thiophen-2- yl)ethyl) pyrrolidin- 1-yl)propan-2-yl) pyridinecitrate
387

1H NMR (300 MHz, MeOD): δ 8.68 (d, J = 2.1 Hz, 1H), 8.03 (d, J = 6.3 Hz, 1H), 7.41 (d, J = 8.4 Hz. 1H), 7.15 (d, J = 5.1 Hz, 1H), 6.88 (dd, J = 5.1, 3.6 Hz, 1H), 6.78 (d, J = 3.3 Hz, 1H), 3.50-3.38 (m, 2H), 3.25-







3.20 (m, 2H),






3.12-3.08 (m,






1H), 2.92-






2.87 (m, 2H),






2.78-2.72 (m,






4H), 2.56 (s,






3H), 2.15-






1.92 (m, 2H),






1.90-1.81 (m,






4H), 1.79 (s,






6H), 1.70-






1.48 (m, 3H),






0.89 (t, J =7.5






Hz, 3H)





15


embedded image


(R or S)-1-((3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-3- ethyl-1,3- dihydro-2H- benzo[d] imidazol-2- one citrate
437

1H NMR (300 MHz, MeOD): δ 8.56 (d, J = 2.4 Hz, 1H), 7.91 (d, J = 8.3 Hz, 1H), 7.27 (d, J = 8.2 Hz, 1H), 7.13 (d, J = 6.8 Hz, 1H), 7.10-6.96 (m, 3H), 3.92- 3.81 (m, 3H), 3.40-3.30 (m, 4H), 3.31 (m, 2H), 3.18 (s, 2H), 2.91 (d, J = 11.5 Hz, 1H), 2.78-







2.61 (m, 4H),






2.45 (s, 3H),






1.96 (m, 1H),






1.83-1.72 (m,






1H), 1.65 (s,






3H), 1.64 (s,






3H), 1.20 (t,






J = 7.2 Hz, 3H),






1.06 (t, J =






6.9 Hz, 3H)





16


embedded image


(R or S)-5-(2-(3- (2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine
509

1H NMR (300 MHz, CDCl3): δ 8.51 (d, J = 2.1 Hz, 1H), 7.64 (dd, J = 8.1, 2.4 Hz, 1H), 7.07- 7.02 (m, 2H), 6.86 (dd, J = 5.1, 3.3 Hz, 1H), 6.74- 6.73 (m, 1H), 3.96-3.80 (m, 2H), 3.01 (t,







J = 8.7 Hz, 2H),






2.89 (d, J =






9.6 Hz, 1H),






2.60-2.56 (m,






2H), 2.55 (s,






3H), 2.36-






2.28 (m, 2H),






2.15-2.08 (m,






1H), 2.00-






1.80 (m, 2H),






1.61 (s, 6H),






1.13 (t, J =






6.9 Hz, 3H)





17


embedded image


5-(2-((R or S)-3- (2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-1- yl)butan-2- yl)-2- methyl- pyridinecitrate
523
1H NMR (300 MHz, MeOD): δ 8.50 (d, J = 2.1 Hz, 1H), 7.92-7.87 (m, 1H), 7.35 (dd, J = 8.4, 2.7 Hz, 1H), 7.19- 7.16 (m, 1H), 6.93-6.90 (m, 1H), 6.85- 6.75 (m, 1H), 4.08-3.90 (m,






2H), 3.19-






3.10 (m, 1H),






3.05-2.98 (m,






2H), 2.91-






2.75 (m, 4H),






2.54 (s, 3H),






2.50-2.35 (m,






2H), 2.22-






2.10 (m, 1H),






2.09-1.90 (m,






2H), 1.89-






1.75 (m, 2H),






1.46 (s, 3H),






1.35-1.30 (m,






2H), 1.22-






1.16 (m, 3H),






0.71-0.64 (m,






3H)





18


embedded image


(R or S)-1-((3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- citrate yl)pyrrolidin-3- yl)methyl)-1,3- dihydro-2H- benzo[d] imidazol-2- one citrate
409

1H NMR (300 MHz, MeOD) δ 8.61 (s, 1H), 7.97 (d, J = 8.2 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.10-7.03 (m, 1H), 6.99- 6.90 (m, 3H), 3.85 (s, 2H), 3.48-3.06 (m, 10H), 2.84- 2.63 (q, J = 15.6 Hz,4H), 2.46 (s, 3H), 1.94 (m, 2H),







1.76 (s, 6H),






1.04 (t, J =






6.9 Hz, 3H)





19


embedded image


2-methyl-5-(2- ((3R or S)-3- (tetrahydrofuran- 2-yl)-3-(3- (thiophen-2- yl)propyl) pyrrolidin-1- yl)propan-2- yl)pyridine
399

1H NMR (300 MHz, CDCl3): δ 8.58 (d, J = 2.1 Hz, 1H), 7.69 (dd, J = 8.1, 2.4 Hz, 1H), 7.12- 7.05 (m, 2H), 6.93-6.90 (m, 1H), 6.78 (d, J = 3.3 Hz, 1H), 3.90-3.75 (m, 2H), 3.74- 3.62 (m, 1H), 2.89-2.75 (m, 2H), 2.64-







2.45 (m, 6H),






2.35-2.25 (m,






1H), 1.90-






1.80 (m, 4H),






1.72-1.58 (m,






4H), 1.52-






1.44 (m, 2H),






1.43-1.36 (m,






6H)





20


embedded image


(R or S)-5-(2-(3- (ethoxymethyl)- 3-(3-(thiophen- 2-yl)propyl) pyrrolidin-1- yl)propan-2-yl)- 2-methylpyridine
387

1H NMR (300 MHz, CDCl3): δ 8.58 (d, J = 2.4 Hz, 1H), 7.68 (dd, J = 8.4, 2.4 Hz, 1H), 7.11- 7.05 (m, 2H), 6.90 (dd, J = 8.4, 3.3 Hz, 1H), 6.78- 6.77 (m, 1H), 3.49 (s, 2H), 3.44 (dd, J =







14.1, 7.5 Hz,






2H), 3.24 (dd,






J= 15.2, 8.7






Hz, 2H), 2.80






(t, J = 7.2 Hz,






2H), 2.60-






2.55 (m, 1H),






2.54-2.50 (m,






4H), 2.43 (d,






J = 9.0 Hz, 1H),






2.23 (d, J =






9.0 Hz, 1H),






1.55-1.48 (m,






4H), 1.36 (s,






6H), 1.15 (t,






J = 6.9 Hz, 3H)





21


embedded image


(R or S)-5-(2-(3- (isopropoxymethyl)- 3-(2- (thiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine
387
1H NMR (300 MHz, CDCl3): δ 8.59 (d, J = 2.1 Hz, 1H), 7.71 (dd, J = 8.1, 2.4 Hz, 1H), 7.10- 7.06 (m, 2H), 6.91 (dd, J = 5.1, 3.3 Hz, 1H), 6.77 (d, J = 2.4 Hz, 1H), 3.52-3.48 (m, 1H), 3.26 (q, J = 8.7 Hz, 2H),






2.79 (t, J =






8.4 Hz, 2H),






2.58-2.52 (m,






5H), 2.28 (d,






J = 9.0 Hz, 1H),






2.95-2.75 (m,






2H), 2.55-






2.50 (m, 2H),






1.37 (s, 6H),






1.30-1.26 (m,






1H), 1.14-






1.12 (m, 6H)





22


embedded image


5-(2-((R or S)-3- (isopropoxymethyl)- 3-(2-(thiophen-2- yl)ethyl)pyrrolidin- 1-yl)butan-2- yl)-2- methylpyridine
401

1H NMR (300 MHz, CDCl3): δ 8.52 (s, 1H), 7.64 (dd, J = 8.1, 2.4 Hz, 1H), 7.10- 7.07 (m, 2H), 6.91 (d, J = 2.1 Hz, 1H), 6.77 (d, J = 0.9 Hz, 1H), 3.55-3.45 (m, 1H), 3.35- 3.20 (m, 2H), 2.85-2.72 (m,







2H), 2.70-






2.60 (m, 1H),






2.53 (s, 3H),






2.50-2.40 (m,






2H), 2.35-






2.18 (m, 1H),






1.90-1.73 (m,






3H), 1.68-






1.62 (m, 1H),






1.57-1.52 (m,






2H), 1.34 (s,






3H), 1.15-






1.11 (m, 6H),






0.62 (t, J =7.2






Hz, 3H)





23


embedded image


(R or S)-1-((3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- citrate yl)pyrrolidin-3- yl)methyl)-3- ethyl-5-fluoro- 1,3-dihydro-2H- benzo[d]imidazol- 2-onecitrate
455

1H NMR (300 MHz, MeOD): δ 8.68 (s, 1H), 8.04 (d, J = 8.1 Hz, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.20-7.16 (m, 1H), 7.06- 7.02 (m, 1H), 6.85 (t, 9.6 Hz, 1H), 3.94- 3.90 (m, 4H), 3.50-3.27 (m, 7H), 3.05 (d, J = 11.4 Hz, 1H), 2.81 (q, J = 15.6 Hz, 4H), 2.56 (s,







3H), 2.10-






1.99 (m, 2H),






1.84-1.73 (m,






6H), 1.32-






1.24 (m, 3H),






1.15 (t, J =






6.9 Hz, 3H)





24


embedded image


(R or S)-2- methyl-5-(1-(2-(6- methylpyridin- 3-yl)propan-2- yl)-3-(2- (thiophen-2- yl)ethyl)pyrrolidin- 3-yl)-1,3,4- thiadiazole citrate
413

1H NMR (300 MHz, MeOD): δ 8.55 (s, 1H), 7.95 (dd, J = 8.1,2.4 Hz, 1H), 7.30 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 4.8 Hz, 1H), 6.78 (t, J = 4.2 Hz, 1H), 6.67 (d, J = 2.7 Hz, 1H), 3.42 (d, J = 11.2 Hz, 1H),







3.05-2.96 (m,






1H), 2.94-






2.83 (m, 1H),






2.70 (m, 6H),






2.52 (m, 2H),






2.47 (s, 3H),






2.30 (m, 1H),






2.11 (s, 3H),






2.03-1.93 (m,






1H), 1.85 (m,






1H), 1.61 (s,






6H)





25


embedded image


(R or S)-5-(2-(3- (ethoxymethyl)- 3-(2-(5- fluorobenzo[b] thiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
450

1H NMR (300 MHz, MeOD): δ 8.68 (s, 1H), 8.02 (d, J = 8.1 Hz, 1H), 7.73 (dd, J = 9.0, 4.8 Hz, 1H), 7.39 (s, 1H), 7.36 (s, 1H), 7.07- 7.00 (m, 2H), 3.50-3.45 (m, 2H), 3.38- 3.43 (m, 2H),







3.27-3.20 (m,






2H), 3.15-






3.08 (m, 1H),






2.92-2.85 (m,






3H), 2.79 (q,






J = 15.6 Hz,






4H), 2.54 (s,






3H), 1.98-






1.82 (m, 4H),






1.77 (s, 6H),






1.14 (t, J =






6.9 Hz, 3H).





26


embedded image


(S or R)-5-(2-(3- (ethoxymethyl)- 3-(thiophen-2- ylmethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
359

1H NMR (300 MHz, MeOD): δ 8.70 (s, 1H), 8.04 (d, J = 6.0 Hz, 1H), 7.44 (d, J = 8.2 Hz, 1H), 7.24 (d, J = 5.3 Hz, 1H), 6.95-6.90 (m, 1H), 6.82 (s, 1H), 3.47- 3.40 (m, 2H), 3.20-3.19 (m,







3H), 3.10-






3.07 (m, 3H),






3.05-2.98 (m,






2H), 2.82 (q,






J = 15.6 Hz,






4H), 2.59 (s,






3H), 2.06-






1.96 (m, 1H),






1.93-1.86 (m,






1H), 1.83 (s,






6H), 1.15 (t,






J = 7.0 Hz, 3H).





27


embedded image


(R or S)-2-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)thieno [3,2-b]pyridine citrate
424

1H NMR (300 MHz, MeOD): δ 8.66 (d, J = 2.1 Hz, 1H), 8.53 (dd, J = 4.8, 1.2 Hz, 1H), 8.27 (d, J = 8.1 Hz, 1H), 8.01 (dd, J = 4.8, 1.2 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.30 (dd, J = 7.8, 3.6 Hz,







1H), 7.23 (s,






1H), 3.52-






3.44 (m, 2H),






3.38-3.35 (m,






2H), 3.18-






3.10 (m, 2H),






3.08-3.02 (m,






1H), 2.96 (t,






J = 8.4 Hz, 2H),






2.92-2.87 (m,






1H), 2.80 (q,






J = 15.6 Hz,






4H), 2.53 (s,






3H), 2.00-






1.83 (m, 4H),






1.74 (s, 6H),






1.14 (t, J =






6.9 Hz, 3H)





28


embedded image


(R or S)-2-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)thieno [2,3-b]pyridine citrate
424

1H NMR (300 MHz, MeOD): δ 8.68 (d, J = 1.8 Hz, 1H), 8.40 (d, J = 3.3 Hz, 1H), 8.10-8.02 (m, 2H), 7.39- 7.34 (m, 2H), 7.08 (s, 1H), 3.50-3.42 (m, 2H), 3.38- 3.36 (m, 1H), 3.25-3.18 (m,







2H), 3.15-






3.10 (m, 1H),






3.09-3.00 (m,






1H), 2.99-






2.88 (m, 3H),






2.81 (q, J =






15.6 Hz, 4H),






2.54 (s, 3H),






2.02-1.88 (m,






4H), 1.77 (s,






6H), 1.14 (t,






J = 7.2 Hz, 3H)





29


embedded image


(S & R)-1-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-3- ethyl-1,3- dihydro-2H- benzo[d] imidazol-2-one
451

1H NMR (300 MHz, MeOD): & 8.67 (d, J = 1.9 Hz, 1H), 8.03 (dd, J = 8.2, 2.4 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.18-7.14 (m, 4H), 4.01- 3.87 (m, 4H), 3.49-3.41 (m, 2H), 3.38- 3.34 (m, 2H), 3.23-3.18 (m,







2H), 3.10 (d,






J = 11.5 Hz,






1H), 2.94 (d,






J = 11.7 Hz,






1H), 2.80 (q,






J = 15.5 Hz,






4H), 2.55 (s,






3H), 2.01-






1.82 (m, 4H),






1.77 (s, 6H),






1.29 (t, J =






7.2 Hz, 3H),






1.13 (t, J =






7.0 Hz, 3H).





30


embedded image


(R or S)-5-(2-(3- (ethoxymethyl)- 3-(2-(5- (trifluoromethyl )thiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
425

1H NMR (300 MHz, MeOD): δ 8.70 (d, J = 2.5 Hz, 1H), 8.06 (dd, J = 8.3, 2.6 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.33 (d, J = 3.8 Hz, 1H), 6.87 (d, J = 3.5 Hz, 1H), 3.52-3.43 (m, 2H), 3.37-







3.33 (m, 1H),






3.28-3.22 (m,






2H), 3.17 (d,






J = 11.7 Hz,






1H), 2.98 (d,






J = 11.7 Hz,






1H), 2.80 (m,






7H), 2.56 (s,






3H), 2.05-






1.84 (m, 4H),






1.81 (s, 6H),






1.13 (t, J =






7.0 Hz, 3H).





31


embedded image


(R or S)-5-(2-(3- (2-(4-chloro-5- fluorothiophen- 2-yl)ethyl)-3- (ethoxymethyl) pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine citrate
425

1H NMR (300 MHz, MeOD): δ 8.68 (d, J = 2.4 Hz, 1H), 8.04 (dd, J = 8.3, 2.5 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), 6.48 (d, J = 3.4 Hz, 1H), 3.49-3.41 (m, 2H), 3.40- 3.37 (m, 2H), 3.35-3.32 (m, 2H), 3.30- 3.22 (m, 2H),







3.09 (d, J =






11.5 Hz, 1H),






2.80 (q, J =






15.5 Hz, 4H),






2.69-2.59 (m,






2H), 2.56 (s,






3H), 2.09-






1.82 (m, 3H),






1.78 (s, 6H),






1.13 (t, J =






7.0 Hz, 3H).





32


embedded image


(R or S)-5-(2-(3- (2-(4- chlorothiophen- 3-yl)ethyl)-3- (ethoxymethyl) pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine
407

1H NMR (500 MHz, MeOD): δ 8.54 (d, J = 2.1 Hz, 1H), 7.87 (dd, J = 8.2, 2.3 Hz, 1H), 7.28- 7.22 (m, 2H), 7.12 (d, J = 3.4 Hz, 1H), 3.47 (q, J = 7.0 Hz, 2H), 3.34-3.32 (m,







1H), 3.30-






3.29 (m, 1H),






2.69- 2.62 (m,






2H), 2.56-






2.52 (m, 3H),






2.50 (s, 3H),






2.37 (d, J =






9.2 Hz, 1H),






1.74-1.66 (m,






2H), 1.63 (t,






J = 6.9 Hz, 2H),






1.45 (s, 6H),






1.16 (t, J =






7.0 Hz, 3H).





33


embedded image


(R or S)-5-(2-(3- (2-(4- chlorothiophen- 2-yl)ethyl)-3- (ethoxymethyl) pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine
407

1H NMR (300 MHz, CDCl3): δ 8.66 (s, 1H), 7.74 (t, J = 6.3 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H), 6.89 (d, J = 6.2 Hz, 1H), 6.66 (m, 1H), 3.73 (t, J = 7.3 Hz, 1H), 3.68-3.21 (m, 7H), 2.87- 2.69 (m, 2H),







2.60 (s, 3H),






2.05-1.89 (m,






2H), 1.86-






1.71 (m, 2H),






1.63 (s, 6H),






1.17-1.12 (m,






3H).





34


embedded image


5-(2-((R & S)-3- ((S or R)-1- ethoxy-2,2,2- trifluoroethyl)- 3-(2-(5- fluorothiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine
459

1H NMR (300 MHz, MeOD): δ 8.59 (dd, J = 9.0, 2.1 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.09 (d, J = 8.1 Hz, 1H), 6.33 (t, J = 3.0 Hz, 1H), 6.23 (dd, J =







2.1, 1.2 Hz,






1H), 3.95-






3.82 (m, 1H),






3.55-3.45 (m,






2H), 2.91-






2.80 (m, 1H),






2.69-2.60 (m,






2H), 2.53 (s,






3H), 2.48-






2.39 (m, 1H),






2.10-1.85 (m,






2H), 1.84-






1.55 (m, 4H),






1.39 (s, 6H),






1.15 (t, J =






6.9 Hz, 3H)





35


embedded image


5-(2-((R or S)-3- ((S or R)-1- ethoxyethyl)-3- (2-(5- fluorothiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
405

1H NMR (300 MHz, MeOD): δ 8.69 (s, 1H), 8.04 (d, J = 8.1 Hz, 1H), 7.41 (d, J = 8.1 Hz, 1H), 6.41 (m, 1H), 6.30 (d, J = 2.1 Hz, 1H), 3.65-3.57 (m, 1H), 3.48- 3.39 (m, 1H), 3.28-3.14 (m,







4H), 3.12-



citrate


2.95 (m, 2H),






2.75 (q, J =






15.5 Hz, 4H),






2.68-2.63 (m,






2H), 2.56 (s,






3H), 2.24-






2.08 (m, 1H),






2.06-1.94 (m,






1H), 1.69 (s,






6H), 1.68-






1.59 (m, 1H),






1.12-1.02 (m,






6H)





36


embedded image


(R or S)-5-(2-(3- (2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)-3-(2-(5- fluorothiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine
527

1H NMR (300 MHz, MeOD): δ 8.58 (d, J = 1.8 Hz, 1H), 7.68 (dd, J = 8.1, 1.8 Hz, 1H), 7.10 (d, J = 8.1 Hz, 1H), 6.36 (d, J = 3.3 Hz, 1H), 6.25 (dd, J = 3.6, 1.8 Hz, 1H), 3.97-







3.88 (m, 2H),






2.95-2.89 (m,






3H), 2.71-






2.56 (m, 2H),






2.53 (s, 3H),






2.45-2.30 (m,






2H), 2.18-






2.02 (m, 1H),






1.92-1.80 (m,






1H), 1.72-






1.65 (m, 1H),






1.40 (s, 6H),






1.20 (t, J =






6.9 Hz, 3H).





37


embedded image


5-(2-((R or S)-3- ((R or S)-1- ethoxyethyl)-3- (2-(5- fluorothiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
405

1H NMR (300 MHz, MeOD): δ 8.70 (d, J = 1.8 Hz, 1H), 8.06 (dd, J = 8.4, 2.4 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 6.41 (d, J = 3.6 Hz, 1H), 6.30 (m, 1H), 3.63-3.55 (m,







1H), 3.50-



citrattext missing or illegible when filed


3.44 (m, 1H),






3.38-3.32 (m,






2H), 3.26-






3.18 (m, 2H),






2.96-2.88 (m,






1H), 2.76 (q,






J = 15.5 Hz,






4H), 2.69-






2.61 (m, 2H),






2.56 (s, 3H),






2.05-1.97 (m,






1H), 1.95-






1.89 (m, 1H),






1.83 (s, 6H),






1.80-1.74 (m,






2 H), 1.11-






1.00 (m, 6H)





38


embedded image


(R or S)-(3-(2- (5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl isopropylcarbamate citrate
448

1H NMR (300 MHz, MeOD): δ 8.66 (s, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.40 (d, J = 8.2 Hz, 1H), 6.42 (m, 1H), 6.35-6.25 (m, 1H), 4.08- 3.91 (m, 2H), 3.83-3.73 (m, 2H), 3.18 (m, 2H), 2.97 (d, J = 10.9 Hz, 1H), 2.90- 2.73 (m, 6H),







2.71-2.64 (m,



citrattext missing or illegible when filed


2H), 2.56 (s,






3H), 1.85-






1.78 (m, 2H),






1.73 (s, 6H),






1.10 (d, J =






6.5 Hz, 6H).





39


embedded image


(R or S)-(3-(2- (5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl phenylcarbamate citrate
482
1H NMR (300 MHz, MeOD): δ 8.66 (s, 1H), 8.05 (d, J = 8.2 Hz, 1H), 7.42 (d, J = 7.8 Hz, 2H), 7.36 (d, J = 8.3 Hz, 1H), 7.28 (t, J = 7.9 Hz, 2H), 7.03 (t, J = 7.3 Hz, 1H), 6.43 (m, 1H),






6.28 (m, 1H),



citrattext missing or illegible when filed


4.09 (q, J =






11.1 Hz, 2H),






3.18 (m, 2H),






2.99 (m, 1H),






2.90-2.68 (m,






5H), 2.49 (s,






3H), 1.96-






1.79 (m, 4H),






1.73 (s, 6H).





40


embedded image


isopropyl (S or R)-((3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) carbamate citrate
448

1H NMR (300 MHz, MeOD): δ 8.66 (s, 1H), 8.03 (d, J = 7.2 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 6.42 (t, J = 3.3 Hz, 1H), 6.28 (dd, J = 2.4, 1.2 Hz, 1H), 4.88- 4.68 (m, 2H), 3.25-3.13 (m,







4H), 3.05-



citrattext missing or illegible when filed


2.93 (m, 1H),






2.73 (q, J =






15.6 Hz, 4H),






2.71-2.62 (m,






2H), 2.55 (s,






3H), 1.92-






1.80 (m, 2H),






1.75 (s, 6H),






1.68-1.63 (m,






2H), 1.26 (m,






6H)





41


embedded image


phenyl (S or R)- ((3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) carbamate
482

1HNMR (300 MHz, MeOD): δ 8.53 (d, J = 1.2 Hz, 1H), 7.89 (dd, J = 6.0, 2.4 Hz, 1H), 7.36 (t, J = 7.8 Hz, 2H), 7.23 (d, J = 8.1 Hz, 1H), 7.20 (m, 1H), 7.08 (d, J = 7.8 Hz, 2H), 6.42 (t, J =







3.3 Hz, 1H),






6.28 (dd, J =






3.3, 2.1 Hz,






1H), 2.85-






2.70 (m, 7H),






2.55 (m, 1H),






2.49 (s, 3H),






1.80-1.60 (m,






4H), 1.45 (s,






6H)





42


embedded image


(S or R)-1-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-3- isopropylurea citrate
447

1H NMR (300 MHz, MeOD): δ 8.72 (s, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.43 (d, J = 8.2 Hz, 1H), 6.50-6.40 (m, 1H), 6.35- 6.25 (m, 1H), 3.91-3.73 (m, 1H), 3.22- 3.09 (m, 3H), 2.90 (d, J =







4.8 Hz, 1H),



citrattext missing or illegible when filed


2.88-2.65 (m,






8H), 2.57 (s,






3H), 1.88-






1.68 (m,






10H), 1.12






(m, 6H).





43


embedded image


(S or R)-1-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-3- phenylurea citrate
481

1H NMR (300 MHz, MeOD): δ 8.71 (s, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.41-7.33 (m, 3H), 7.27 (t, J = 7.8 Hz, 2H), 7.00 (t, J = 7.2 Hz, 1H), 6.48-6.44 (m, 1H), 6.34- 6.26 (m, 1H), 3.44-3.34 (m,







3H), 3.18 (m,



citrate


1H), 2.95 (m,






1H), 2.91-






2.68 (m, 7H),






2.50 (s, 3H),






2.00-1.87 (m,






2H), 1.84 (m,






6H), 1.81-






1.71 (m, 2H).





44


embedded image


(R or S)-(3-(4- fluorophenethyl)- 1-(pyridin-3- ylmethyl) pyrrolidin-3- yl)methanol citrate
315
1H NMR (300 MHz, MeOD): δ 8.69 (s, 1H), 8.63 (d, J = 4.8 Hz, 1H), 8.03 (s, 1H), 7.54 (s, 1H), 7.21 (dd, J = 8.4, 5.4 Hz, 2H), 6.98 (t, J = 8.6 Hz, 2H),






4.45-4.26 (m,



citrate


2H), 3.57 (s,






4H), 3.06 (d,






J = 10.5 Hz,






1H), 2.87-






2.71 (m, 5H),






2.59 (t, J = 8.6






Hz, 2H), 2.04






(s, 2H), 1.81






(d, J = 9.2 Hz,






2H).





45


embedded image


(R or S)-3-((3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1- yl)methyl)-5- fluoropyridine citrate
361

1H NMR (300 MHz, MeOD): δ 8.58 (s, 2H), 7.91 (d, J = 9.1 Hz, 1H), 7.26-7.15 (m, 2H), 6.98 (t, J = 8.6 Hz, 2H), 4.54-4.35 (m, 2H), 3.61- 3.51 (m, 2H), 3.49-3.34 (m, 5H), 3.15 (d,







J = 11.5 Hz,



citrate


1H), 2.81 (q,






J = 15.6 Hz,






4H), 2.59 (s,






2H), 2.04 (s,






2H), 1.84 (d,






J = 11.9 Hz,






2H), 1.22 (t,






J = 7.0 Hz, 3H).


46


embedded image


(R or S)-3- (ethoxymethyl)- 3-(4- fluorophenethyl)- N-(pyridin-3- yl)pyrrolidine-1- carboxamide







47


embedded image


(R or S)-3-(2-(3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1- yl)ethyl)pyridine







48


embedded image


(R or S)-3,3′- ((3-(ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1- yl)methylene) dipyridine







49


embedded image


(R or S)-N-(3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1- yl)pyridin-3- amine







50


embedded image


3-(1-((R or S)-3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1-yl)- 2,2,2- trifluoroethyl) pyridine







51


embedded image


(R or S)-3,5- dichloro-4-((3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1- yl)methyl)pyridine







52


embedded image


(R or S)-4-(2-(3- (ethoxymethyl)- 1-(pyridin-3- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile







53


embedded image


(R or S)-3-((3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1- yl)methyl) isonicotinonitrile







54


embedded image


(R or S)-3-((3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1- yl)methyl) picolinonitrile







55


embedded image


(R or S)-5-((3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1- yl)methyl)-2- methoxypyridine







56


embedded image


(R or S)-5-((3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1- yl)methyl)-2- methoxy- isonicotinonitrile







57


embedded image


(R or S)-3-((3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1- yl)methyl) picolinamide







58


embedded image


5-((R or S)-3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1-yl)- 6,7-dihydro-1,7- naphthyridin- 8(5H)-one







59


embedded image


5-((R or S)-3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1-yl)- 6,6-dimethyl- 6,7-dihydro-1,7- naphthyridin- 8(5H)-one







60


embedded image


(R or S)-4-(2-(1- (di(pyridin-3- yl)methyl)-3- (ethoxymethyl) pyrrolidin-3- yl)ethyl) benzonitrile







61


embedded image


(R or S)-2-(3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1-yl)- 1-(6- methylpyridin- 3-yl)ethan-1-one







62


embedded image


(R or S)-2-(3- (ethoxymethyl)- 3-(4- fluorophenethyl) pyrrolidin-1-yl)- 2-methyl-1-(6- methylpyridin- 3-yl)propan-1- one







63


embedded image


(R or S)-2-(3- (ethoxymethyl)- 3-(2-(5- fluoropyridin-2- yl)ethyl)pyrrolid in-1-yl)-1-(6- methylpyridin- 3-yl)ethan-1-one







64


embedded image


(R or S)-2-(3- (ethoxymethyl)- 3-(2-(5- fluoropyridin-2- yl)ethyl)pyrrolid in-1-yl)-2- methyl-1-(6- methylpyridin- 3-yl)propan-1- one







65


embedded image


(R or S)-4-(2-(3- (oxetan-3-yl)-1- (pyridin-3- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile







66


embedded image


(R or S)-3-((3- (4- fluorophenethyl)- 3-(oxetan-3- yl)pyrrolidin-1- yl)methyl)pyridine







67


embedded image


(R or S)-4-(2-(1- (2-(6- methylpyridin- 3-yl)propan-2- yl)-3-(oxetan-3- yl)pyrrolidin-3- yl)ethyl)benzonitrile







68


embedded image


(R or S)5-(3-(3- (4- fluorophenethyl)- 3-(oxetan-3- yl)pyrrolidin-1- yl)oxetan-3-yl)-2- methylpyridine







69


embedded image


(R or S)-5-(2-(3- (1,1,1,3,3,3- hexafluoro-2- methoxypropan- 2-yl)-3-(2- (thiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine







70


embedded image


(R or S)-5-((3- (2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)-3-(2- (thiophen-2- yl)ethyl)pyrrolidin- 1-yl)methyl)-2- methylpyridine







71


embedded image


(R or S)-3-((3- (2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)-3-(2- (thiophen-2- yl)ethyl)pyrrolidin- 1-yl)methyl) pyridine







72


embedded image


(R or S)-5-(2-(3- (2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)-3-(4- fluorophenethyl) pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine







73


embedded image


(R or S)-5-(2-(3-(4- fluorophenethyl)- 3-(1,1,1,3,3,3- hexafluoro-2- methoxypropan- 2-yl)pyrrolidin- 1-yl)propan-2- yl)-2- methylpyridine







74


embedded image


(R or S)- 1,1,1,3,3,3- hexafluoro-2-(3-(4- fluorophenethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-ol







75


embedded image


(R or S)-5-((3- (2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)-3-(4- fluorophenethyl) pyrrolidin-1- yl)methyl)-2- methylpyridine







76


embedded image


(R or S)-3-((3- (2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)-3-(4- fluorophenethyl) pyrrolidin-1- yl)methyl)pyridine







77


embedded image


(R or S)-4-(2-(3- (2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)benzonitrile







78


embedded image


(R or S)-4-(2-(3- (1,1,1,3,3,3- hexafluoro-2- methoxypropan- 2-yl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile







79


embedded image


(R or S)-4-(2-(3- (1,1,1,3,3,3- hexafluoro-2- hydroxypropan- 2-yl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile







80


embedded image


(R or S)-4-(2-(3- (2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)-1-((6- methylpyridin- 3-yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile







81


embedded image


(R or S)-4-(2-(3- (2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)-1- (pyridin-3- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile







82


embedded image


(R or S)-5-(2-(3- ((difluoromethoxy) methyl)-3- (2-(thiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citarte
395

1H NMR (300 MHz, MeOD) : δ 8.63 (s, 1H), 7.98 (dd, J = 5.7, 2.7 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.17 (dd, J = 3.9, 1.2 Hz, 1H), 6.88 (dd, J = 3.6, 1.2 Hz, 1H), 6.79 (d, J = 3.3 Hz, 1H), 6.38 (t,







J = 75.3 Hz,



citrate


1H), 3.88-






3.75 (m, 2H),






3.05-2.98 (m,






2H), 2.93-






2.78 (m, 6H),






2.75-2.65 (m,






2H), 2.54 (s,






3H), 1.89-






1.80 (m, 4H),






1.65 (s, 6H)





83


embedded image


(R or S)-3-((3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-3H- imidazo[4,5- c]pyridine citarte
422

1H NMR (300 MHz, MeOD): δ 8.98 (s, 1H), 8.59 (d, J = 2.4 Hz, 1H), 8.45-8.31 (m, 2H), 7.96 (m, 1H), 7.79 (m, 1H), 7.34 (d, J = 8.2 Hz, 1H), 4.53-4.37 (m, 2H), 3.41 (t,







J = 7.1 Hz, 2H),



citrate


3.21-3.09 (m,






2H), 3.02-






2.96 (m, 1H),






2.93-2.75 (m,






4H), 2.75-






2.66 (m, 3H),






2.55 (s, 3H),






1.96-1.85 (m,






1H), 1.70 (m,






1H), 1.57 (m,






6H), 1.16 (t,






J = 7.0 Hz, 3H).





84


embedded image


(R or S)-1-((3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-3- ethyl-5,6- difluoro-1,3- dihydro-2H- benzo[d] imidazol- 2-one citarte
473

1H NMR (300 MHz, MeOD): δ 8.59 (s, 1H), 7.97 (dd, J = 8.3, 2.6 Hz, 1H), 7.31 (d, J = 8.3 Hz, 1H), 7.14-7.08 (m, 2H), 3.91- 3.75 (m, 4H), 3.46-3.26 (m, 4H), 3.13 (m, 1H), 2.91 (m, 1H), 2.75- 2.64 (m, 6H), 2.47 (s, 3H), 1.96 (m, 1H),







1.80 (m, 1H),



citrate


1.70 (d, J =






3.2 Hz, 6H),






1.18 (t, J =






7.2 Hz, 3H),






1.08 (t, J =






7.0 Hz, 3H).





85


embedded image


(R or S)-1-((3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-1H- imidazo[4,5- c]pyridine citrate
394

1H NMR (300 MHz, MeOD): δ 9.04 (s, 1H), 8.60 (d, J = 2.3 Hz, 1H), 8.42 (s, 1H), 8.38 (d, J = 5.8 Hz, 1H), 8.01 (dd, J = 8.2, 2.4 Hz, 1H), 7.76 (d, J = 5.7 Hz, 1H),







7.37 (d, J =



citrate


8.2 Hz, 1H),






4.64-4.45 (m,






2H), 3.38 (m,






2H), 3.13 (m,






2H), 2.91 (m,






2H), 2.99-






2.80 (m, 4H),






2.76 (m, 2H),






2.56 (s, 3H),






1.97 (m, 1H),






1.60-1.58 (m,






7H), 1.17 (t,






J = 7.0 Hz, 3H).





86


embedded image


5-(2-((S or R)-3- ((R& S)- ethoxy(pyridin- 2-yl)methyl)-3- (2-(thiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
450

1HNMR (300 MHz, MeOD): δ 8.64 (t, J = 3.0 Hz, 1H), 8.54 (t, J = 3.9 Hz, 1H), 8.02-7.96 (m, 1H), 7.88- 7.79 (m, 1H), 7.50-7.45 (m, 1H), 7.43- 7.34 (m, 2H), 7.15-7.11 (m, 1H), 6.88- 6.83 (m, 1H), 6.75-6.71 (m,







1H), 4.49 (s,



citrate


0.5H), 4.47 (s,






0.5H), 3.73






(d, J = 11.4






Hz, 0.5 H),






3.46 (d, J =






11.4 Hz, 0.5






H), 3.39-3.35






(m, 2H), 3.30-






3.25 (m, 1H),






3.23-3.03 (m,






2H), 3.01-






2.96 (m, 1H),






2.83-2.73 (m,






5H), 2.56 (m,






3H), 2.41-






2.20 (m, 1H),






1.93-1.84 (m,






1H), 1.76 (m,






6H), 1.74-






1.42 (m, 2H),






1.17-1.06 (m,






3H





87


embedded image


5-(2-((R or S)-3- ((S or R)- isochroman-1- yl)-3-(2- (thiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
447

1H NMR (300 MHz, MeOD): δ 8.72 (s, 1H), 8.06 (s, 1H), 7.42 (s, 1H), 7.20-7.18 (m, 4H), 7.09 (d, J = 4.8 Hz, 1H), 6.82 (t, J = 3.3 Hz, 1H), 6.56 (s, 1H), 4.11-4.05 (m, 1H), 3.61- 3.50 (m, 2H), 3.10-3.05 (m, 1H), 2.98-







2.86 (m, 2H),



citrate


2.75 (q, J =






15.6 Hz, 4H),






2.65-2.55 (m,






4H), 2.54-






2.45 (m, 4H),






2.20-2.00 (m,






2H), 1.83 (s,






6H), 1.70-






2.55 (m, 2H)





88


embedded image


5-(2-((R or S)-3- ((R or S)- isochroman-1- yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
447

1H NMR (300 MHz, MeOD): δ 8.65 (s, 1H), 7.98 (d, J = 6.9 Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.21-7.16 (m, 5H), 6.88 (t, J = 3.9 Hz, 1H), 6.75 (s, 1H), 4.08-4.06 (m, 1H), 3.56- 3.46 (m, 2H), 3.16-3.08 (m, 1H), 2.85 (q,







J = 15.5 Hz,



citrate


4H), 2.58 (s,






6H), 2.19 (t,






J = 7.5 Hz, 1H),






2.09-1.97 (m,






3H), 1.87-






1.81 (m, 8H),






1.66-1.54 (m,






2H)





89


embedded image


5-(2-((R or S)-3- ((S or R)- isochroman-1- yl)-3-(2- (thiophen-2- yl)ethyl)pyrrolidin- 1-yl)butan-2- yl)-2- methylpyridine citrate
461

1H NMR (300 MHz, MeOD): δ 8.68 (s, 1H), 8.06 (s, 1H), 7.46 (s, 1H), 7.20 (m, 4H), 7.10 (t, J = 5.7 Hz, 1H), 6.81 (m, 1H), 6.55 (m, 1H), 4.15-4.02 (m, 1H), 3.62- 3.45 (m, 4H), 3.21-2.95 (m, 2H), 2.80 (q, J = 15.5 Hz,







4H), 2.58-



citrate


2.49 (m, 6H),






2.47-2.25 (m,






2H), 2.19-






2.05 (m, 2H),






1.95-1.78 (m,






4H), 1.76-






1.50 (m, 2H),






0.90-0.81 (m,






3H)





90


embedded image


5-(2-((R or S)-3- ((S&R)-1- ethoxy-2,2,2- trifluoroethyl)- 3-(2-(5- fluorothiophen-2- yl)ethyl)pyrrolidin- 1-yl)butan-2- yl)-2- methylpyridine
473

1H NMR (300 MHz, MeOD): δ 8.54 (m, 1H), 7.65-7.59 (m, 1H), 7.10 (d, J = 7.8 Hz, 1H), 6.33 (s, 1H), 6.23 (d, J = 1.8 Hz, 1H), 4.01-3.80 (m, 1H), 3.64-







3.42 (m, 2H),






3.04-2.64 (m,






3H), 2.54 (s,






6H), 2.00-






1.91 (m, 1H),






1.90-1.74 (m,






3H), 1.72-






1.61 (m, 2H),






1.35 (s, 3H),






1.24-1.17 (m,






2H), 1.16-






1.06 (m, 1H),






0.63 (t, J =






7.2 Hz, 3H)





91


embedded image


1-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-1H- imidazo[4,5- c]pyridine citrate
408

1H NMR (300 MHz, MeOD): δ 8.98 (s, 1H), 8.66 (s, 1H), 8.47 (s, 1H), 8.40 (d, J = 5.8 Hz, 1H), 8.08-7.97 (m, 1H), 7.75 (d, J = 5.7 Hz, 1H), 7.39 (d, J = 8.5 Hz, 1H),







4.45 (t, J =



citrate


8.2 Hz, 2H),






3.48 (q, J =






7.0 Hz, 3H),






3.39 (m, 2H),






3.24-3.12 (m,






2H), 3.10-






3.02 (m, 1H),






2.81 (q, J =






15.6 Hz, 4H),






2.55 (s, 3H),






2.21-2.05 (m,






2H), 1.95-






1.85 (m, 2H),






1.75 (s, 6H),






1.16 (t, J =






7.0 Hz, 3H).





92


embedded image


1-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-1,3- dihydro-2H- imidazo[4,5- c]pyridin-2-one citrate
424

1H NMR (500 MHz, MeOD): δ 8.66 (d, J = 2.1 Hz, 1H), 8.33 (s, 1H), 8.22 (d, J = 5.4 Hz, 1H), 8.02 (dd, J = 8.3, 2.4 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.17 (d, J = 5.4 Hz, 1H), 3.94 (t, J =







7.7 Hz, 2H),



citrate


3.46 (t, J =






7.1 Hz, 2H),






3.38 (q, J =






9.2 Hz, 2H),






3.22-3.10 (m,






2H), 3.05 (d,






J = 11.3 Hz,






1H), 2.90 (d,






J = 11.4 Hz,






1H), 2.80 (q,






J = 15.5 Hz,






4H), 2.55 (s,






3H), 2.01-






1.82 (m, 4H),






1.74 (s, 6H),






1.14 (t, J =






7.0 Hz, 3H).





93


embedded image


5-(2-((R or S)-3- (2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)-3-(2-(5- fluorothiophen-2- yl)ethyl)pyrrolid in-1-yl)butan-2- yl)-2- methylpyridine
541

1HNMR (300 MHz, MeOD): δ 8.51 (dd, J = 11.4, 1.8 Hz, 1H), 7.68- 7.55 (m, 1H), 7.11 (d, J = 8.1 Hz, 1H), 6.38-6.26 (m, 1H), 6.25 (d, J = 1.8 Hz, 1H),







4.01-3.82 (m,






2H), 3.11-






2.75 (m, 4H),






2.55 (s, 3H),






2.51-2.45 (m,






1H), 2.40-






2.27 (m, 2H),






2.23-1.98 (m,






1H), 1.97-






1.70 (m, 4H),






1.41-1.32 (m,






3H), 1.21-






1.15 (m, 3H),






0.63 (t, J =






7.2 Hz, 3H)





94


embedded image


5-(2-((R or S)-3- (2-(5- fluorothiophen- 2-yl)ethyl)-3- ((R or S)- isochroman-1- yl)pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine citrate
465

1HNMR (300 MHz, MeOD): δ 8.61 (d, J = 2.1 Hz, 1H), 7.94 (m, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.19-7.08 (m, 4H), 6.31 (d, J = 3.0 Hz, 1H), 6.27 (t, J = 3.6 Hz, 1H), 4.15-4.02 (m, 1H), 3.55- 3.49 (m, 1H), 3.20-3.11 (m,







2H), 3.07-



citrate


3.01 (m, 1H),






2.98-2.88 (m,






2H), 2.87-






2.84 (m, 1H),






2.79 (q, J =






15.6 Hz, 4H),






2.74-2.66 (m,






2H), 2.64-






2.60 (m, 1H),






2.55 (s, 3H),






2.25-2.18 (m,






1H), 1.95-






1.82 (m, 2H),






1.81-1.75 (m,






1H), 1.71 (m,






6H).





95


embedded image


5-(2-((R or S)-3- (2-(5- fluorothiophen- 2-yl)ethyl)-3-((S or R)- isochroman-1- yl)pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine citrate
465

1HNMR (300 MHz, MeOD): δ 8.74 (s, 1H), 8.10 (d, J = 6.0 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.26-7.20 (m, 4H), 6.23- 6.22 (m, 1H), 6.18 (d, J = 2.7 Hz, 1H), 4.15-4.02 (m, 1H), 3.52- 3.49 (m, 2H), 3.15-3.05 (m,







1H), 2.79 (q,



citrate


J = 15.6 Hz,






4H), 2.74 (s,






3H), 2.54-






2.43 (m, 2H),






2.38-2.28 (m,






2H), 2.20-






2.08 (m, 2H),






1.87 (s, 6H),






1.80-1.75 (m,






1H), 1.65-






1.60 (m, 1H),






1.18 (t, J =






6.9 Hz, 3H).





96


embedded image


5-(2-((R or S)-3- ((R or S)- ethoxy(phenyl) methyl)-3-(2-(5- fluorothiophen- 2- yl)ethyl)pyrrolid in-1-yl)butan-2- yl)-2- methylpyridine citrate
481

1HNMR (300 MHz, MeOD): d 8.69 (d, J = 2.1 Hz, 1H), 8.04 (d, J = 8.1 Hz, 1H), 7.52-7.47 (m, 1H), 7.40- 7.34 (m, 3H), 7.26 (d, J = 6.9 Hz, 1H), 7.22 (t, J = 3.9 Hz, 1H), 6.37 (d, J = 3.9 Hz, 1H),







6.28 (m, 1H),



citrate


4.39 (m, 1H),






3.58-3.40 (m,






2H), 3.30-






3.12 (m, 4H),






3.11-2.93 (m,






1H), 2.79 (q,






J = 15.6 Hz,






4H), 2.78-






2.70 (m, 3H),






2.60 (d, J =






6.3 Hz, 3H),






2.28-2.20 (m,






1H), 2.10-






2.00 (m, 1H),






1.83 (m, 3H),






1.75-1.62 (m,






1H), 1.58 (m,






1H), 1.03 (t,






J = 7.2 Hz, 3H),






0.82 (t, J =






6.9 Hz, 3H)





97


embedded image


5-(2-((R or S)-3- ((R or S)- ethoxy(phenyl) methyl)-3-(2-(5- fluorothiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
467

1HNMR (300 MHz, MeOD): δ 8.75 (s, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.40-7.34 (m, 3H), 7.24 (d, J = 6.3 Hz, 2H), 6.37 (s, 1H), 6.29 (t, J = 2.9 Hz, 1H), 4.40 (s, 1H), 3.56-3.50 (m, 1H), 3.49-







3.38 (m, 3H),



citrate


3.28-3.22 (m,






2H), 2.98-






2.90 (m, 2H),






2.79 (q, J =






15.6 Hz, 4H),






2.60 (s, 3H),






2.32-2.21 (m,






1H), 2.08-






1.97 (m, 1H),






1.88 (m, 6H),






1.70-1.52 (m,






2H), 1.03 (t,






J = 6.9 Hz, 3H).





98


embedded image


5-(2-((R or S)-3- ((S or R)- ethoxy(phenyl) methyl)-3-(2-(5- fluorothiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
467

1HNMR (300 MHz, MeOD): δ 8.70 (d, J = 1.8 Hz, 1H), 8.03 (m, 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.35-7.28 (m, 5H), 6.37 (t, J = 3.3 Hz, 1H), 6.30-6.28 (m, 1H), 4.40 (s, 1H), 3.47- 3.40 (m, 2H), 3.25-3.15 (m, 2H), 3.08-







2.90 (m, 2H),



citrate


2.79 (q, J =






15.6 Hz, 4H),






2.75-2.65 (m,






2H), 2.59 (s,






3H), 2.38-






2.30 (m, 1H),






2.15-1.92 (m,






1H), 1.84 (m,






6H), 1.70-






1.62 (m, 1H),






1.58-1.49 (m,






1H), 1.11 (t,






J = 7.2 Hz, 3H).





99


embedded image


1-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-5,6- difluoro-1,3- dihydro-2H- benzo[d]imidazol- 2-one citrate
459

1H NMR (300 MHz, MeOD): δ 8.67 (d, J = 1.8 Hz, 1H), 8.03 (dd, J = 8.3, 2.3 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.11 (t, J = 8.5 Hz, 1H), 7.01 (t, J = 8.5 Hz, 1H), 3.85 (t, J = 7.8 Hz, 2H),







3.46 (m, 3H),



citrate


3.38 (m, 2H),






3.24-3.15 (m,






2H), 3.08 (d,






J = 11.4 Hz,






1H), 2.91 (d,






J = 11.7 Hz,






1H), 2.80 (q,






J = 15.5 Hz,






4H), 2.56 (s,






3H), 1.95-






1.83 (m, 3H),






1.77 (s, 6H),






1.14 (t, J =






7.0 Hz, 3H).





100


embedded image


1-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-5,6- difluoro-3- isobutyl-1,3- dihydro-2H- benzo[d]imidazol- 2-one citrate
515

1H NMR (300 MHz, MeOD): δ 8.68 (s, 1H), 8.04 (d, J = 8.9 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.20 (ddd, J = 16.9, 10.0, 6.9 Hz, 2H), 3.89 (t, J = 7.5 Hz, 2H), 3.67 (d, J = 7.5 Hz, 2H), 3.46 (q, J = 7.0 Hz, 2H),







3.36 (m, 2H),



citrate


3.22 (m, 2H),






3.11 (d, J =






11.5 Hz, 1H),






2.96 (d, J =






11.7 Hz, 1H),






2.80 (q, J =






15.5 Hz, 4H),






2.56 (s, 3H),






2.19-2.08 (m,






1H), 2.01-






1.82 (m, 4H),






1.79 (s, 6H),






1.14 (t, J =






7.0 Hz, 3H),






0.93 (d, J =






4.8 Hz, 6H).





101


embedded image


1-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-3- ethyl-5,6- difluoro-1,3- dihydro-2H- benzo[d]imidazol- 2-one citrate
487

1H NMR (300 MHz, MeOD): δ 8.65 (s, 1H), 8.00 (d, J = 6.2 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.24 (dd, J = 10.1, 6.9 Hz, 1H), 7.15 (dd, J= 10.1, 7.0 Hz, 1H), 3.96- 3.84 (m, 4H), 3.46 (q, J =







6.9 Hz, 3H),



citrate


3.37 (s, 2H),






3.14 (m, 2H),






3.02 (m, 1H),






2.80 (q, J =






15.5 Hz, 4H),






2.55 (s, 3H),






1.97-1.78 (m,






4H), 1.73 (s,






6H), 1.27 (t,






J = 7.1 Hz, 3H),






1.14 (t, J =






7.0 Hz, 3H).





102


embedded image


(S)-4-((3- (ethoxymethyl)- 3-(2-(thiophen-2- yl)ethyl) pyrrolidin-1- yl)methyl)pyridine H3PO4 salt
331

1H NMR (300 MHz, MeOD): δ 8.46 (d, J = 5.2 Hz, 2H), 7.45 (s, 2H), 7.13 (dd, J = 5.2, 1.2 Hz, 1H), 6.87 (dd, J = 5.2, 3.4 Hz, 1H), 6.78 (d, J = 3.4 Hz, 1H), 3.66 (s, 2H), 3.49 (q, J = 7.0 Hz, 2H), 3.34 (d, J = 3.5 Hz, 2H), 2.81 (t, J =







7.8 Hz, 2H),



H3PO4


2.63 (q, J =






7.0 Hz, 2H),






2.56 (d, J =






9.6 Hz, 1H),






2.34 (d, J =






9.6 Hz, 1H),






1.86 (m, 2H),






1.68 (t, J =






6.9 Hz, 2H),






1.18 (t, J =






7.0 Hz, 3H).





103


embedded image


5-(2-((R or S)-3- ((S&R)- ethoxy(pyridin- 2-yl)methyl)-3- (2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine citrate
468

1H NMR (300 MHz, MeOD): δ 8.68 (s, 1H), 8.56 (s, 1H), 8.05 (m, 1H), 7.84 (m, 1H), 7.53-7.31 (m, 3H), 6.43- 6.32 (m, 1H), 6.31-6.22 (m, 1H), 4.47 (m, 1H), 3.79 (d, J = 11.7 Hz, 1H), 3.51 (d, J = 11.5 Hz, 1H), 3.25-




citrate


3.15 (m, 1H),






3.08 (d, J =






11.4 Hz, 1H),






3.02-2.87 (m,






2H), 2.79 (q,






J = 15.5 Hz,






4H), 2.70-






2.63 (m, 1H),






2.58 (s, 3H),






2.42-2.23 (m,






1H), 2.12-






1.89 (m, 1H),






1.82 (s, 6H),






1.79-1.59 (m,






2H), 1.52-






1.36 (m, 1H),






1.18-1.01 (m,






3H).





104


embedded image


5-(2-((R or S)-3- ((S or R)-1- ethoxyethyl)-3- (2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)butan-2- yl)-2- methylpyridine citrate
419

1H NMR (300 MHz, MeOD): δ 8.64 (s, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 6.41 (m, 1H), 6.30 (m, 1H), 3.64-3.57 (m, 1H), 3.50-







3.38 (m, 2H),



citrat


3.26-3.07 (m,






4H), 2.75 (q,






J = 15.6 Hz,






4H), 2.71-






2.61 (m, 2H),






2.57 (s, 3H),






2.53-2.44 (m,






1H), 2.21-






2.11 (m, 1H),






2.07-2.00 (m,






1H), 1.80 (s,






3H), 1.76-






1.57 (m, 3H),






1.13-1.02 (m,






6H), 0.78 (t,






J = 7.2 Hz, 3H)





105


embedded image


5-(2-((R or S)-3- ((R or S)-1- ethoxyethyl)-3- (2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)butan-2- yl)-2- methylpyridine citrate
419

1HNMR (300 MHz, MeOD): δ 8.65 (s, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 6.41 (d, J = 3.9 Hz, 1H), 6.30 (m, 1H), 3.64-3.56 (m,







1H), 3.50-



citrate


3.42 (m, 2H),






3.22-3.08 (m,






2H), 2.77 (q,






J = 15.6 Hz,






4H), 2.68-






2.62 (m, 2H),






2.56 (s, 3H),






2.55-2.47 (m,






2H), 2.07-






2.00 (m, 2H),






1.82 (s, 6H),






1.75-1.69 (m,






1H), 1.08-






0.99 (m, 6H),






0.80 (t, J =






7.2 Hz, 3H)





106


embedded image


(S or R)-4-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) morpholine
432

1HNMR (300 MHz, MeOD): δ 8.53 (d, J = 1.8 Hz, 1H), 7.85 (dd, J = 8.1, 2.1 Hz, 1H), 7.25 (d, J = 8.1 Hz, 1H), 6.38 (t, J = 3.3 Hz, 1H), 6.28 (m, 1H), 3.63 (t, J =







4.5 Hz, 4H),






2.68-2.58 (m,






4H), 2.52 (s,






3H), 2.50-






2.38 (m, 6H),






2.36-2.28 (m,






2H), 1.82-






1.70 (m, 2H),






1.66-1.54 (m,






2H), 1.42 (s,






6H)





107


embedded image


(S or R)-1-ethyl- 3-((3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-1,3- dihydro-2H- benzo[d] imidazol- 2-one citrate
507

1H NMR (300 MHz, MeOD): δ 8.59 (s, 1H), 7.90 (s, 1H), 7.30 (t, J = 5.1 Hz, 1H), 7.17 (d, J = 18.9 Hz, 4H), 6.43 (s, 1H), 6.29 (s, 1H), 3.99 (d, J = 4.0 Hz, 4H), 3.14-3.05 (m, 1H), 2.98 (s, 2H), 2.90- 2.68 (m, 5H),







2.52 (d, J =



citrate


3.3 Hz, 3H),






2.07-1.95 (m,






1H), 1.87-






1.77 (m, 3H),






1.65-1.55 (m,






6H), 1.35-






1.29 (m, 5H).





108


embedded image


(R or S)-5-(2-(3- (2-(4,5- dimethylthiophen- 2-yl)ethyl)-3- (ethoxymethyl) pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine citrate
401

1H NMR (300 MHz, MeOD): δ 8.70 (s, 1H), 8.06 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 8.3 Hz, 1H), 6.43 (s, 1H), 3.43 (q, J = 6.6 Hz, 2H), 3.18 (d, J = 11.8 Hz, 1H), 2.96 (d, J = 11.8 Hz, 1H),







2.80 (q, J =



citrate


15.5 Hz, 4H),






2.70-2.59 (m,






4H), 2.57 (s,






3H), 2.24 (s,






3H), 2.09-






1.91 (m, 5H),






1.90-1.67 (m,






10H), 1.12 (t,






J = 6.9 Hz,






3H).





109


embedded image


(R or S)-N-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) methanesulfonamide citrate
440

1HNMR (300 MHz, MeOD): δ 8.63 (d, J = 1.8 Hz, 1H), 8.00 (dd, J = 8.1, 2.4 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 6.43 (t, J = 3.6 Hz, 1H), 6.29 (dd, J = 3.9, 2.1 Hz,







1H), 3.12-



citrat


3.02 (m, 4H),






3.01-2.95 (m,






1H), 2.94 (s,






3H), 2.77 (q,






J = 15.6 Hz,






4H), 2.72-






2.64 (m, 3H),






2.54 (s, 3H),






1.92-1.75 (m,






4H), 1.74 (s,






6H)





110


embedded image


(R or S)-N-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-4- methylbenzene- sulfonamide citrate
516

1HNMR (300 MHz, MeOD): δ 8.67 (s, 1H), 8.07 (d, J = 8.1 Hz, 1H), 7.72 (d, J = 8.1 Hz, 2H), 7.39 (t, J = 8.4 Hz, 3H), 6.40 (t, J = 3.6 Hz, 1H), 6.27 (dd, J = 3.6, 2.1 Hz, 1H), 3.32-







3.30 (m, 3H),



citrate


3.29-3.18 (m,






2H), 3.15-






3.05 (m, 1H),






2.90-2.80 (m,






3H), 2.75 (q,






J = 15.6 Hz,






4H), 2.65-






2.60 (m, 1H),






2.55 (s, 3H),






2.42 (s, 3H),






1.95-1.82 (m,






2H), 1.72 (s,






6H)





111


embedded image


(S or R)-4- fluoro-N-((3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) benzene- sulfonamide citrate
520

1H NMR (300 MHz, MeOD): δ 8.65 (s, 1H), 8.03 (d, J = 7.9 Hz, 1H), 7.90 (dd, J = 8.7, 4.9 Hz, 2H), 7.49- 7.24 (m, 3H), 6.50-6.37 (m, 1H), 6.35- 6.22 (m, 1H), 3.20-2.99 (m, 3H), 2.95- 2.69 (m, 8H), 2.67-2.50 (m, 5H), 1.87- 1.68 (m, 9H).







citrate








112


embedded image


(S & R)-5-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)oxazolidin-2- one citrate
418

1H NMR (300 MHz, MeOD): δ 8.61 (s, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 6.44 (t, J = 3.4 Hz, 1H), 6.30 (dd, J = 3.7, 2.1 Hz, 1H), 4.88- 4.70 (m, 1H),







3.69-3.42 (m,



citrate


2H), 2.98-






2.61 (m,






10H), 2.54 (s,






3H), 1.97-






1.68 (m, 4H),






1.61 (s, 6H).





113


embedded image


(R or S)-5-(2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-3- (1H-imidazol-2- yl)pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine citrate
399
1H NMR (300 MHz, MeOD): & 8.43 (s, 1H), 7.79 (d, J = 8.3 Hz, 1H), 7.34-7.23 (m, 3H), 6.36- 6.29 (m, 1H), 6.28-6.23 (m, 1H), 3.15 (m, 1H), 3.05- 2.95 (m, 2H), 2.93-2.73 (m, 5H), 2.57-






2.45 (m, 5H),



citrate


2.41-2.29 (m,






1H), 2.24-






2.01 (m, 3H),






1.51 (d, J =






7.7 Hz, 6H).





114


embedded image


(R or S)-5-(2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-3-(1- methyl-1H- imidazol-2- yl)pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine citrate
413

1H NMR (300 MHz, MeOD): δ 8.55 (d, J = 1.9 Hz, 1H), 7.92 (dd, J = 8.3, 2.3 Hz, 1H), 7.32 (d, J = 8.3 Hz, 1H), 7.16 (d, J = 1.3 Hz, 1H), 7.04 (d, J = 1.2 Hz, 1H), 6.33-6.18 (m, 2H), 3.74 (s,







3H), 3.05 (m,



citrate


2H), 2.90-






2.72 (m, 5H),






2.53 (s, 3H),






2.50-2.43 (m,






1H), 2.40-






2.08 (m, 6H),






1.56 (s, 6H).





115


embedded image


(R or S)-5-(2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-3- (4H-1,2,4- triazol-3- yl)pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine
400

1HNMR (300 MHz, MeOD): δ 8.56 (s, 1H), 8.01 (s, 1H), 7.66 (t, J = 4.1 Hz, 1H), 7.12 (d, J = 8.1 Hz, 1H), 6.28-6.19 (m, 1H), 6.18 (d, J = 2.1 Hz, 1H), 3.10-3.00 (m, 1H), 2.99- 2.85 (m, 1H),







2.80-2.68 (m,






1H), 2.66-






2.55 (m, 2H),






2.53 (s, 3H),






2.50-2.42 (m,






1H), 2.40-






2.25 (m, 2H),






2.15-2.05 (m,






1H), 1.98-






1.88 (m, 1H),






1.45 (s, 3H),






1.45 (s, 3H).





116


embedded image


(R or S)-5-(2-(3- ((cyclopropyl- methoxy)methyl)- 3-(2-(5- fluorothiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
417

1H NMR (300 MHz, MeOD): δ 8.73 (s, 1H), 8.09 (dd, J = 8.4, 1.7 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 6.46-6.39 (m, 1H), 6.32- 6.26 (m, 1H), 3.40-3.34 (m, 4H), 3.27- 3.32 (m, 3H),







3.00 (d, J =



citrate


12.2 Hz, 1H),






2.82 (q, J =






15.6 Hz, 4H),






2.66 (t, J =






8.0 Hz, 2H),






2.57 (s, 3H),






2.06-1.99 (m,






1H), 1.93-






1.83 (m, 8H),






1.79 (d, J =






8.3 Hz, 1H),






1.02-0.89 (m,






1H), 0.56-






0.46 (m, 2H),






0.22-0.13 (m,






2H).





117


embedded image


(R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidine-3- carboxamide citrate
376

1H NMR (300 MHz, MeOD): δ 8.61 (s, 1H), 7.98 (d, J = 7.3 Hz, 1H), 7.36 (d, J = 8.5 Hz, 1H), 6.43-6.36 (m, 1H), 6.31- 6.25 (m, 1H), 3.05-2.94 (m,







2H), 2.81 (q,



citrate


J = 15.5 Hz,






4H), 2.68 (m,






1H), 2.62-






2.57 (m, 1H),






2.55 (s, 3H),






2.42-2.28 (m,






1H), 2.16-






2.00 (m, 2H),






1.97-1.72 (m,






3H), 1.64 (s,






6H).





118


embedded image


(R or S,E)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidine-3- carbaldehyde O- methyl oxime citrate
390

1H NMR (500 MHz, MeOD): δ 8.65 (d, J = 2.1 Hz, 1H), 8.03 (d, J = 8.3 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.30 (s, 1H), 6.40 (t, J = 3.6 Hz, 1H), 6.28 (dd, J = 3.9, 2.1 Hz, 1H), 3.78 (s,







3H), 3.36-



citrate


3.32 (m, 1H),






3.24-3.15 (m,






1H), 3.05 (m,






1H), 2.93-






2.88 (m, 1H),






2.81 (q, J =






15.5 Hz, 4H),






2.69-2.57 (m,






2H), 2.56 (s,






3H), 2.24-






2.17 (m, 1H),






1.97-1.89 (m,






2H), 1.89-






1.82 (m, 1H),






1.72 (s, 6H).





119


embedded image


(S or R)-((3-(2- (5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) sulfamoyl amine
441

1HNMR (300 MHz, MeOD): δ 8.51 (s, 1H), 7.87 (dd, J = 5.7, 2.4 Hz, 1H), 7.26 (d, J = 8.1 Hz, 1H), 6.42 (s, 1H), 6.28 (t, J = 3.0 Hz, 1H), 3.04 (s, 2H), 2.78-2.51 (m, 5H), 2.50 (s, 3H), 2.34 (m, 1H), 1.80- 1.71 (m, 3H),







1.68-1.51 (m,






1H), 1.30 (s,






6H)





120


embedded image


(S or R)- ((3-(2- (5-fluoro- thiophen-2- yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)(pyridin-2- yl)methyl) sulfamoyl amine
518

1H NMR (300 MHz, MeOD): δ 8.63 (s, 1H), 8.59-8.51 (m, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.78 (t, J = 7.6 Hz, 1H), 7.48 (dd, J = 22.1, 7.7 Hz, 1H), 7.41- 7.26 (m, 2H), 6.40-6.34 (m, 1H), 6.28 (t, J = 3.1 Hz, 1H), 4.57 (d, J =







15.3 Hz, 1H),



citrate


3.52 (d, J =






10.4 Hz, 1H),






2.96-2.75 (m,






7H), 2.56 (s,






3H), 2.33-






2.28 (m, 1H),






1.85-1.75 (m,






1H), 1.71 (d,






J = 4.1 Hz, 6H),






1.58-1.43 (m,






2H).





121


embedded image


(S or R)- ((3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) sulfamoyl dimethylamine
469

1H NMR (300 MHz, MeOD): δ 8.64 (s, 1H), 8.01 (d, J = 7.5 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 6.43 (s, 1H), 6.29 (s, 1H), 3.11-3.00 (m, 5H), 2.91- 2.61 (m, 14H), 2.55 (s, 3H), 1.95- 1.74 (m, 3H), 1.61 (s, 6H).







citrate








122


embedded image


(R or S)-((3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) sulfamoyl 4- fluorophenylamine citrate
535

1H NMR (300 MHz, MeOD): δ 8.65 (d, J = 2.3 Hz, 1H), 8.04 (dd, J = 8.7, 2.3 Hz, 1H), 7.40 (d, J = 8.2 Hz, 1H), 7.22 (dd, J = 8.9, 4.7 Hz, 2H), 7.04 (t, J = 8.5 Hz, 2H), 6.36 (d, J = 3.6 Hz, 1H), 6.27 (dd, J = 3.9, 2.1 Hz, 1H), 3.18 (t, J = 7.0 Hz, 2H), 3.09 (d, J = 11.6 Hz, 1H), 2.98 (s, 2H),







2.92-2.69 (m,



citrate


5H), 2.63-






2.49 (m, 5H),






1.89-1.79 (m,






2H), 1.75 (s,






6H), 1.71-






1.64 (m, 2H).





123


embedded image


(R or S)-((3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) sulfamoyl 4- methylphenyl amine


1H NMR (300 MHz, MeOD): δ 8.58 (s, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.35 (d, J = 7.9 Hz, 1H), 7.10 (s, 4H), 6.33 (s, 1H), 6.26 (s, 1H), 2.95 (s, 3H), 2.89-2.69 (m, 5H), 2.62- 2.49 (m, 6H), 2.26 (s, 3H), 1.79-1.69 (m, 5H), 1.60 (s, 6H).







citrate








124


embedded image


(R or S)-((3-(2- (5- fluorothiophen- 2-yl)ethyl)-1-(2- (6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) sulfamoyl 2,4- dichloro phenyl amine
531

1H NMR (300 MHz, MeOD): 8.60 (s, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.61 (d, J = 8.8 Hz, 1H), 7.49 (d, J = 2.4 Hz, 1H), 7.33 (dd, J = 19.1, 8.4 Hz, 2H), 6.36 (s, 1H), 6.31- 6.24 (m, 1H), 3.05-2.98 (m, 3H), 2.89- 2.73 (m, 6H), 2.66-2.57 (m, 3H), 2.55 (s, 3H), 1.83- 1.70 (m, 4H),







1.64 (s, 6H).



Exact Mass: 584.12






tPSA: 73.8






CLogP: 6.67








125


embedded image


(S or R)-4- methyl-N-((1- (pyridin-3- ylmethyl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-3- yl)methyl) benzene- sulfonamide citrate
456

1H NMR (300 MHz, MeOD): δ 8.63 (s, 1H), 8.57 (d, J = 4.9 Hz, 1H), 7.99 (d, J = 7.9 Hz, 1H), 7.74 (d, J = 8.0 Hz, 2H), 7.52-7.48 (m, 1H), 7.38 (d, J = 7.9 Hz, 2H), 7.19- 7.11 (m, 1H), 6.88 (dd, J = 5.1, 3.5 Hz, 1H), 6.81 (d, J = 3.4 Hz, 1H), 4.19 (s, 2H), 3.23-3.11 (m, 3H), 2.91 (d,







J = 7.0 Hz, 2H),



citrate


2.88-2.69 (m,






7H), 2.42 (s,






3H), 1.99-






1.81 (m, 4H).





126


embedded image


(S or R)-N-((3- (2-(4,5- dimethylthiophen- 2-yl)ethyl)-1- (2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-4- methylbenzene- sulfonamide citrate
526

1H NMR (300 MHz, MeOD): δ 8.65 (s, 1H), 8.02 (d, J = 8.3 Hz, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.39 (t, J = 6.9 Hz, 3H), 6.41 (s, 1H), 3.22-3. 15 (m, 2H), 3.10- 3.06 (m, 1H), 2.89-2.71 (m, 8H), 2.62- 2.53 (m, 5H), 2.43 (s, 3H), 2.23 (s, 3H), 2.02 (s, 3H),







1.87-1.83 (m,



citrate


1H), 1.77-






1.69 (m, 8H).





127


embedded image


(S or R)-N-((3- (4- fluorophenethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-4- methylbenzene- sulfonamide citrate
510

1H NMR (300 MHz, MeOD): δ 8.65 (s, 1H), 8.02 (d, J = 8.1 Hz, 1H), 7.73 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 8.0 Hz, 3H), 7.20-7.11 (m, 2H), 6.95 (t, J = 8.7 Hz, 2H), 3.15 (t, J = 5.8 Hz, 2H), 3.05 (d, J = 11.0 Hz, 1H), 2.87-2.71 (m, 7H), 2.55 (s, 3H), 2.51- 2.44 (m, 2H), 2.43 (s, 3H), 1.90-1.79 (m,







2H), 1.74 (s,



citrate


6H), 1.70-






1.59 (m, 2H).





128


embedded image


(R or S)-5-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)thieno [3,4-b]pyrazine







129


embedded image


(R or S)-5-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-7- fluorothieno[3,4- b]pyrazine







130


embedded image


1-((R or S)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-3- yl)-3,4- dihydro-1H- pyrano[4,3- c]pyridine







131


embedded image


5-(2-((3R or S)- 3-(6- fluoroisochroman- 1-yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







132


embedded image


5-(2-((3R or S)- 3-((4,5-dihydro- 1H-imidazol-2- yl)(ethoxy) methyl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







133


embedded image


(R or S)-5-(2-(3- (((4,5-dihydro- 1H-imidazol-2- yl)methoxy) methyl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







134


embedded image


5-(2-((S or R)-3- ((S or R)- ethoxy(pyridin- 3-yl)methyl)-3- (2-(thiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







135


embedded image


5-(2-((S or R)-3- ((S or R)- ethoxy(pyridin- 2-yl)methyl)-3- (2-(thiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







136


embedded image


5-(2-((3R or S)-3- (ethoxy(pyridin- 4-yl)methyl)-3- (2-(thiophen-2- yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine







137


embedded image


(R or S)-2-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)thieno [2,3-c]pyridine







138


embedded image


(R or S)-2-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)thieno [3,2-c]pyridine







139


embedded image


(R or S)-6-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)thieno [2,3-b]pyrazine







140


embedded image


(R or S)-5-(2-(3- (2-(4,5- difluorothiophen- 2-yl)ethyl)-3- (ethoxymethyl) pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine







141


embedded image


(R or S)-4-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl) thiophene- 3-carbonitrile







142


embedded image


(R or S)-5-(2-(3- (ethoxymethyl)- 3-(2-(4- fluorothiophen-3- yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine







143


embedded image


(R or S)-5-(2-(3- (ethoxymethyl)- 3-(2-(4- fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







144


embedded image


(R or S)-5-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl) thiophene- 3-carbonitrile







145


embedded image


1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)-3,4-dihydro- 1H-pyrano[4,3- c]pyridine







146


embedded image


5-(2-((3R or S)- 3-(6- fluoroisochroman- 1-yl)-3-(2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine







147


embedded image


5-(2-((3R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-3- (isochroman-1- yl)pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine







148


embedded image


5-(2-((3R or S)- 3-((4,5-dihydro- 1H-imidazol-2- yl)(ethoxy) methyl)-3-(2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







149


embedded image


(R or S)-5-(2-(3- (((4,5-dihydro- 1H-imidazol-2- yl)methoxy) methyl)-3-(2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







150


embedded image


5-(2-((S or R)-3- ((R or S)- ethoxy(pyridin- 3-yl)methyl)-3- (2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







151


embedded image


5-(2-((S or R)-3- ((R or S)- ethoxy(pyridin- 2-yl)methyl)-3- (2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







152


embedded image


5-(2-((S or R)-3- ((R or S)- ethoxy(pyridin- 4-yl)methyl)-3- (2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine







153


embedded image


(S or R)-5-(2-(3- (ethoxymethyl)- 3-((5- fluorothiophen- 2-yl)methyl) pyrrolidin-1- yl)propan-2-yl)- 2-methylpyridine







154


embedded image


5-(2-((3R or S)- 3-(ethoxy(1- methyl-1H- imidazol-2- yl)methyl)-3-(2-(5- fluorothiophen-2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine







155


embedded image


8-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)-5,6-dihydro- 8H-imidazo[2,1- c][1,4]oxazine







156


embedded image


5-(2-((3R or S)- 3-(ethoxy(1H- imidazol-2- yl)methyl)-3-(2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







157


embedded image


7-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)-5H,7H- imidazo[1,2- c]oxazol-5-one







158


embedded image


3-ethyl-5-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)oxazolidin-2- one







159


embedded image


(R or S)-2-(1-(2- (6-methylpyridin- 3-yl)propan-2- yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin- 3-yl)propan- 2-ol







160


embedded image


(R or S)- 1,1,1,3,3,3- hexafluoro-2-(1- (2-(6- methylpyridin- 3-yl)propan-2- yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-3- yl)propan- 2-ol







161


embedded image


(R or S)-5-(2-(3- (1-ethoxy-2,2,2- trifluoroethyl)- 3-(2-(thiophen-2- yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine







162


embedded image


(R or S)-2,2,2- trifluoro-1-(1- (2-(6- methylpyridin- 3-yl)propan-2- yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-3- yl)ethan-1-ol







163


embedded image


(R or S)-1-(1-(2- (6-methylpyridin- 3-yl)propan-2- yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-3- yl)ethane- 1,2-diol







164


embedded image


(R or S)-2- ethoxy-2-(1-(2-(6- methylpyridin- 3-yl)propan-2- yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin- 3-yl)ethan-1-ol







165


embedded image


(R or S)-2- ethoxy-2-(1-(2-(6- methylpyridin- 3-yl)propan-2- yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-3- yl)ethan-1- amine







166


embedded image


(R or S)-5-(2-(3- (1,4-dioxan-2- yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







167


embedded image


(R or S)-2-(1-(2- (6-methylpyridin- 3-yl)propan-2- yl)-3-(2- (thiophen-2- yl)ethyl) pyrrolidin-3- yl)morpholine







168


embedded image


5-(2-((R or S)-3- ((S)-ethoxyfluoro- methyl)-3-(2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







169


embedded image


5-(2-((R or S)-3- ((R)-ethoxyfluoro- methyl)-3-(2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







170


embedded image


(R or S)-5-(2-(3-(1- ethoxycyclopropyl)- 3-(2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







171


embedded image


(R or S)-5-(2-(3-(2- ethoxypropan-2- yl)-3-(2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







172


embedded image


2-ethoxy-2-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)acetonitrile







173


embedded image


(R or S)-2-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methoxy) acetonitrile







174


embedded image


(R or S)-5-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl) thiophene- 2-carbonitrile







175


embedded image


(R or S)-(3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl carbamate







176


embedded image


(R or S)-2-(3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl carbamate







177


embedded image


(R or S)-2-(3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl isopropylcarbamate







178


embedded image


(R or S)-2-(3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl phenylcarbamate







179


embedded image


(R or S)- difluoro(3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl carbamate







180


embedded image


(R or S)- difluoro(3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl isopropylcarbamate







181


embedded image


(R or S)- difluoro(3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl phenylcarbamate







182


embedded image


(R or S)- 1,1,1,3,3,3- hexafluoro-2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl carbamate







183


embedded image


(R or S)- 1,1,1,3,3,3- hexafluoro-2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl isopropylcarbamate







184


embedded image


(R or S)- 1,1,1,3,3,3- hexafluoro-2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl phenylcarbamate







185


embedded image


(S)-1-((R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl carbamate







186


embedded image


(R)-1-((R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl carbamate







187


embedded image


(S)-1-((R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl isopropylcarbamate







188


embedded image


(R)-1-((R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl isopropylcarbamate







189


embedded image


(S)-1-((R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl phenylcarbamate







190


embedded image


(R)-1-((R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl phenylcarbamate







191


embedded image


(S)-fluoro((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl carbamate







192


embedded image


(R)-fluoro((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl carbamate







193


embedded image


(S)-fluoro((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl isopropylcarbamate







194


embedded image


(R)-fluoro((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl isopropylcarbamate







195


embedded image


(S)-fluoro((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl phenylcarbamate







196


embedded image


(R)-fluoro((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl phenylcarbamate







197


embedded image


(R)-2,2,2- or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl carbamate







198


embedded image


(S)-2,2,2- trifluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl carbamate







199


embedded image


(R)-2,2,2- trifluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl isopropylcarbamate







200


embedded image


(S)-2,2,2- trifluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl isopropylcarbamate







201


embedded image


(R)-2,2,2- trifluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl phenylcarbamate







202


embedded image


(S)-2,2,2- trifluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl phenylcarbamate







203


embedded image


1-fluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl carbamate







204


embedded image


1-fluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl isopropylcarbamate







205


embedded image


1-fluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl phenylcarbamate







206


embedded image


1,1,1-trifluoro- 2-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl carbamate







207


embedded image


1,1,1-trifluoro- 2-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl isopropylcarbamate







208


embedded image


1,1,1-trifluoro- 2-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl phenylcarbamate







209


embedded image


1-(1,2,2,2- tetrafluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)urea







210


embedded image


1-isopropyl-3- (1,2,2,2- tetrafluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)urea







211


embedded image


1-phenyl-3- (1,2,2,2- tetrafluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)urea







212


embedded image


isopropyl ((S)- 1-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)carbamate isopropyl ((1S)- 1-(3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3-






yl)ethyl)carbamate







213


embedded image


isopropyl ((R)- 1-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)carbam ate







214


embedded image


isopropyl ((R)- fluoro((R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) carbamate







215


embedded image


isopropyl ((S)- fluoro((R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) carbamate







216


embedded image


isopropyl ((S)- 2,2,2-trifluoro- 1-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)carbamate







217


embedded image


isopropyl ((R)- 2,2,2-trifluoro- 1-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)carbamate







218


embedded image


isopropyl (R or S)-(2-(3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)carbamate







219


embedded image


isopropyl (1,1,1- trifluoro-2-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)carbamate







220


embedded image


isopropyl (R or S)-(difluoro(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) carbamate







221


embedded image


isopropyl (1,2,2,2- tetrafluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)carbamate







222


embedded image


isopropyl (R or S)-(1,1,1,3,3,3- hexafluoro-2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)carbamate







223


embedded image


phenyl ((R)-1- ((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)carbamate







224


embedded image


phenyl ((S)-1- ((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)carbamate







225


embedded image


phenyl ((R)- fluoro((R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) carbamate







226


embedded image


phenyl ((S)- fluoro((R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) carbamate







227


embedded image


phenyl ((S)- 2,2,2-trifluoro- 1-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)carbamate







228


embedded image


phenyl ((R)- 2,2,2-trifluoro- 1-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl) carbamate







229


embedded image


phenyl (R or S)- (2-(3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)carbamate







230


embedded image


phenyl (1- fluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)carbamate







231


embedded image


phenyl (1,1,1- trifluoro-2-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)carbamate







232


embedded image


phenyl (R or S)- (difluoro(3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) carbamate







233


embedded image


phenyl (1,2,2,2- tetrafluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl) carbamate







234


embedded image


phenyl (R or S)- (1,1,1,3,3,3- hexafluoro-2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)carbamate







235


embedded image


(R or S)-1-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) guanidine citrate
404
1H NMR (300 MHz, MeOD): δ 8.78 (s, 1H), 8.27 (d, J = 6.6 Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 6.46 (s, 1H), 6.32 (s, 1H), 3.11-2.99 (m, 2H), 2.94- 2.76 (m, 7H), 2.71-2.55 (m, 5H), 2.05-






1.90 (m, 2H),






1.88-1.72 (m,






9H).





236


embedded image


(S or R)-1-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)urea







237


embedded image


1-((R)-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)urea







238


embedded image


1-((S)-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)urea







239


embedded image


1-((R)-fluoro((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)urea







240


embedded image


1-((S)-fluoro((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)urea







241


embedded image


1-((S)-2,2,2- trifluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)urea







242


embedded image


1-((R)-2,2,2- trifluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)urea







243


embedded image


(R or S)-1-(2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)urea







244


embedded image


1-(1-fluoro-1- ((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)urea







245


embedded image


1-(1,1,1- trifluoro-2-((Ror S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)urea







246


embedded image


(R or S)-1- (difluoro(3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)urea







247


embedded image


(R or S)-1- (1,1,1,3,3,3- hexafluoro-2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)urea







248


embedded image


1-((R)-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-3- isopropylurea







249


embedded image


1-((S)-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-3- isopropylurea







250


embedded image


1-((R)-fluoro((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-3- isopropylurea







251


embedded image


1-((S)-fluoro((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-3- isopropylurea







252


embedded image


1-isopropyl-3- ((S)-2,2,2- trifluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)urea







253


embedded image


1-isopropyl-3- ((R)-2,2,2- trifluoro-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)urea







254


embedded image


(R or S)-1-(2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl)- 3-isopropylurea







255


embedded image


1-(1-fluoro-1- ((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-3- isopropylurea







256


embedded image


1-isopropyl-3- (1,1,1-trifluoro- 2-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)urea







257


embedded image


(R or S)-1- (difluoro(3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-3- isopropylurea







258


embedded image


(R or S)-1- (1,1,1,3,3,3- hexafluoro-2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl)- 3-isopropylurea







259


embedded image


1-((R)-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-3- phenylurea







260


embedded image


1-((S)-1-((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-3- phenylurea







261


embedded image


1-((R)-fluoro((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-3- phenylurea







262


embedded image


1-((S)-fluoro((R or S)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-3- phenylurea







263


embedded image


1-phenyl-3-((S)- 2,2,2-trifluoro- 1-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)urea







264


embedded image


1-phenyl-3-((R)- 2,2,2-trifluoro- 1-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)urea







265


embedded image


(R or S)-1-(2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl)- 3-phenylurea







266


embedded image


1-(1-fluoro-1- ((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-3- phenylurea







267


embedded image


1-phenyl-3- (1,1,1-trifluoro- 2-((R or S)-3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)urea







268


embedded image


(R or S)-1- (difluoro(3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-3- phenylurea







269


embedded image


(R or S)-1- (1,1,1,3,3,3- hexafluoro-2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl)- 3-phenylurea







270


embedded image


(R or S)-1-(4- fluorophenyl)-3- ((3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)guani dine citrate
498
1H NMR (300 MHz, MeOD): δ 8.76 (s, 1H), 8.21 (s, 1H), 7.47 (d, J = 8.3 Hz, 1H), 7.32 (dd, J = 8.8, 4.5 Hz, 2H), 7.21 (t, J = 8.5 Hz, 2H), 6.47 (s, 1H), 6.35-6.27 (m, 1H), 3.48- 3.41 (m, 2H), 2.94-2.74 (m, 7H), 2.72- 2.64 (m, 2H), 2.58 (s, 3H), 2.10-1.91 (m,






2H), 1.83-






1.74 (m, 9H).





271


embedded image


(R or S)-5-(2-(3- (ethoxydifluoro methyl)-3-(2-(5- fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







272


embedded image


(R or S)-4-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-1H- thieno[3,4- d]imidazol- 2(3H)-one







273


embedded image


(R or S)-4-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-1H- thieno[3,4- d]imidazole







274


embedded image


(R or S)-4-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-1- methyl-1H- thieno[3,4- d]imidazole







275


embedded image


(R or S)-5-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-1H- thieno[2,3- d]imidazole







276


embedded image


(R or S)-5-(2-(3- (ethoxymethyl)- 1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-1- methyl-1H- thieno[2,3- d]imidazole







277


embedded image


(S)-4-((R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)-3,4- dihydroquinazolin- 2(1H)-one







278


embedded image


(R)-4-((R or S)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)-3,4- dihydroquinazolin- 2(1H)-one







279


embedded image


(R or S)-5-(2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-3-(4- methyl-4H- 1,2,4-triazol-3- yl)pyrrolidin-1- yl)propan-2-yl)- 2- methylpyridine







280


embedded image


(S or R)-5-(2-(3- (5-(4- fluorophenyl)- 1H-imidazol-2- yl)-3-(2-(5- fluorothiophen- 2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine citrate
493

1H NMR (300 MHz, MeOD): δ 8.62 (s, 1H), 7.99 (dd, J = 8.4, 2.3 Hz, 1H), 7.70 (dd, J= 8.5, 5.3 Hz, 2H), 7.46- 7.31 (m, 2H), 7.14 (t, J = 8.8 Hz, 2H), 6.31 (t, J = 3.6 Hz, 1H), 6.22 (dd, J = 3.9, 2.1 Hz, 1H), 3.72 (d,







J = 11.1 Hz,






1H), 3.41-






3.28 (m, 1H),






3.21 (d, J =






10.9 Hz, 2H),






2.92-2.73 (m,






4H), 2.68-






2.59 (m, 1H),






2.48 (s, 4H),






2.41- 2.27 (m,






1H), 2.22 (m,






3H), 1.74 (d,






J = 5.0 Hz, 6H).





281


embedded image


(S or R)-6- fluoro-2-(3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)-1H- benzo[d] imidazole citrate
467

1H NMR (300 MHz, MeOD): δ 8.62 (s, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.51 (dd, J = 8.7, 4.6 Hz, 1H), 7.27 (dd, J = 22.7, 8.5 Hz, 2H), 7.04 (s, 1H), 6.27 (s, 1H), 6.19 (s, 1H), 3.73 (d, J = 10.0 Hz, 1H), 3.39- 3.33 (m, 1H), 3.25-3.10 (m,







2H), 2.93-






2.74 (m, 6H),






2.48 (s, 3H),






2.35-2.11 (m,






4H), 1.72 (d,






J = 6.7 Hz, 6H).





282


embedded image


(S or R)-5-(2-(3- (5-(tert-butyl)- 1H-imidazol-2- yl)-3-(2-(5- fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine citrate
455

1H NMR (300 MHz, MeOD): δ 8.45 (s, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H), 7.06 (s, 1H), 6.30 (s, 1H), 6.24 (s, 1H), 3.11 (d, J = 9.3 Hz, 1H), 3.05-2.96 (m, 2H), 2.93- 2.74 (m, 4H),







2.65-2.43 (m,








embedded image




6H), 2.36-









2.25 (m, 1H),






2.22-2.11 (m,






2H), 1.99 (s,






1H), 1.50 (d,






J = 6.2 Hz, 6H),






1.34 (s, 9H).





283


embedded image


5-(2-((R or S)-3- ((R)-6,7- difluoroisochroman- 1-yl)-3-(2-(5- fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







284


embedded image


5-(2-((R or S)-3- ((R)-6,7- difluoroisochro man-3-yl)-3-(2- (5-fluorothiophen- 2-yl)ethyl) pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine







285


embedded image


(R or S)-5-(2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-3- (isobutoxymethyl) pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine







286


embedded image


(S or R)-1-(4- fluorophenyl)-3- ((3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2-(6- methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)urea







287


embedded image


(S or R)-1-(4- chlorophenyl)- 3-((3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)urea







288


embedded image


(S or R)-1-(3,4- difluorophenyl)- 3-((3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)urea







289


embedded image


(S or R)-1-(5- fluoropyridin-2- yl)-3-((3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)urea







290


embedded image


5-(2-((R or S)-3- (ethoxy(pyridin- 3-yl)methyl)-3- (2-(5- fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)butan-2- yl)-2- methylpyridine







291


embedded image


(S or R)-5-(2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-3- (piperidin-1- ylmethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







292


embedded image


(S or R)-1-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) piperazine







293


embedded image


(S or R)-1-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-4- isopropylpiperazine







294


embedded image


(R or S)-1-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) piperidin-2-one







295


embedded image


(R or S)-4-(2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)morpholine







296


embedded image


(S or R)-1-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl)-3,3- dimethylpiperazine







297


embedded image


5-(2-(3- (ethoxymethyl)- 3-(2-(5- fluorothiophen- 2-yl)-2- methylpropyl) pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine







298


embedded image


5-(2-(3-(2,2- difluoro-2-(5- fluorothiophen- 2-yl)ethyl)-3- (ethoxymethyl) pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine







299


embedded image


5-(2-(3- (ethoxymethyl)- 3-(2-(5- fluorothiophen-2- yl)propyl) pyrrolidin-1- yl)propan-2-yl)- 2-methylpyridine















300


embedded image


5-(2-(3- (ethoxymethyl)- 3-(2-fluoro-2- (5-fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine






301


embedded image


5-(2-(3- (ethoxymethyl)- 4,4-difluoro-3- (2-(5- fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine






302


embedded image


5-(2-(3- (ethoxymethyl)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-4,4- dimethylpyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine






303


embedded image


5-(2-(3- (ethoxymethyl)- 4-fluoro-3-(2- (5-fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine















304


embedded image


5-(2-(3- (ethoxymethyl)- 3-(2-(5- fluorothiophen- 2-yl)ethyl)-4- methylpyrrolidin- 1-yl)propan-2- yl)-2- methylpyridine







305


embedded image


5-(2-(4- (ethoxymethyl)- 4-(2-(5- fluorothiophen- 2-yl)ethyl)-2,2- dimethylpyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine







306


embedded image


5-(2-(4- (ethoxymethyl)- 2,2-difluoro-4- (2-(5- fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







307


embedded image


5-(2-(4- (ethoxymethyl)- 4-(2-(5- fluorothiophen- 2-yl)ethyl)-2- methylpyrrolidin- 1-yl)propan-2- yl)-2- methylpyridine







308


embedded image


5-(2-(4- (ethoxymethyl)- 2-fluoro-4-(2- (5-fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







309


embedded image


(S or R)-5-(2-(3- (2,2- difluorobutyl)- 3-(2-(5- fluorothiophen-2- yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







310


embedded image


(R or S)-5-(2-(3- ((1,1- difluoroethoxy) methyl)-3-(2-(5- fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







311


embedded image


(R or S)-5-(2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-3- ((1,1,2,2- tetrafluoroethox y)methyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







312


embedded image


5-(1-((R or S)-3- (ethoxymethyl)- 3-(2-(5- fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)-1- fluoroethyl)-2- methylpyridine







313


embedded image


(S or R)-N-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) methane- sulfonamide citrate
440

1H NMR (300 MHz, MeOD): & 8.67 (s, 1H), 8.06 (d, J = 8.1 Hz, 1H), 7.41 (d, J = 8.2 Hz, 1H), 6.44 (t, J = 3.6 Hz, 1H), 6.29 (dd, J = 3.9, 2.1 Hz, 1H), 3.26- 3.17 (m, 2H),







3.15-3.06 (m,






3H), 2.94 (s,






3H), 2.90-






2.72 (m, 6H),






2.71-2.64 (m,






2H), 2.56 (s,






3H), 1.92-






1.83 (m, 2H),






1.78 (s, 6H),






1.75-1.72 (m,






1H).





314


embedded image


(S or R)-4- fluoro-N-((3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) benzene- sulfonamide







315


embedded image


(S or R)-5-(2-(3- (2-(5- fluorothiophen- 2-yl)ethyl)-3- ((2,2,2- trifluoroethoxy) methyl) pyrrolidin-1- yl)propan-2- yl)-2- methylpyridine







316


embedded image


(S or R)-N-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) propane-2- sulfonamide







317


embedded image


(S or R)-2-(3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- amine







318


embedded image


(S or R)-N-(2- (3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl) methane- sulfonamide







319


embedded image


N-((R & S)-((S or R)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)(pyridin-2- yl)methyl) methane- sulfonamide citrate
517

1H NMR (300 MHz, MeOD): δ 8.58 (d, J = 7.5 Hz, 2H), 7.96 (d, J = 8.4 Hz, 1H), 7.82 (t, J = 7.9 Hz, 1H), 7.53 (d, J = 7.7 Hz, 1H), 7.37 (d, J = 7.8 Hz, 2H), 6.39 (s, 1H), 6.28 (s, 1H), 4.64 (s, 1H), 3.50 (m, 1H),







2.88-2.72 (m,






8H), 2.70-






2.62 (m, 1H),






2.56-2.52 (m,






6H), 2.32-






2.18 (m, 1H),






1.93-1.90 (m,






1H), 1.87-






1.50 (m, 8H).





320


embedded image


(S or R)-N-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) propane-2- sulfonamide citrate
468

1H NMR (300 MHz, MeOD): δ 8.64 (s, 1H), 8.00 (d, J = 8.2 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 6.44 (s, 1H), 6.30 (d, J = 3.0 Hz, 1H), 3.34 (s, 3H), 3.15-3.03 (m, 4H), 2.80 (q, J = 15.5 Hz, 4H), 2.70- 2.63 (m, 3H),







2.55 (s, 3H),






1.85-1.75 (m,






3H), 1.72 (s,






6H), 1.33 (d,






J = 6.7 Hz, 6H).





321


embedded image


N-((R & S)-((S or R)-3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)(pyridin-2- yl)methyl)-4- methylbenzene- sulfonamide citrate
593

1H NMR (300 MHz, MeOD): δ 8.61 (s, 1H), 8.40-8.28 (m, 1H), 8.09- 7.81 (m, 1H), 7.41 (q, J = 7.9, 7.1 Hz, 4H), 7.14- 7.08 (m, 1H), 6.98 (dd, J = 34.6, 8.0 Hz, 3H), 6.37 (s, 1H), 6.27 (t, J = 3.1 Hz, 1H), 4.41 (s, 1H), 3.55 (m, 1H), 3.08-2.67 (m, 1H), 2.88-







2.72 (m, 8H),






2.55 (d, J =






7.2 Hz, 3H),






2.27 (m, 3H),






2.22-2.17 (m,






1H), 1.93-






1.60 (m, 9H).





322


embedded image


(S or R)-((3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) sulfamic acid citrate
442

1H NMR (300 MHz, MeOD): δ 8.70 (s, 1H), 8.11 (d, J = 4.8 Hz, 1H), 8.46 (d, J = 8.1 Hz, 1H), 6.45 (s, 1H), 6.30 (s, 1H), 3.60-3.54 (m, 2H), 3.11- 3.03 (m, 2H), 2.88-2.81 (m, 6H), 2.79-







2.62 (m, 2H),






2.58 (s, 3H),






2.15-1.93 (m,






2H), 1.87 (s,






6H), 1.76 (d,






J = 8.4 Hz, 2H).





323


embedded image


(S or R)-N-(2- (3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)acetamide







324


embedded image


(S or R)-N-(2- (3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2- yl)benzene- sulfonamide







325


embedded image


(R or S)-1-((3- (2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) guanidine







326


embedded image


(R or S)-1-(4- fluorophenyl)-3- ((3-(2-(5- fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) guanidine







327


embedded image


(R or S)-2-(3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)propan-2-yl sulfamoylamine







328


embedded image


(R or S)-((3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) sulfamoyl propan-2- yl-amine







329


embedded image


(R or S)-((3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)methyl) sulfamoyl 4- fluorophenylamine







330


embedded image


(S or R)-5-(2-(3- (1-(tert-butyl)- 1H-imidazol-2- yl)-3-(2-(5- fluorothiophen- 2-yl)ethyl) pyrrolidin-1- yl)propan- 2-yl)-2- methylpyridine







331


embedded image


(S or R)-5-(2-(3- (5-(tert-butyl)- 1H-imidazol-2- yl)-3-(2-(5- fluorothiophen- 2- yl)ethyl)pyrrolidin- 1-yl)propan- 2-yl)-2- methylpyridine







332


embedded image


(S or R)-6- fluoro-2-(3-(2- (5-fluorothiophen- 2-yl)ethyl)-1-(2- (6-methylpyridin- 3-yl)propan-2- yl)pyrrolidin-3- yl)-1H- benzo[d]imidazole






text missing or illegible when filed indicates data missing or illegible when filed







Legend for Tables I, III, V; 4th & 5th Columns: Electrospray ionization (ESI) was used in mass spectrometry for the compounds with a measured mass result shown in the fourth column. The right-most (fifth) column shows the H NMR of such compounds in MeOD at 300 MHZ.









TABLE II







Chirality and in vivo testing of certain compounds of Table I













ED50 (mg/kg)



Compound

at 30 min on C57BL/6 mice



No.
Configuration
in Warm-water Tail-flick Test















1
S
++



2
S
++



3
S
++



4
S
++



5
(S&R, S)
++



6
S
++



7
S
++



8
S
++



9
S
++



10
(S, S or R)
++



11
(S, S or R)
++



12
(S, S or R)
++



13
(S, S or R)
++



14
S
++



15
S
++



16
S
++



17
S
+



18
S
++



19
S
++



20
S
++



21
S
++



22
S
++



23
S
++



24
S
++



25
S
++



26
S
++



27
S
++



28
S
++



29
(S&R)
++



30
S
++



31
S
++



32
S
++



33
S
++



34
(R&S, S)
++



35
(S or R, S)
++



36
S
++



37
(S or R, S)
++



38
S
++



39
S
++



40
S
++



41
S
++



42
S
++



43
S
++



44
R
++



45
R
+



82
S
++



83
S
++



84
S
++



85
S
++



86
(S, R&S)
++



87
(S, S or R)
++



88
(S, S or R)
++



89
(S, S or R)
++



90
(S, R&S)
++



91
(R&S)
++



92
(R&S)
++



93
S
++



94
(S, S or R)
++



95
(S, S or R)
++



96
(S, S or R)
++



97
(S, S or R)
++



98
(S, S or R)
++



99
(R&S)
++



100
(R&S)
++



101
(R&S)
++



102
S
+



103
(S, R&S)
++



104
(S, S or R)
++



105
(S, S or R)
++



106
S
++



107
S
++



108
S
++



109
S
++



110
S
+



111
S
++



112
(R&S, S)
++



113
S
++



114
S
++



115
S
++



116
S
++



117
S
++



118
S
++



119
S
++



120
S
++



121
S
++



122
R
++



123
R
++



124
R
+



125
S
+



126
S
++



127
S
++



235
R
+



270
R
+



280
S
++



281
S
++



282
S
++



313
S
++



319
(R&S, S)
++



320
S
++



321
(R&S, S)
++



322
S
++










Legend for Table II, Middle Column:





    • “S” means the S enantiomer was tested with the result shown in the right-most column.

    • “R” means the R enantiomer was tested with the result shown in the right-most column.

    • “R&S” means the racemate was tested.

    • “S, S or R” means the compound has two chiral centers and can possibly have four diastereomers. The compound with S at the 1st chiral center and S or R at the 2nd chiral center was tested.

    • “R, R&S” means the compound has two chiral centers and can possibly have four diastereomers. The compound with R at the 1st chiral center and the racemate at the 2nd chiral center was tested.

    • “S, R&S” means the compound has two chiral centers and can possibly have four diastereomers. The compound with S at the 1st chiral center and the racemate at the 2nd chiral center was tested.





Right-Most Column in Table II:

Shows results from an antinociception and warm-water tail-flick test, using male C57BL/6 mice (20-30 g; 6-12 wks), maintained on a 12-h light/dark cycle with rodent chow and water available ad libitum, and housed separately until testing. Antinociception was assessed using the 55° C. warm-water tail-flick test. The latency to the first sign of a rapid tail flick was taken as the behavioral endpoint. Each mouse was first tested for baseline latency by immersing its tail in the water and recording the time to response. Mice not responding within 2 secs were excluded from further testing. Responsive mice were then s.c. administered the test compound and tested for antinociception at 30 min, 60 min, 90 min, and 120 min time points afterward. Antinociception was calculated using the following formula: percentage of antinociception=100×(test latency−control latency)/(20−control latency). To avoid tissue damage, a maximum score was assigned (100%) to animals that failed to respond within 20 secs.









TABLE III







New Compounds with a pyrrolidine ring and a non-pyridine-like molecule bonded to the pyrrolidine N-constituent











Compound


MS



No.
Structure
Name
(ESI+): [M + H]+
H-NMR














1


embedded image


(R or S)-3-(ethoxymethyl)-3- (2-(5-methylthiophen- 2-yl)ethyl)-1-(2-(p-tolyl)propan- 2-yl)pyrrolidine
386

1H NMR (300 MHz, CDCl3): δ 7.39-7.28 (m, 2H), 7.03 (d, J = 8.0 Hz, 2H), 6.46 (s, 2H), 3.43-3.36 (m, 2H), 3.19 (q, J = 8.8 Hz, 2H), 2.62 (t, J = 8.4 Hz, 2H), 2.49 (dd, J = 11.1, 6.9 Hz, 2H), 2.39 (d, J = 9.0 Hz, 1H), 2.35 (s, 3H), 2.25 (d, J = 9.1 Hz, 1H), 1.78-1.67 (m, 2H), 1.47 (t, J = 6.8 Hz,







2H), 1.33 (t, J = 7.2






Hz, 3H), 1.28 (s, 6H),






1.09 (t, J = 7.2 Hz, 3H).





2


embedded image


(S)-1-(4-bromobenzyl)-3- (ethoxymethyl)-3- phenethylpyrrolidine
402

1H NMR (300 MHz, MeOD): δ 7.53 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.30- 7.21 (m, 2H), 7.19-7.10 (m, 3H), 3.86-3.77 (m, 2H), 3.51 (q, J = 7.2 Hz, 2H), 3.37 (s, 2H), 2.91-2.77 (m, 3H), 2.60-2.51 (m, 3H), 1.86-1.71 (m, 4H), 1.21 (t, J = 6.9 Hz, 3H).






3


embedded image


(S)-1-(2-(4-bromophenyl) propan-2-yl)-3-(ethoxymethyl)- 3-phenethylpyrrolidine citrate
430

1H NMR (300 MHz, MeOD): δ 7.68-7.59 (m, 4H), 7.27-7.22 (m, 2H), 7.17-7.12 (m, 3H), 3.52 (q, J = 8.4 Hz, 2H), 3.42-3.39 (m, 3H), 3.25-3.14 (m, 2H), 2.97-2.88 (m, 1H), 2.85-2.69 (m, 4H), 2.55-2.49 (m, 2H), 2.04-1.81 (m, 2H), 1.78 (s, 6H), 1.18 (t, J = 6.9 Hz, 3H).






4


embedded image


(R)-1-(4-bromobenzyl)-3- (ethoxymethyl)-3- phenethylpyrrolidine
402

1H NMR (300 MHz, MeOD): δ 7.43 (d, J = 8.1 Hz, 2H), 7.33-7.25 (m, 2H), 7.22-7.14 (m, 5H), 3.52-3.43 (m, 4H), 3.35-3.25 (m, 2H), 2.62-2.57 (m, 5H), 2.28 (d, J = 9.6 Hz, 1H), 1.81-1.68 (m, 2H), 1.69-1.61 (m, 2H), 1.18 (t, J = 6.9 Hz, 3H).






5


embedded image


(R)-1-(2-(4-bromophenyl) propan-2-yl)-3-(ethoxymethyl)- 3-phenethylpyrrolidine
430

1H NMR (300 MHz, MeOD): δ 7.41-7.36 (m, 4H), 7.28-7.22 (m, 2H), 7.18-7.11 (m, 3H), 3.48 (q, J = 6.9 Hz, 2H), 3.33-3.25 (m, 2H), 2.62-2.52 (m, 4H), 2.48 (d, J = 9.0 Hz, 1H), 2.31 (d, J = 9.0 Hz, 1H), 1.82-1.65 (m, 2H), 1.68-1.51 (m, 2H), 1.33 (s, 6H), 1.18 (t, J = 6.9 Hz, 3H).






6


embedded image


(S)-1-(4-chlorobenzyl)-3- (ethoxymethyl)-3- phenethylpyrrolidine
358

1H NMR (300 MHz, MeOD): δ 7.34-7.31 (m, 4H), 7.25-7.21 (m, 2H), 7.16-7.12 (m, 3H), 3.52 (s, 2H), 3.48 (q, J = 6.9 Hz, 2H), 3.33- 3.30 (m, 2H), 2.65-2.59 (m, 3H), 2.58-2.51 (m, 2H), 2.33-2.30 (m, 1H), 1.78-1.64 (m, 4H), 1.18 (t, J = 6.9 Hz, 3H).






7


embedded image


(R or S)-3-(ethoxymethyl)-1- (4-fluorobenzyl)-3-(4- fluorophenethyl)pyrrolidine







8


embedded image


(R or S)-1-(4-chlorobenzyl)-3- (ethoxymethyl)-3-(4- fluorophenethyl) pyrrolidine citrate
376

1H NMR (300 MHz, MeOD): δ 7.50 (s, 4H), 7.20 (t, J = 6.8 Hz, 2H), 6.98 (t, J = 8.6 Hz, 2H), 4.50-4.20 (m, 2H), 3.64-3.51 (m, 3H), 3.49-3.39 (m, 4H), 3.21-3.08 (m, 1H), 2.81 (q, J = 15.6 Hz, 4H), 2.65-2.51 (m, 2H), 2.17-1.96 (m, 2H), 1.92-1.74 (m, 2H), 1.21 (t, J = 6.9 Hz, 3H).






9


embedded image


(R or S)-(1-(4-chlorobenzyl)-3- (4-fluorophenethyl) pyrrolidin-3-yl)methanol citrate
348

1H NMR (300 MHz, MeOD): δ 7.50 (s, 4H), 7.21 (dd, J = 8.4, 5.4 Hz, 2H), 6.98 (t, J = 8.6 Hz, 2H), 4.86-4.68 (m, 2H), 4.44-4.23 (m, 2H), 3.60-3.53 (m, 2H), 2.92-2.72 (m, 6H), 2.59 (t, J = 8.4 Hz, 2H), 2.13-1.99 (m, 2H), 1.87-1.72 (m, 2H).






10


embedded image


(S or R)-1-(4-chlorobenzyl)-3- (ethoxymethyl)-3-(4- fluorophenethyl) pyrrolidine citrate
376

1H NMR (300 MHz, MeOD): δ 7.50 (s, 4H), 7.20 (dd, J = 8.3, 5.4 Hz, 2H), 6.98 (t, J = 8.6 Hz, 2H), 4.36 (q, J = 12.9 Hz, 2H), 3.56 (dd, J = 7.2, 2.2 Hz, 2H), 3.45 (s, 2H), 3.35 (s, 3H), 3.14 (d, J = 11.9 Hz, 1H), 2.94-2.71 (m, 4H), 2.59 (s, 2H), 2.05 (s, 2H), 1.83 (q, J = 8.5 Hz, 2H), 1.22 (t, J = 7.0 Hz 3H).






11


embedded image


(S)-2-(2-(1-(2-(4-bromophenyl) propan-2-yl)-3-(ethoxymethyl) pyrrolidin-3-yl)ethyl)pyridine
431

1H NMR (300 MHz, MeOD): δ 8.43 (d, J = 4.2 Hz, 1H), 7.79-7.73 (m, 1H), 7.68-7.59 (m, 4H), 7.31-7.24 (m, 2H), 3.45 (q, J = 6.9 Hz, 2H), 3.40-3.32 (m, 3H), 3.19-3.13 (m, 1H), 2.98-2.95 (m, 1H), 2.70 (t, J = 8.1 Hz, 2H), 2.03-1.95 (m, 1H), 1.83-1.74 (m, 10H), 1.14 (t, J = 6.9 Hz, 3H).






12


embedded image


(R)-2-(2-(1-(2-(4-bromophenyl) propan-2-yl)-3-(ethoxymethyl) pyrrolidin-3-yl)ethyl)pyridine
431

1H NMR (300 MHz, MeOD): δ 8.43 (d, J = 4.2 Hz, 1H), 7.79-7.73 (m, 1H), 7.68-7.60 (m, 4H), 7.31-7.24 (m, 2H), 3.45 (q, J = 6.9 Hz, 2H), 3.36-3.32 (m, 3H), 3.19-3.13 (m, 1H), 2.98-2.91 (m, 1H), 2.70 (t, J = 8.1 Hz, 2H), 2.03-1.95 (m, 1H), 1.83-1.74 (m, 10H), 1.14 (t, J = 6.9 Hz, 3H).






13


embedded image


(S)-1-(2-(4-chlorophenyl) propan-2-yl)-3- (ethoxymethyl)-3- phenethylpyrrolidine citrate
386

1H NMR (300 MHz, MeOD): δ 7.50 (d, J = 2.1 Hz, 2H), 7.28-7.20 (m, 4H), 7.13-7.10 (m, 3H), 3.49 (q, J = 6.9 Hz, 2H), 3.32-3.31 (m, 2H), 2.62-2.59 (m, 2H), 2.53-2.47 (m, 3H), 2.29 (d, J = 9 Hz, 1H), 1.69- 1.60 (m, 4H), 1.38 (s, 6H), 1.14 (t, J = 6.9 Hz, 3H).






14


embedded image


(R)-1-(2-(4-chlorophenyl) propan-2-yl)-3-(ethoxymethyl)- 3-phenethylpyrrolidine
386

1H NMR (300 MHz, MeOD): δ 7.65 (d, J = 8.7 Hz, 2H), 7.44 (d, J = 8.7 Hz, 2H), 7.23- 7.21 (m, 2H), 7.15-7.13 (m, 3H), 3.49 (q, J = 6.9 Hz, 2H), 3.34-3.30 (m, 4H), 3.14-3.09 (m, 2H), 2.98 (d, J = 10.5 Hz, 1H), 2.75 (d, J = 11.1 Hz, 1H), 2.54 (t, J = 8.4 Hz, 2H), 1.90-1.74 (m, 2H), 1.68 (s, 6H), 1.17 (t, J = 6.9 Hz, 3H).






15


embedded image


(S or R)-1-(2-(2-chlorophenyl) propan-2-yl)-3-phenethyl-3- ((S&R)-tetrahydrofuran- 2-yl)pyrrolidine
398

1H NMR (300 MHz, MeOD): δ 7.72-7.68 (m, 1H), 7.68-7.58 (m, 1H), 7.49-7.47 (m, 2H), 7.27-7.16 (m, 5H), 4.01-3.96 (m, 2H), 3.80 (m, 1H), 3.45-3.34 (m, 3H), 3.08-3.04 (m, 1H), 2.80 (q, J = 15.3 Hz, 4H), 2.69-2.63 (m, 2H), 2.28 (t, J = 8.4 Hz, 2H), 2.02 (m, 3H), 2.00 (d, J = 8.7 Hz, 6H), 1.96- 1.83 (m, 2H), 1.76-1.51 (m, 1H).






16


embedded image


4-(2-((S or R)-3-phenethyl- 3-((S&R)-tetrahydrofuran- 2-yl)pyrrolidin-1-yl)propan- 2-yl)-1H-pyrazole citrate
354

1H NMR (300 MHz, MeOD): δ 7.98 (s, 1H), 7.93 (s, 1H), 7.25-7.03 (m, 5H), 3.93-3.85 (m, 2H), 3.59-3.49 (m, 3H), 3.16-3.10 (m, 2H), 2.80 (q, J = 15.3 Hz, 4H), 2.75 (m, 1H), 2.63-2.60 (m, 1H), 2.16-0.98 (m, 5H), 1.70 (s, 6H), 1.60 (m, 1H), 1.54-1.29 (m, 2H).






17


embedded image


(S or R)-1-(2-(4-(furan-2- yl)phenyl)propan-2-yl)-3- phenethyl-3-((S&R)-tetra- hydrofuran-2-yl) pyrrolidine
431

1H NMR (300 MHz, MeOD): δ 7.84-7.61 (m, 5H), 7.30-7.00 (m, 5H), 6.89 (d, J = 3.3 Hz, 1H), 6.56 (d, J = 4.5 Hz, 1H), 4.93 (br s, 1H), 3.45-3.31 (m, 2H), 2.80 (q, J = 15.3 Hz, 4H), 2.68-2.45 (m, 2H), 2.30-1.95 (m, 4H), 1.88 (s, 6H), 1.86-1.60 (m, 4H), 1.39-1.29 (m, 4H).






18


embedded image


5-(2-((S or R)-3-phenethyl-3- ((S&R)-tetrahydrofuran- 2-yl)pyrrolidin-1-yl)propan- 2-yl)-1-phenyl-1H- pyrazole citrate
431

1H NMR (300 MHz, MeOD): δ 7.62 (s, 1H), 7.61-7.47 (m, 5H), 7.28-7.14 (m, 5H), 6.60 (d, J = 5.1 Hz, 1H), 3.88-3.70 (m, 3H), 2.90-2.70 (m, 8H), 2.58-2.53 (t, J = 9.0 Hz, 2H), 1.93-1.84 (m, 4H), 1.71-1.57 (m, 3H), 1.49-1.46 (m, 7H).






19


embedded image


2-methyl-5-(2-((S or R)-3- phenethyl-3-((S&R)- tetrahydrofuran 2-yl)pyrrolidin- 1-yl)propan-2-yl)thiazole citrate
385

1H NMR (300 MHz, MeOD): δ 7.87 (d, J = 6.3 Hz, 1H), 7.27-7.12 (m, 5H), 3.89-3.81 (m, 1H), 3.49-3.41 (m, 2H), 3.40 (m, 3H), 3.30 (s, 1H), 3.32-3.10 (m, 1H), 2.80 (q, J = 15.3 Hz, 4H), 3.71 (s, 3H), 3.61- 3.50 (m, 2H), 2.20-2.01 (m, 2H), 2.00-1.90 (m,







2H), 1.85-1.80 (m, 6H),






1.78-1.73 (m, 3H).





20


embedded image


1-methyl-5-(2-((S or R)-3- phenethyl-3-((S&R)- tetrahydrofuran-2-yl)pyrrolidin- 1-yl)propan-2-yl)-1H-pyrazole citrate
368

1H NMR (300 MHz, MeOD): δ 7.38 (s, 1H), 7.28-7.23 (m, 2H), 7.17-7.15 (m, 3H), 6.31 (m, 1H), 4.11 (s, 3H), 3.93-3.79 (m, 1H), 3.76-3.70 (m, 2H), 2.91-2.75 (m, 4H), 2.71-2.58 (m, 6H), 2.00-1.75 (m, 8H), 1.63-1.62 (m, 6H).






21


embedded image


2-methyl-4-(2-((S or R)-3- phenethyl-3-((S&R)- tetrahydrofuran-2-yl)pyrrolidin- 1-yl)propan-2-yl)thiazole citrate
385

1H NMR (300 MHz, MeOD): δ 7.61 (s, 1H), 7.29-7.24 (m, 2H), 7.19-7.14 (m, 3H), 4.04-3.81 (m, m, 2H), 3.66-3.39 (m, 3H), 3.26 (s, 3H), 3.03 (m, 1H), 2.43 (q, J = 15.6 Hz, 4H), 2.72-2.66 (m, 5H), 2.24-2.16 (m, 2H), 2.14- 2.00 (m, 2H), 1.80 (s, 6H), 1.62-1.53 (m, 2H).






22


embedded image


2-methyl-4-(2-((S or R)-3- ((S&R)-tetrahydrofuran-2-yl)-3- (2-(thiophen-2-yl)ethyl) pyrrolidin-1-yl)propan-2-yl) thiazole citrate
391

1H NMR (300 MHz, MeOD): δ 7.61 (d, J = 5.1 Hz, 1H), 7.19 (dd, J = 2.4, 1.2 Hz, 1H), 6.90 (dd, J = 3.6, 1.5 Hz, 1H), 6.82 (s, 1H), 3.93- 3.90 (m, 2H), 3.88-3.65 (m, 1H), 3.56-3.44 (m, 3H), 2.92-2.80 (m, 7H), 2.77-2.68 (m, 3H), 2.11-1.95 (m, 6H),







1.80-1.73 (m, 8H).





23


embedded image


2-methyl-5-(2-((S or R)-3- ((S&R)-tetrahydrofuran-2-yl)- 3-(2-(thiophen-2-yl)ethyl) pyrrolidin-1-yl)propan-2-yl) thiazole citrate
391

1H NMR (300 MHz, MeOD): δ 7.81-7.76 (m, 1H), 7.17 (d, J = 4.8 Hz, 1H), 6.89 (s, 1H), 6.80 (s, 1H), 3.89- 3.81 (m, 1H), 3.70-3.57 (m, 2H), 3.22-3.19 (m, 2H), 3.09-3.05 (m, 1H), 2.87-2.77 (m, 6H), 2.71-2.68 (m, 3H), 2.03-1.87 (m, 6H),







1.82-1.73 (m, 8H),






1.72-1.56 (m, 1H).





24


embedded image


(S or R)-3-((S&R)-tetrahydro- furan-2-yl)-3-(2-(thiophen-2-yl) ethyl)-1-(2-(thiophen-3-yl) propan-2-yl)pyrrolidine citrate
376

1H NMR (300 MHz, MeOD): δ 7.79-7.78 (m, 1H), 7.61-7.59 (m, 1H), 7.40-7.39 (m, 1H), 7.17 (d, J = 5.1 Hz, 1H), 6.90-6.87 (m, 1H), 6.80-6.78 (m, 1H), 3.89-3.84 (m, 2H), 3.78-3.55 (m, 2H), 3.78-3.55 (m, 1H), 3.42-3.31 (m, 3H),







3.24-3.06 (m, 1H), 2.78






(q, J = 15.3 Hz, 4H),






2.23-1.93 (m, 1H),






1.95-1.90 (m, 4H), 1.84






(s, 6H), 1.80-1.61 (m,






2H), 1.55-1.31 (m, 1H).





25


embedded image


(S or R)-1-(2-(4- (furan-2-yl)phenyl)propan-2- yl)-3-((S&R)-tetrahydrofuran- 2-yl)-3-(2-(thiophen-2-yl) ethyl)pyrrolidine citrate
436

1H NMR (300 MHz, MeOD): δ 7.84-7.81 (m, 2H), 7.76-7.70 (m, 2H), 7.61 (s, 1H), 7.11- 7.01 (m, 1H), 6.89 (d, J = 3.3 Hz, 1H), 6.81- 6.80 (m, 2H), 6.56- 6.55 (m, 1H), 3.90-3.72 (m, 2H), 3.69-3.65 (m, 1H), 3.55-3.36 (m, 2H), 3.26-3.00 (m, 2H), 2.91-







2.75 (m, 6H), 2.25-2.02






(m, 2H), 1.99-1.89 (m,






2H), 1.87 (s, 6H), 1.82-






1.75 (m, 4H).





26


embedded image


1-methyl-4-(2-((S or R)-3- ((S&R)-tetrahydrofuran-2-yl)- 3-(2-(thiophen-2-yl)ethyl) pyrrolidin-1-yl)propan-2-yl)- 1H-pyrazole citrate
374

1H NMR (300 MHz, MeOD): δ 7.97 (s, 1H), 7.74 (s, 1H), 7.19 (s, 1H), 6.91 (s, 1H), 6.91- 6.75 (m, 1H), 3.99-3.88 (m, 5H), 3.75-3.35 (m, 5H), 3.12-3.03 (m, 1H), 2.84 (q, J = 15.3 Hz, 4H), 2.73-2.66 (m, 1H), 2.22-2.16 (m, 6H), 1.96







(s, 6H), 1.77-1.30 (m,






2H).





27


embedded image


(S or R)-3-((S&R)-tetrahydro- furan-2-yl)-3-(2-(thiophen-2- yl)ethyl)-1-(2-(4-(thiophen-2- yl)phenyl)propan-2-yl) pyrrolidine citrate
452

1H NMR (300 MHz, MeOD): δ 7.80-7.69 (m, 4H), 7.49-7.44 (m, 2H), 7.13-7.08 (m, 2H), 6.85-6.74 (m, 2H), 4.88-3.37 (m, 5H), 3.25-2.91 (m, 2H), 2.86-2.74 (m, 6H), 2.17-1.73 (m, 14H).






28


embedded image


2,4-dimethyl-5- (2-((S or R)-3-((S&R)- tetrahydrofuran-2-yl)-3-(2- (thiophen-2-yl)ethyl) pyrrolidin-1-yl) propan-2-yl)thiazole citrate
405

1H NMR (300 MHz, MeOD): δ 7.17 (d, J = 4.8 Hz, 1H), 6.90 (br s, 1H), 6.81 (br s, 1H), 3.90-3.86 (m, 2H), 3.75-3.70 (m, 2H), 3.20-2.95 (m, 3H), 2.94-2.86 (m, 4H), 2.85-2.70 (m, 4H), 2.60-2.58 (m, 3H), 2.53-2.51 (m, 3H), 1.93-1.79 (m, 6H),







1.72-1.68 (m, 6H).





29


embedded image


(R or S)-6-((3- (ethoxymethyl)-3- phenethylpyrrolidin-1- yl)methyl)benzo [d]oxazol-2(3H)- one citrate
381

1H NMR (300 MHz, MeOD): δ 7.40 (s, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.28-7.23 (m, 2H), 7.20-7.13 (m, 4H), 4.44-4.31 (q, J = 12.9 Hz, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.45-3.31 (m, 5H), 3.12 (m, 1H), 2.78 (q, J = 15.6 Hz, 4H), 2.60-2.57 (m, 2H), 2.10-1.99 (m, 2H), 1.89-1.80 (m, 2H), 1.21 (t, J = 7.2 Hz, 3H).






30


embedded image


(R or S)-3-(ethoxymethyl)-3- (4-fluorophenethyl)-1-(2- (furan-2-yl)benzyl)pyrrolidine







31


embedded image


(R or S)-3-(ethoxymethyl)-3- (4-fluorophenethyl)-1-(2- (thiophen-2-yl)benzyl) pyrrolidine







32


embedded image


(R or S)-1-(2,4- dichlorobenzyl)-3-(ethoxy- methyl)-3-(4-fluorophenethyl) pyrrolidine







33


embedded image


(R or S)-1-(2,6-dichloro-4- fluorobenzyl)-3- (ethoxymethyl)-3-(4- fluorophenethyl)pyrrolidine







34


embedded image


(3R or S)-1-(chroman-4-yl)-3- (ethoxymethyl)-3-(4- fluorophenethyl)pyrrolidine







35


embedded image


(3R or S)-3-(ethoxymethyl)-1- (6-fluorochroman-4-yl)-3-(4- fluorophenethyl)pyrrolidine







36


embedded image


(R or S)-3-((3- (ethoxymethyl)-3-(4-fluoro- phenethyl)pyrrolidin-1-yl) methyl)-1H-pyrazolo[4,3- d]pyrimidine







37


embedded image


4-((R or S)-3- (ethoxymethyl)-3-(4-fluoro- phenethyl)pyrrolidin-1-yl)- 3,3-dimethyl-3,4-dihydro- isoquinolin-1(2H)-one







38


embedded image


(R or S)-3-((3- (ethoxymethyl)-3-(4- fluorophenethyl)pyrrolidin-1- yl)methyl)pyridazine-4- carbonitrile







39


embedded image


(R or S)-3-((3- (ethoxymethyl)-3-(4- fluorophenethyl)pyrrolidin-1- yl)methyl)-4-(trifluoromethyl) pyridazine







40


embedded image


(R or S)-4-(2-(1-(bis(2- methylthiazol-4-yl)methyl)-3- (ethoxymethyl)pyrrolidin-3- yl)ethyl)benzonitrile







41


embedded image


(3R or S)-1- (1,1,3,3,3-hexafluoro-2-(p- tolyl)propan-2-yl)-3- (tetrahydrofuran-2-yl)-3-(2- (thiophen-2-yl)ethyl) pyrrolidine





*Legend for 4th & 5th columns in Table III is same as for Table I.













TABLE IV







Chirality and in vivo testing of compound Nos. 1 to 25 of Table III











ED50 (mg/kg)




at 30 min on C57BL/6




mice in Warm-water



Configuration
Tail-flick Test (same


Compound
tested
as Table II)












1
S
++


2
S
+


3
S
++


4
R
+


5
R
++


6
S
+


7
S
++


8
R
+


9
R
+


10
S
+


11
S
++


12
S
++


13
S
++


14
S
++


15
(S, S&R)
+


16
(S, S&R)
++


17
(S, S&R)
++


18
(S, S&R)
+


19
(S, S&R)
++


21
(S, S&R)
++


22
(S, S&R)
++


23
(S, S&R)
++


24
(S, S&R)
++


24
(S, S&R)
++


25
(S, S&R)
++


26
(S, S&R)
++


27
(S, S&R)
+


28
(S, S&R)
+


29
S
+









Legend for Table IV, Middle Column

“S, S&R” means the compound has two chiral centers and can possibly have four diastereomers. The compound with S at the 1st chiral center and the racemate at the 2nd chiral center was tested.









TABLE V







New Compounds with a pyridine ring and other groups bonded to the pyridine N-constituent














MS






(ESI+):



Compound
Structure
Name
[M + H]+
H-NMR














 1


embedded image


5-((4-(4- fluorophenethyl)-4- (pyridin-2- yl)piperidin-1- yl)methyl)- 2- methylpyridine
390

1H NMR (300 MHz, MeOD): δ 8.56 (d, J = 4.2 Hz, 1H), 8.31 (d, J = 1.5 Hz, 1H), 7.80 (td, J = 7.5, 1.5 Hz, 1H), 7.69 (dd, J = 8.1, 2.0 Hz, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.39-7.21 (m, 2H), 7.02-6.82 (m, 4H), 3.45 (s, 2H), 2.75- 2.68 (m, 2H), 2.50 (s, 3H), 2.47-2.43 (m, 2H), 2.19-2.14 (m, 4H), 1.93- 1.85 (m, 4H).






 2


embedded image


4-fluoro-N- ((1-((6- methylpyridin-3- yl)methyl)- 4-(pyridin-2- yl)piperidin-4- yl)methyl)aniline
391

1H NMR (300 MHz, MeOD): δ 8.55 (d, J = 3.6 Hz, 1H), 8.30 (d, J = 1.8 Hz, 1H), 7.72-7.65 (m, 2H), 7.48 (d, J = 7.8 Hz, 1H), 7.24-7.18 (m, 2H), 6.70 (t, J = 8.7, Hz, 2H), 6.40-6.30 (m, 2H), 3.43 (s, 2H), 3.29 (s, 2H), 2.72- 2.66 (m, 2H), 2.49-2.47 (m, 5H), 1.88 (t, J = 8.4 Hz, 2H), 1.98-1.94 (m, 2H).






 3


embedded image


4-fluoro-N- methyl-N- ((1-((6- methylpyridin-3- yl)methyl)- 4-(pyridin- 2- yl)piperidin-4- yl)methyl)aniline
405

1H NMR (300 MHz, MeOD): δ 8.55 (dd, J = 4.5, 0.9 Hz, 1H), 8.27 (d, J = 1.8 Hz, 1H), 7.65-7.60 (m, 2H), 7.40 (d, J = 8.1 Hz, 1H), 7.24-7.18 (m, 2H), 6.73-6.67 (m, 2H), 6.4-6.35 (m, 2H), 3.42 (s, 2H), 3.34 (s, 2H), 2.73 (d, J = 8.7 Hz, 2H), 2.62 (s, 3H), 2.60-2.56 (m, 2H), 2.48 (s, 3H), 2.02-1.87 (m, 4H).






 4


embedded image


5-((4-((4- fluorophenoxy) methyl)- 4-(pyridin-2- yl)piperidin-1- yl)methyl)-2- methylpyridine
392

1H NMR (300 MHz, MeOD): δ 8.52 (s, 1H), 8.32 (s, 1H), 7.80-7.75 (m, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.28-7.21 (m, 2H), 6.93-6.86 (m, 2H), 6.75-6.72 (m, 2H), 4.00 (s, 2H), 3.45 (s, 2H), 2.72- 2.68 (m, 2H), 2.57-2.46 (m, 5H), 2.28-2.20 (m, 2H), 2.18-2.03 (m, 2H).






 5


embedded image


1-(2-(4- (2H-1,2,3- triazol-4- yl)phenyl) propan-2-yl)-4- (ethoxymethyl)-4- phenethylpiperidine
433

1H NMR (300 MHz, MeOD): δ 8.26 (s, 1H), 8.01 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 8.4 Hz, 2H), 7.24-7.20 (m, 2H), 7.15- 7.12 (m, 3H), 3.48-3.42 (m, 4H), 3.28-3.22 (m, 2H), 2.54-2.48 (m, 2H), 1.90 (s, 6H), 1.84-1.70 (m, 4H), 1.67-1.55 (m, 2H), 1.35-1.28 (m, 2H), 1.19-1.17 (m, 3H).






 6


embedded image


5-(2-(4- (ethoxymethyl)- 4-(2- (thiophen- 2- yl)ethyl)piperidin-1- yl)propan- 2-yl)-2- methylpyridine citrate
387

1H NMR (300 MHz, MeOD): δ 8.70 (s, 1H), 8.05-8.03 (m, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.16 (d, J = 5.1 Hz, 1H), 6.90- 6.87 (m, 1H), 6.80-6.79 (m, 1H), 3.52-3.41 (m, 4H), 3.24-3.13 (m, 4H), 2.90-2.72 (m, 6H), 2.58 (s, 3H), 1.97-1.86 (m, 2H), 1.85 (s, 6H), 1.77- 1.70 (m, 4H), 1.23 (t, J = 7.2 Hz, 3H).






 7


embedded image


3-(1-(4- (ethoxymethyl)- 4-(2- (thiophen- 2- yl)ethyl) piperidin-1- yl)ethyl)- 2,6- dimethylpyridine
387

1H NMR (300 MHz, MeOD): δ 8.21 (s, 1H), 7.25 (s, 1H), 7.14 (dd, J = 5.1, 1.2 Hz, 1H), 6.88 (dd, J =5.1, 2.4 Hz, 1H), 6.81-6.80 (m, 1H), 3.79 (br s. 2H), 3.53 (q, J = 6.9 Hz, 2H), 3.38 (s, 2H), 3.29-3.26 (m, 5H), 2.85- 2.79 (m, 2H), 2.51 (s, 3H), 2.31 (s, 3H), 1.85- 1.80 (m, 2H), 1.70-1.43 (m, 5H), 1.17 (t, J = 6.9 Hz, 3H).






 8


embedded image


5-((4- (ethoxymethyl)-4- phenethylpiperidin- 1-yl)methyl)- 1-methyl- 1,3-dihydro-2H- benzo[d]imidazol-2-one citrate
407

1H NMR (300 MHz, MeOD): δ 7.27-7.12 (m, 8H), 4.30 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.32-3.30 (m, 5H), 3.21 (m, 4H), 2.79 (q, J = 15.6 Hz, 4H), 2.61-2.53 (m, 2H), 1.90- 1.71 (m, 6H), 1.18 (t, J = 7.2 Hz, 3H).






 9


embedded image


6-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)-3- methylbenzo [d]oxazol- 2(3H)-one HCl
406

1H NMR (300 MHz, D2O): δ 7.32-7.24 (m, 4H), 7.22-7.18 (m, 4H), 4.26-4.25 (m, 2H), 3.50- 3.44 (m, 3H), 3.35 (s, 3H), 3.32-3.28 (m, 3H), 3.06-2.98 (m, 2H), 2.51- 2.47 (m, 2H), 1.89-1.51 (m, 6H), 1.08 (t, J = 7.2 Hz, 3H).






10


embedded image


6-((4- (ethoxymethyl)-4- phenethylpi peridin-1- yl)methyl)-2- methylbenzo [d]oxazole citrate
392

1H NMR (300 MHz, MeOD): δ 7.78 (s, 1H), 7.71 (d, J = 8.1 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.27-7.12 (m, 5H), 4.42 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.47-3.45 (m, 2H), 3.22 (m, 4H), 2.79 (q, J = 15.3 Hz, 4H), 2.66 (s, 3H), 2.59-2.54 (m, 2H), 1.91-1.86 (m, 2H), 1.77-1.72 (m, 4H), 1.18 (t, J = 7.2 Hz, 3H).






11


embedded image


6-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)- 2-methyl-1H- benzo[d]imidazole citrate
391

1H NMR (300 MHz, MeOD): δ 7.68 (s, 1H), 7.57 (d, J = 8.1 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 7.27-7.12 (m, 5H), 4.40 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.40 (s, 2H), 3.26 (m, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.60 (s, 3H), 2.58-2.54 (m, 2H), 1.86-1.75 (m, 6H), 1.17 (t, J = 7.2 Hz, 3H).






12


embedded image


1-((2,2- dimethylbenzo[d][1,3] dioxol-5- yl)methyl)-4- (ethoxymethyl)-4- phenethylpiperidine citrate
409

1H NMR (300 MHz, MeOD): δ 7.28-7.15 (m, 5H), 6.93-6.90 (m, 2H), 6.81 (d, J = 7.8 Hz, 1H), 4.18 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.40 (m, 2H), 3.22 (m, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.60-2.54 (m, 2H), 1.87-1.71 (m, 6H), 1.66 (s, 6H), 1.18 (t, J = 7.2 Hz, 3H).






13


embedded image


6-((4- ((benzyloxy) methyl)-4- phenethylpiperidin-1- yl)methyl) benzo[d]oxazol-2(3H)- one citrate
459

1H NMR (300 MHz, MeOD): 7.37-7.30 (m, 5H), 7.28-7.22 (m, 4H), 7.17-7.12 (m, 4H), 4.52 (s, 2H), 4.27 (s, 2H), 3.54 (s, 2H), 3.17 (m, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.55-2.49 (m, 2H), 1.91- 1.86 (m, 2H), 1.82-1.71 (m, 4H).






14


embedded image


2-chloro-5-((4- (ethoxymethyl)-4- phenethylpiperidin- 1-yl)methyl) phenol citrate
388

1H NMR (300 MHz, MeOD): δ 7.33 (d, J = 8.7 Hz, 1H), 7.28-7.09 (m, 5H), 7.05 (s, 1H), 6.87 (d, J = 8.7 Hz, 1H), 4.33 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.42 (s, 2H), 3.34- 3.29 (m, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.60-2.54 (m, 2H), 1.91-1.87 (m, 2H), 1.78-1.68 (m, 4H), 1.29 (t, J = 7.2 Hz, 3H).






15


embedded image


4-chloro-3-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)phenol citrate
388

1H NMR (300 MHz, MeOD): δ 7.32-7.23 (m, 3H), 7.20-7.14 (m, 2H), 7.12-7.10 (m, 2H), 7.04 (d, J = 8.1 Hz, 1H), 4.44 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.42 (s, 2H), 3.34 (m, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.60-2.54 (m, 2H), 1.93-1.88 (m, 2H), 1.79-1.69 (m, 4H), 1.21 (t, J = 7.2 Hz, 3H).






16


embedded image


6-(2-(4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)ethyl) benzo[d]oxazol- 2(3H)-one citrate
409

1H NMR (300 MHz, MeOD): δ 7.40-7.19 (m, 4H), 7.15-7.10 (m, 2H), 7.05 (d, J = 7.8 Hz, 2H) 3.67-3.34 (q, J = 7.2 Hz, 2H), 3.31-3.30 (m, 4H), 3.18-3.00 (m, 4H), 3.11- 3.00 (m, 2H), 2.78 (q, J = 15.6 Hz, 4H), 2.61-2.56 (m, 2H), 1.92-1.55 (m, 6H), 1.22 (t, J = 6.9 Hz, 3H).






17


embedded image


6-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl) isobenzofuran-1(3H)- one citrate
394

1H NMR (300 MHz, MeOD): δ 8.02 (s, 1H), 7.90 (d, J = 7.2 Hz, 1H), 7.73 (d, J = 7.2 Hz, 1H), 7.29-7.12 (m, 5H), 5.43 (s, 2H), 4.37 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.40 (s, 2H), 3.18 (m, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.59-2.54 (m, 2H), 1.89- 1.84 (m, 2H), 1.75-1.69 (m, 4H), 1.29 (t, J = 6.9 Hz, 3H).






18


embedded image


6-(2-(4-(1- ethoxycyclopropyl)-4- phenethylpiperidin-1- yl)ethyl)benzo [d]oxazol-2(3H)-one citrate
435

1H NMR (300 MHz, MeOD): δ 7.26-7.20 (m, 4H), 7.16-7.10 (m, 3H), 7.04 (d, J = 7.8 Hz, 1H), 3.54 (q, J = 7.2 Hz, 2H), 3.44 (m, 2H), 3.31-3.21 (m, 2H), 3.23-3.08 (m, 4H), 2.86-2.71 (m, 6H), 2.05-2.00 (m, 2H), 1.87 (d, J = 14.4 Hz, 2H), 1.67- 1.59 (m, 2H), 1.14 (t, J = 6.9 Hz, 3H), 0.89 (m, 2H), 0.74 (m, 2H).






19


embedded image


2-chloro-4- ((4 (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)phenol citrate
388

1H NMR (300 MHz, MeOD): δ 7.49 (s, 1H), 7.28-7.23 (m, 3H), 7.20- 7.12 (m, 3H), 6.98 (d, J = 8.4 Hz, 1H), 4.18 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.39 (m, 2H), 3.20 (m, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.64-2.53 (m, 2H), 1.85-1.71 (m, 6H), 1.19 (t, J = 7.2 Hz, 3H).






20


embedded image


3-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)phenyl methylcarbamate citrate
410

1H NMR (300 MHz, MeOD): δ 7.49 (t, J = 7.6 Hz, 1H), 7.34-7.12 (m, 8H), 4.28 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.40 (s, 2H), 3.23 (br s, 4H), 2.80- 2.71 (m, 7H), 2.60-2.54 (m, 2H), 1.86-1.75 (m, 6H), 1.20 (t, J = 6.9 Hz, 3H).






21


embedded image


6-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)- 1,4- dihydro- 2H- benzo[d][1, 3]oxazin-2- one citrtate
408

1H NMR (300 MHz, MeOD): δ 7.40 (d, J = 8.1 Hz, 1H), 7.34 (s, 1H), 7.28-7.12 (m, 5H), 6.96 (d, J = 7.8 Hz, 1H), 5.35 (s, 2H), 4.22 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.39 (br s, 2H), 3.20 (br s, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.59-2.54 (m, 2H), 1.90- 1.59 (m, 6H), 1.20 (t, J = 6.9 Hz, 3H).






22


embedded image


7-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)-2H- benzo[b][1,4]oxazin- 3(4H)-one citrate
408

1H NMR (300 MHz, MeOD): δ 7.28-7.07 (m, 7H), 6.97 (d, J = 8.1 Hz, 1H), 4.61 (s, 2H), 4.19 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.40 (br s, 2H), 3.20 (br s, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.59-2.54 (m, 2H), 1.85-1.62 (m, 6H), 1.19 (t, J = 7.2 Hz, 3H).






23


embedded image


1-((2,3- dihydrobenzofuran-6- yl)methyl)-4- (ethoxymethyl)-4- phenethylpiperidine citrate
379

1H NMR (300 MHz, MeOD): δ 7.31-7.23 (m, 3H), 7.20-7.12 (m, 3H), 6.94 (d, J = 6.6 Hz, 1H), 6.87 (s, 1H), 4.58 (t, J = 8.7 Hz, 2H), 4.20 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.34 (br s, 2H), 3.29-3.20 (m, 6H), 2.78 (q, J = 15.6 Hz, 4H), 2.59-2.54 (m, 2H), 1.86-1.74 (m, 6H), 1.19 (t, J = 6.9 Hz, 3H).






24


embedded image


methyl (4-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)phenyl) carbamate citrate
410

1H NMR (300 MHz, MeOD): δ 7.56 (d, J = 8.1 Hz, 2H), 7.41 (d, J = 8.1 Hz, 2H), 7.28-7.12 (m, 5H), 4.23 (s, 2H), 3.74 (s, 3H), 3.57 (q, J = 7.2 Hz, 2H), 3.39 (br s, 2H), 3.22 (br s, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.59-2.54 (m, 2H), 1.86-1.74 (m, 6H), 1.19 (t, J = 6.9 Hz, 3H).






25


embedded image


5-((4- (ethoxymethyl)-4- phenethylpiperidin- 1-yl)methyl) benzo[d]oxaz ol-2(3H)- one citrate
394

1H NMR (300 MHz, MeOD): δ 7.39-7.23 (m, 5H), 7.22-7.12 (m, 3H), 4.19 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.47 (br s, 2H), 3.21 (br s, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.59- 2.54 (m, 2H), 1.85-1.75 (m, 6H), 1.19 (t, J = 6.9 Hz, 3H).






26


embedded image


5-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)- 3-methylbenzo [d]oxazol- 2(3H)-one citrate
408

1H NMR (300 MHz, MeOD): δ 7.35-7.29 (m, 2H), 7.25-7.12 (m, 6H), 4.32 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.43-3.20 (m, 5H), 3.22 (br s, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.60- 2.54 (m, 2H), 1.91-1.65 (m, 6H), 1.19 (t, J = 6.9 Hz, 3H).






27


embedded image


6-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)- 1-methyl-1,4- dihydro-2H- benzo[d][1, 3]oxazin-2- one citrate
422

1H NMR (300 MHz, MeOD): δ 7.52 (d, J = 8.4 Hz, 1H), 7.39 (s, 1H), 7.28-7.12 (m, 6H), 5.28 (s, 2H), 4.31 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.40- 3.34 (m, 5H), 3.20 (br s, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.60-2.54 (m, 2H), 1.90-1.71 (m, 6H), 1.19 (t, J = 6.9 Hz, 3H)






28


embedded image


7-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)-3,4- dihydro-2H- benzo[e][1,3]oxazin- 2-one citrate
408

1H NMR (300 MHz, MeOD): δ 7.33-7.12 (m, 8H), 4.51 (s, 2H), 4.22 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.39 (s, 2H), 3.16 (br s, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.59-2.54 (m, 2H), 1.89-1.70 (m, 6H), 1.19 (t, J = 6.9 Hz, 3H).






29


embedded image


6-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)benzo [d]thiazol-2(3H)- one citrate
410

1H NMR (300 MHz, MeOD): δ 7.64 (s, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.28-7.12 (m, 6H), 4.28 (s, 2H), 3.53 (q, J = 7.2 Hz, 2H), 3.40 (br s, 2H), 3.22 (br s, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.59-2.21 (m, 2H), 1.90-1.71 (m, 6H), 1.19 (t, J = 6.9 Hz, 3H).






30


embedded image


6-((4- (ethoxy(phenyl) methyl)-4- phenethylpiperidin-1- yl)methyl)-1,4- dihydro-2H- benzo[d][1, 3]oxazin-2- one citrate
484

1H NMR (300 MHz, MeOD): δ 7.38-7.30 (m, 7H), 7.25-7.20 (m, 2H), 7.17-7.13 (m, 3H), 6.94 (d, J = 8.1 Hz, 1H), 5.33 (s, 2H), 4.37 (s, 1H), 4.21 (s, 2H), 3.41-3.36 (m, 2H), 3.30-3.26 (m, 2H), 3.10-3.08 (m, 2H), 2.78 (q, J = 15.6 Hz, 4H), 2.67- 2.61 (m, 2H), 2.04-1.61 (m, 6H), 1.67 (t, J = 6.9 Hz, 3H).






31


embedded image


6-((4-(1- ethoxyethyl)-4- phenethylpiperidin-1- yl)methyl)- 1,4- dihydro- 2H- benzo[d][1, 3]oxazin-2- one citrate
422

1H NMR (300 MHz, MeOD): δ 7.41 (d, J = 8.4 Hz, 1H), 7.36 (s, 1H), 7.29-7.13 (m, 5H), 6.96 (d, J = 8.1 Hz, 1H), 5.35 (s, 2H), 4.23 (s, 2H), 3.71- 3.66 (m, 1H), 3.42-3.34 (m, 4H), 3.12 (br s, 2H), 2.78 (q, J = 15.6 Hz, 4H), 2.71-2.50 (m, 2H), 2.03- 1.82 (m, 3H), 1.72-1.62 (m, 3H), 1.17-1.13 (m, 6H).






32


embedded image


6-((4- (hydroxymethyl)-4- phenethylpiperidin-1- yl)methyl)-1,4- dihydro-2H- benzo[d][1, 3]oxazin-2- one citrate
380

1H NMR (300 MHz, MeOD): δ 7.41 (d, J = 8.7 Hz, 1H), 7.36 (s, 1H), 7.28-7.11 (m, 5H), 6.96 (d, J = 7.8 Hz, 1H), 5.35 (s, 2H), 4.24 (s, 2H), 3.53 (s, 2H), 3.11 (br s, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.60-2.54 (m, 2H), 1.84- 1.73 (m, 6H).






33


embedded image


6-((4-(2- hydroxypropan-2-yl)- 4-phenethylpiperidin- 1-yl)methyl)- 1,4-dihydro-2H- benzo[d][1, 3]oxazin-2- one citrate
408

1H NMR (300 MHz, MeOD): δ 7.42 (d, J = 8.1 Hz, 1H), 7.37 (s, 1H), 7.29-7.13 (m, 5H), 6.96 (d, J = 8.1 Hz, 1H), 5.35 (s, 2H), 4.25 (s, 2H), 3.39 (s, 2H), 3.05 (q, J = 12.9 Hz, 2H), 2.85-2.68 (m, 6H), 2.08 (t, J = 11.7 Hz, 2H), 1.79-1.75 (m, 4H), 1.27 (s, 6H).






34


embedded image


1-benzyl-6-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)-1,4- dihydro-2H- benzo[d][1, 3]oxazin-2- one citrate
498

1H NMR (300 MHz, MeOD): δ 7.39-7.32 (m, 2H), 7.30-7.22 (m, 4H), 7.18-7.11 (m, 6H), 7.00 (d, J = 8.4 Hz, 1H), 5.38 (s, 2H), 5.19 (s, 2H), 4.19 (s, 2H), 3.54 (q, J = 7.2 Hz, 2H), 3.45 (s, 2H), 3.16 (br s, 4H), 2.78 (q, J = 15.6 Hz, 4H), 2.57-2.52 (m, 2H), 1.87-1.68 (m, 6H), 1.17 (t, J = 6.9 Hz, 3H).






35


embedded image


1-((2-oxo-1,4- dihydro-2H- benzo[d][1, 3]oxazin-6- yl)methyl)-4- phenethylpiperidine- 4-carboxamide citrate
393

1H NMR (300 MHz, MeOD): δ 7.42 (d, J = 8.1 Hz, 1H), 7.33 (s, 1H), 7.28-7.15 (m, 5H), 6.98 (d, J = 7.8 Hz, 1H), 5.35 (s, 2H), 4.28 (s, 2H), 3.41- 3.10 (m, 2H), 3.07-3.06 (m, 2H), 2.80 (q, J = 15.6 Hz, 4H), 2.58-2.45 (m, 4H), 1.82-1.68 (m, 4H).






36


embedded image


6-((4-(2- ethoxypropan- 2-yl)-4- phenethylpiperidin-1- yl)methyl)- 1,4-dihydro-2H- benzo[d][1, 3]oxazin-2- one citrate
436

1H NMR (300 MHz, MeOD): δ 7.42 (d, J = 7.8 Hz, 1H), 7.35 (s, 1H), 7.29-7.13 (m, 5H), 6.98 (d, J = 7.5 Hz, 1H), 5.35 (s, 2H), 4.27 (s, 2H), 3.54- 3.42 (m, 4H), 3.11 (br s, 2H), 2.89-2.73 (m, 6H), 2.09 (m, 2H), 1.84-1.79 (m, 4H), 1.22 (s, 6H), 1.15 (t, J = 7.2 Hz, 3H).






37


embedded image


1-(2-(4-(2H-1,2,3- triazol-4-yl)phenyl) propan-2-yl)-4- (ethoxy(phenyl)methyl)- 4-phenethylpiperidine







38


embedded image


1-(2-(4-(2H- tetrazol-5- yl)phenyl)propan-2-yl)- 4-(ethoxy(phenyl) methyl)-4- phenethylpiperidine







39


embedded image


6-((4- phenethyl-4- (phenoxy (phenyl)methyl) piperidin-1-yl)methyl)- 1Hbenzo[d][1, 3]oxazin- 2(4H)-one







40


embedded image


6-((4- (isopropoxy(phenyl) methyl)-4- phenethylpiperidin- 1-yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







41


embedded image


6-((4- ((benzyloxy)(phenyl) methyl)-4- phenethylpiperidin- 1-yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







42


embedded image


6-((4-phenethyl-4- (phenyl(propoxy) methyl)piperidin-1- yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







43


embedded image


6-((4- (methoxy(phenyl) methyl)-4- phenethylpiperidin- 1-yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







44


embedded image


6-((4-phenethyl-4- (tetrahydro-2H- pyran-2- yl)piperidin-1- yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







45


embedded image


6-((4-phenethyl-4- (tetrahydrofuran-2- yl)piperidin-1- yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







46


embedded image


N,N-dimethyl-1- ((2-oxo-2,4- dihydro-1H- benzo[d][1,3]oxazin- 6-yl)methyl)-4- phenethylpiperidine- 4-carboxamide







47


embedded image


1-((2-oxo-2,4- dihydro-1H- benzo[d][1,3]oxazin- 6-yl)methyl)-4- phenethylpiperidine- 4-carboxamide







48


embedded image


6-((4-(1H-imidazol- 2-yl)-4- phenethylpiperidin- 1-yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







49


embedded image


6-((4-(5-methyl- 1,3,4-thiadiazol-2- yl)-4- phenethylpiperidin- 1-yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







50


embedded image


6-((4-(1,3,4- oxadiazol-2-yl)-4- phenethylpiperidin- 1-yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







51


embedded image


6-((4-phenethyl-4- (pyridin-4- yl)piperidin-1- yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







52


embedded image


6-((4-phenethyl-4- phenylpiperidin-1- yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







53


embedded image


6-((4-phenethyl-4- (pyridin-2- yl)piperidin-1- yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







54


embedded image


6-((4-phenethyl-4- (pyridin-3- yl)piperidin-1- yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







55


embedded image


N-((1-((2-oxo-2,4- dihydro-1H- benzo[d][1,3]oxazin- 6-yl)methyl)-4- phenethylpiperidin- 4-yl)methyl) methanesulfonamide







56


embedded image


6-((4-methyl-4- phenethylpiperidin- 1-yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







57


embedded image


6-((4-butyl-4- phenethylpiperidin- 1-yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







58


embedded image


N-((1-((2-oxo-2,4- dihydro-1H- benzo[d][1,3]oxazin- 6-yl)methyl)-4- phenethylpiperidin-4- yl)methyl)acetamide







59


embedded image


N-((1-((2-oxo-2,4- dihydro-1H- benzo[d][1,3]oxazin- 6-yl)methyl)-4- phenethylpiperidin-4- yl)methyl)benzamide







60


embedded image


6-((4-(2- hydroxypropan-2- yl)-4- phenethylpiperidin- 1-yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







61


embedded image


6-((4-(1- ethoxyethyl)-4- phenethylpiperidin- 1-yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







62


embedded image


6-((4-(2- ethoxypropan-2-yl)-4- phenethylpiperidin- 1-yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one







63


embedded image


7-((4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)methyl)benzo[d] imidazo[2,1- b]thiazole







64


embedded image


7-((4- (ethoxymethyl)-4- phenethylpiperidin- 1-yl)methyl)-3,4- dihydro-2H- benzo[b][1,4]oxazin- 2-one







65


embedded image


6-(2-(4- (ethoxymethyl)-4- phenethylpiperidin- 1-yl)propan-2- yl)benzo[d]oxazol- 2(3H)-one







66


embedded image


6-(1-(4- (ethoxymethyl)-4- phenethylpiperidin-1- yl)ethyl)benzo[d] oxazol-2(3H)-one







67


embedded image


ethyl 1-((2-oxo-2,4- dihydro-1H- benzo[d][1,3]oxazin- 6-yl)methyl)-4- phenethylpiperidine- 4-carboxylate







68


embedded image


6-((4- (hydroxymethyl)-4- phenethylpiperidin- 1-yl)methyl)-1H- benzo[d][1,3]oxazin- 2(4H)-one





*Legend for 4th & 5th columns in Table V is same as for Table I.













TABLE VI







in vivo testing of compound Nos. 1 to 36 of Table V











ED50 (mg/kg)




at 30 min on




C57BL/6 mice in




Warm-water Tail-




flick Test (same



Compound
conditions as



No.
Table II)














1
+



2
+



3
++



4
++



5
++



6
++



7
++



8
+



9
+



10
+



11
+



12
+



13
+



14
+



15
+



16
+



17
+



18
+



19
+



20
+



21
+



22
+



23
+



24
+



25
+



26
+



27
+



28
++



29
+



30
+



31
+



32
+



33
+



34
+



35
+



36
+










Table VII—New Compounds

The following new compounds were also made and tested to determine the half maximal possible effective dose, or ED50 (mg/kg), in mice, using one of: the warm water tail-flick test as in Table II, spared nerve injury, chronic constriction injury, or Complete Freund's adjuvant induced inflammatory pain. The symbols in the last column are: + indicates ED 50>50 mg/kg; ++ indicates ED 50 is less than or equal to 30 mg/kg. The fourth column, “MS”, shows the mass spectrometry results and fifth column shows the NMR results.




















MS







(ESI+):

Bio-


Com-


[M +

logical


pound
Structure
Name
H]+
H-NMR
Activity




















 1


embedded image


(R)-5-((3- (ethoxymethyl)- 3- (4- fluorophenethyl) pyrrolidin-1- yl)methyl)-2- methoxypyridine
373

1H NMR (300 MHz, MeOD) δ 8.27 (s, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.20 (dd, J = 8.5, 5.5 Hz, 2H), 6.98 (t, J = 8.8 Hz, 2H), 6.88 (d, J = 8.0 Hz, 1H), 4.35 (q, J = 13.5 Hz, 2H), 3.56 (qd, J = 6.9, 1.6 Hz, 2H), 3.49 − 3.33 (m, 5H), 3.16 (d, J = 11.8 Hz, 1H), 2.83 (dd, J = 34.4, 15.6 Hz, 9H), 2.59 (t, J = 7.1 Hz, 2H), 2.14 − 1.96 (m, 2H), 1.94 − 1.72 (m, 2H), 1.21 (t, J = 7.0 Hz, 3H).

+





 2


embedded image


(R)-5-((3- (ethoxymethyl)- 3- (4- fluorophenethyl) pyrrolidin-1- yl)methyl)-2- methoxy- isonicotino nitrile
398

1H NMR (300 MHz, MeOD) δ 8.41 (s, 1H), 7.26 − 7.15 (m, 3H), 6.97 (t, J = 8.8 Hz, 2H), 4.11 (s, 2H), 3.98 (s, 3H), 3.53 (q, J = 7.0 Hz, 2H), 3.44 − 3.37 (m, 2H), 3.14 − 2.97 (m, 3H), 2.81 (q, J = 15.6 Hz, 6H), 2.59 (t, J = 8.6 Hz, 2H), 1.94 − 1.70 (m, 4H), 1.20 (t, J = 7.0 Hz, 3H).

++





 3


embedded image


(R)-4-(2-(3- (ethoxymethyl)- 1- (pyridin-3- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile
350

1H NMR (300 MHz, MeOD) δ 8.66 (d, J = 18.1 Hz, 2H), 8.05 (d, J = 7.6 Hz, 1H), 7.63 (d, J = 8.1 Hz, 3H), 7.55 (d, J = 5.1 Hz, 1H), 7.40 (d, J = 8.1 Hz, 2H), 4.48 − 4.28 (m, 2H), 3.60 − 3.50 (m, 2H), 3.45 (s, 2H), 3.41 − 3.32 (m, 3H), 3.26 (d, J = 11.6 Hz, 1H), 3.12 (d, J = 11.6 Hz, 1H), 2.79 (dd, J = 32.3, 15.5 Hz, 5H), 2.68 (d, J = 8.1 Hz, 1H), 2.00 (d, J = 7.3 Hz, 2H), 1.86 (td, J = 16.1, 7.3 Hz, 2H), 1.21 (t, J = 7.0 Hz, 4H).

++





 4


embedded image


(S)-1-benzyl-3- (ethoxymethyl)- 3- (4- fluorophenethyl) pyrrolidine
342

1H NMR (300 MHz, MeOD) δ 7.49 (s, 5H), 7.25 − 7.16 (m, 2H), 6.98 (t, J = 8.7 Hz, 2H), 4.49 − 4.25 (m, 2H), 3.61 − 3.51 (m, 3H), 3.50 − 3.40 (m, 2H), 2.84 (dd, J = 36.5, 15.7 Hz, 6H), 2.67 − 2.53 (m, 2H), 2.23 − 2.15 (m, 1H), 2.14 − 1.97 (m, 3H), 1.91 − 1.75 (m, 2H), 1.66 − 1.47 (m, 1H), 1.22 (t, J = 7.0 Hz, 3H).

+





 5


embedded image


(R)-3-((3- (ethoxymethyl)- 3- (4- fluorophenethyl) pyrrolidin-1- yl)methyl) picolinamide
386

1H NMR (300 MHz, MeOD) δ 8.77 (d, J = 4.5 Hz, 1H), 8.01 (d, J = 7.6 Hz, 1H), 7.72 − 7.64 (m, 1H), 7.21 (dd, J = 8.4, 5.5 Hz, 2H), 6.99 (t, J = 8.7 Hz, 2H), 4.68 − 4.56 (m, 1H), 4.53 − 4.38 (m, 1H), 3.67 − 3.48 (m, 4H), 3.48 − 3.38 (m, 2H), 2.84 (dd, J = 35.9, 15.7 Hz, 11H), 2.61 (dd, J = 16.1, 7.9 Hz, 3H), 2.19 (t, J = 7.5 Hz, 2H), 2.06 − 1.95 (m, 1H), 1.83 (t, J = 8.2 Hz, 2H), 1.21 (t, J = 6.9 Hz, 3H).

+





 6


embedded image


(R)-4-(2-(3-(2- ethoxy-1,1,1, 3,3,3- hexafluoropropan- 2-yl)-1-(2-(6- methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
528

1H NMR (300 MHz, MeOD) δ 8.58 (s, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.36 (t, J = 14.8, 8.1 Hz, 3H), 4.07 − 3.86 (m, 2H), 3.03 (d, J = 9.5 Hz, 1H), 2.93 (m, 2H), 2.93 − 2.79 (q, J = 15.6 Hz, 4H), 2.75 (s, 1H), 2.70 (d, J = 10.3 Hz, 1H), 2.55 (m, 1H), 2.53 (s, 3H), 2.46 (m, 1H), 2.03 (m, 1H), 1.85 (m, 2H), 1.49 (s, 6H), 1.21 (t, J = 6.8 Hz, 3H).

++





 7


embedded image


(R)-5-(2-(3-(2- ethoxy-1,1,1, 3,3,3- hexafluoropropan- 2-yl)-3-(4- methylphenethyl) pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine
517

1H NMR (300 MHz, MeOD) δ 8.59 (s, 1H), 7.95 (d, J = 7.0 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 12.5 Hz, 2H), 7.03 (d, J = 12.5 Hz, 2H), 4.03 − 3.92 (m, 2H), 3.06 (d, J = 9.8 Hz, 1H), 2.88 (q, J = 15.6 Hz, J = 7.8 Hz, 4H), 2.73-2.65 (m, 6H), 2.58 (d, J = 7.8 Hz, 1H), 2.52 (s, 3H), 2.41 (s, 1H), 2.29 (s, 3H), 1.99 (d, J = 14.1 Hz, 1H), 1.83 (d, J = 6.4 Hz, 2H), 1.50 (s, 6H), 1.21 (t, J = 6.9 Hz, 3H).

+





 8


embedded image


(R)-4-(2-(3-(2- ethoxy-1,1,1, 3,3,3- hexafluoropropan- 2-yl)-1-((6- methylpyridin-3- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile
500

1H NMR (300 MHz, MeOD) δ 8.41 (s, 1H), 7.76 (d, J = 1.2 Hz, 1H), 7.64 (d, J = 7.9 Hz, 2H), 7.41 − 7.28 (m, 3H), 3.98 (m, 2H), 3.71 (s, 2H), 2.94 (m, 2H), 2.83 (d, J = 15.6 Hz, J = 6.8 Hz, 4H), 2.75 (m, 2H), 2.53 (s, 3H), 2.42 (m, 2H), 1.94 (s, 3H), 1.93 − 1.74 (m, 2H), 1.25 (t, J = 6.8 Hz, 3H).

+





 9


embedded image


(R)-4-(2-(3-(2- ethoxy-1,1,1,3,3,3- hexafluoropropan- 2-yl)-1-(pyridin-3- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile
486

1H NMR (300 MHz, MeOD) δ 8.55 (s, 1H), 8.47 (d, J = 4.4 Hz, 1H), 7.87 (d, J = 7.4 Hz, 1H), 7.64 (d, J = 7.8 Hz, 2H), 7.48 − 7.40 (m, 1H), 7.37 (d, J = 8.0 Hz, 2H), 4.02 (m, 2H), 3.76 (d, J = 8.3 Hz,2H), 2.98 (m, 3H), 2.91 (d, J = 8.3 Hz, 2H), 2.89 − 2.73 (q, J = 15.6 Hz, J = 7.8 Hz, 4H), 2.53 (m, 1H), 2.43 (m, 1H), 1.89 (m, 3H), 1.26 (t, J = 6.9 Hz, 3H).

+





 10


embedded image


(R)-4-(2-(1- (di(pyridin-3- yl)methyl)-3- (ethoxymethyl) pyrrolidin-3- yl)ethyl) benzonitrile
427

1H NMR (300 MHz, MeOD) δ 8.67 (s, 2H), 8.42 (d, J = 4.4 Hz, 2H), 7.99 (d, J = 7.5 Hz, 2H), 7.62 (d, J = 7.9 Hz, 2H), 7.38 (s, 4H), 4.49 (s, 1H), 3.51 (d, J = 6.9 Hz, 3H), 3.40 (dd, J = 14.2, 7.8 Hz, 2H), 2.84 (q, J = 15.7 Hz,7.8Hz, 4H), 2.73 − 2.63 (m, 2H), 2.51 (d, J = 9.5 Hz, 2H), 2.25 (d, J = 9.5 Hz, 1H), 1.75 (m, 4H), 1.17 (t, J = 6.9 Hz, 3H).

+





 11


embedded image


4-(2-((R)-3-((R or S)-oxetan-2-yl)-1- (pyridin-3- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile
348

1H NMR (300 MHz, MeOD) δ 8.69 (d, J = 12.1 Hz, 1H), 8.65 − 8.56 (m, 1H), 8.13 − 8.00 (m, 1H), 7.63 (d, J = 7.7 Hz, 2H), 7.54 (dd, J = 12.6, 7.3 Hz, 1H), 7.40 (d, J = 7.7 Hz, 2H), 5.06 − 4.94 (m, 2H), 4.77 − 4.69 (m, 1H), 4.51 − 4.25 (m, 3H), 3.46 − 3.34 (m, 2H), 3.27 − 3.15 (m, 2H), 2.80 (dd, J = 34.4, 15.6 Hz, 6H), 2.69 − 2.44 (m, 4H), 2.11 − 1.97 (m, 1H), 1.89 − 1.71 (m, 2H).

++





 12


embedded image


3-(((R)-3-(4- fluorophenethyl)-3- ((R or S)-oxetan-2- yl)pyrrolidin-1- yl)methyl)pyridine
341

1H NMR (300 MHz, MeOD) δ 8.72 − 8.56 (m, 2H), 8.08 − 7.95 (m, 1H), 7.58 − 7.48 (m, 1H), 7.24 − 7.15 (m, 2H), 6.98 (t, J = 8.4 Hz, 2H), 4.99 (dd, J = 17.4, 7.8 Hz, 2H), 4.73 (dd, J = 14.2, 7.9 Hz, 1H), 4.50 − 4.17 (m, 3H), 3.56 (d, J = 11.2 Hz, 1H), 3.10 (dd, J = 26.5, 11.5 Hz, 2H), 2.80 (q, J = 15.5 Hz, 7H), 2.67 − 2.51 (m, 4H), 2.11 − 1.89 (m, 2H), 1.81 − 1.66 (m, 2H).

++





 13


embedded image


(R)-5-((3-(2- ethoxy-1,1,1,3,3,3- hexafluoropropan- 2-yl)-3-(4- fluorophenethyl) pyrrolidin-1- yl)methyl)-2- methylpyridine
493

1H NMR (300 MHz, MeOD) δ 8.55 (s, 1H), 7.87 (d, J = 7.4 Hz, 1H), 7.34 (d, J = 7.8 Hz, 1H), 7.28 (t, J = 8.0 Hz, 2H), 7.37 (t, J = 8.0 Hz, 2H), 4.02 (m, 2H), 3.76 (d, J = 8.3 Hz, 2H), 2.98 (m, 1H), 2.91 (d, J = 8.3 Hz, 2H), 2.89 − 2.73 (q, J = 15.6 Hz, J = 7.8 Hz, 4H), , 2.53 (s, 3H), 2.43 (m, 3H), 2.00 (m,2H),1.89 (m, 2H), 1.26 (t, J = 6.9 Hz, 3H).

+





 14


embedded image


(R)-3-((3-(2- ethoxy-1,1,1,3,3,3- hexafluoropropan- 2-yl)-3-(4- fluorophenethyl) pyrrolidin-1- yl)methyl)pyridine
479

1H NMR (300 MHz, MeOD) δ 8.55 (s, 1H), 8.47 (d, J = 4.4 Hz, 1H), 7.87 (d, J = 7.4 Hz, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.18 (t, J = 8.0 Hz, 1H), 7.0 (t, J = 8.0 Hz, 2H), 4.02 (m, 2H), 3.76 (m,2H), 2.98 (m, 1H), 2.89 − 2.73 (m, 8H), 2.53 (m, 2H), 2.03 (m, 2H), 1.89 (m, 1H), 1.26 (t, J = 6.9 Hz, 3H).

+





 15


embedded image


(R)-(3-(4- fluorophenethyl)-1- (2-(6- methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)methanol
357

1H NMR (300 MHz, MeOD) δ 8.68 (s, 1H), 8.02 (d, J = 6.2 Hz, 1H), 7.41 (d, J = 8.1 Hz, 1H), 7.21 − 7.12 (m, 2H), 6.96 (t, J = 8.6 Hz, 2H), 3.50 (s, 2H), 3.27 − 3.19 (m, 2H), 3.10 (t, J = 10.2 Hz, 1H), 2.80 (q, J = 15.5 Hz, 7H), 2.57 − 2.48 (m, 5H), 2.07 − 1.83 (m, 3H), 1.80 (s, 6H), 1.70 (dd, J = 16.0, 7.6 Hz, 2H).

++





 16


embedded image


(R)-5-(2-(3-(4- fluorophenethyl)-3- ((methylsulfonyl) methyl)pyrrolidin-1- yl)propan-2-yl)-2- methylpyridine
419

1H NMR (300 MHz, MeOD) δ 8.64 (s, 1H), 8.02 (d, J = 8.1 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 7.21 (dd, J = 8.2, 5.5 Hz, 2H), 6.96 (t, J = 8.7 Hz, 2H), 3.58 − 3.44 (m, 2H), 3.21 (d, J = 11.0 Hz, 2H), 3.14 − 3.04 (m, 2H), 3.01 (s, 3H), 2.81 (dd, J = 34.0, 15.5 Hz, 6H), 2.70 − 2.60 (m, 2H), 2.53 (s, 3H), 2.07 − 1.81 (m, 4H), 1.65 (s, 6H).

++





 17


embedded image


(R)-4-(2-(3- ((benzyloxy) methyl)- 1-(2-(6- methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
454

1H NMR (300 MHz, MeOD) δ 8.65 (s, 1H), 8.05 − 7.95 (m, 1H), 7.60 (d, J = 8.1 Hz, 2H), 7.42 − 7.26 (m, 8H), 4.47 (s, 2H), 3.44 − 3.35 (m, 2H), 3.25 − 3.16 (m, 2H), 3.11 (d, J = 11.5 Hz, 1H), 2.92 (d, J = 11.4 Hz, 1H), 2.79 (q, J = 15.5 Hz, 5H), 2.62 − 2.48 (m, 5H), 1.98 − 1.68 (m, 10H).

++





 18


embedded image


(R)-4-(2-(3- (hydroxymethyl)-1- (2-(6- methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
364

1H NMR (300 MHz, MeOD) δ 8.70 (s, 1H), 8.08 (d, J = 7.6 Hz, 1H), 7.62 (d, J = 7.5 Hz, 2H), 7.40 (t, J = 9.7 Hz, 3H), 3.51 (s, 2H), 3.25 (m, 2H), 3.18 (d, J = 12.0 Hz, 1H), 2.93 (d, J = 11.9 Hz, 1H), 2.80 (q, J = 15.5 Hz, 5H), 2.68 − 2.59 (m, 2H), 2.56 (s, 3H), 2.02 − 1.65 (m, 10H).

++





 19


embedded image


(R)-4-(2-(1-(2-(6- methylpyridin-3- yl)propan-2-yl)-3- ((methylsulfonyl) methyl)pyrrolidin-3- yl)ethyl)benzonitrile
426

1H NMR (300 MHz, MeOD) δ 8.65 (s, 1H), 8.05 (d, J = 6.7 Hz, 1H), 7.63 (d, J = 8.1 Hz, 2H), 7.40 (t, J = 7.8 Hz, 3H), 3.55 (dt, J = 20.3, 12.6 Hz, 4H), 3.17 − 3.06 (m, 2H), 3.02 (s, 3H), 2.80 (dt, J = 14.9, 11.4 Hz, 11H), 2.54 (s, 3H), 2.12 − 1.83 (m, 4H), 1.67 (s, 6H).

++





 20


embedded image


((R)-3-(4- cyanophenethyl)-1- (2-(6- methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)methyl methanesulfinate
426

1H NMR (300 MHz, MeOD) δ 8.71 (d, J = 8.1 Hz, 1H), 8.08 (d, J = 7.5 Hz, 1H), 7.63 (d, J = 7.9 Hz, 2H), 7.47 − 7.34 (m, 3H), 4.09 − 3.95 (m, 1H), 3.51 (s, 1H), 3.28 − 3.15 (m, 3H), 3.09 (d, J = 11.8 Hz, 1H), 2.98 (d, J = 11.9 Hz, 1H), 2.83 (dd, J = 34.4, 15.6 Hz, 9H), 2.71 − 2.61 (m, 4H), 2.57 (s, 3H), 2.27 (s, 1H), 2.04 − 1.90 (m, 2H), 1.77 (s, 6H).

++





 21


embedded image


4-(2-((S)-3-((R or S)-oxetan-2-yl)-1- (pyridin-3- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile
348

1H NMR (300 MHz, MeOD) δ 8.75 − 8.56 (m, 2H), 8.13 − 7.96 (m, 1H), 7.63 (d, J = 8.1 Hz, 2H), 7.53 (d, J = 6.1 Hz, 1H), 7.39 (d, J = 7.8 Hz, 2H), 5.00 (dd, J = 18.5, 8.7 Hz, 6H), 4.52 − 4.20 (m, 1H), 3.67 − 3.42 (m, 2H), 3.13 (dd, J = 25.4, 12.0 Hz, 1H), 2.81 (dd, J = 33.6, 15.6 Hz, 8H), 2.70 − 2.41 (m, 3H), 2.21 − 1.92 (m, 1H), 1.87 − 1.63 (m, 2H), 0.88 (dd, J = 13.6, 6.5 Hz, 1H).

+





 22


embedded image


(R)-4-(2-(3-(2- ethoxy-1,1,1,3,3,3- hexafluoropropan- 2-yl)-1-(2- (isothiazol-5- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
520

1H NMR (300 MHz, MeOD) δ 8.42 (s, 1H), 7.66 (d, J = 7.9 Hz, 2H), 7.39 (d, J = 7.9 Hz, 2H), 7.30 (s, 1H), 3.97 (m, 2H), 3.21-3.05 (m, 2H), 3.0(m,3H),2.84 (q, J = 15.7 Hz,7.8Hz, 4H), 2.80-2.75 (m, 4H),2.53 (m, 1H), 2.01 (m, 1H), 1.95 (m, 1H),1.17 (m, 6H).

++





 23


embedded image


(R)-5-(2-(3- ((benzyloxy)methyl )-3-(2-ethoxy- 1,1,1,3,3,3- hexafluoropropan- 2-yl)pyrrolidin-1- yl)propan-2- yl)isothiazole
511

1H NMR (300 MHz, MeOD) δ 8.37 (s, 1H), 7.30 (m,5H), 7.18 (s, 1H), 4.49 (s, 2H), 3.95 (m, 2H), 3.65(m,1H),3.52 (dd, J = 14.2, 7.8 Hz, 2H), 3.02 (d, J = 7.8 Hz, 1H),2.84 (q, J = 15.7 Hz,7.8Hz, 4H), 2.73 − 2.63 (m, 4H), 2.31 (m, 1H), 2.25 (m, 1H), 1.95 (m, 1H), 1.17 (m, 6H).

+





 24


embedded image


(R)-3-(3-(3- ((benzyloxy)methyl )-3-(1,1,1,3,3,3- hexafluoro-2- methoxypropan-2- yl)pyrrolidin-1- yl)oxetan-3-yl)- 1,2,4-oxadiazole
496

1H NMR (300 MHz, MeOD) δ 9.17 (s, 1H), 7.25 (m, 5H), 4.49 (s, 2H), 3.78 (m, 4H), 3.49 (m,4H),3.05(m,1H), 2.84 (q, J = 15.7 Hz,7.8Hz, 4H), 2.73 − 2.63 (m,4H), 2.11 (d, J = 9.5 Hz, 1H), 1.95 (d, J = 9.5 Hz, 1H).

+





 25


embedded image


4-(2-((3R)-3- (ethoxymethyl)-1- (1-(pyridazin-4- yl)ethyl)pyrrolidin- 3- yl)ethyl)benzonitrile
365

1H NMR (300 MHz, MeOD) δ 9.25 (s, 1H), δ 9.19 (s, 1H), δ 7.81 (s, 1H), 7.62 (d, J = 7.9 Hz, 2H), 7.35 (d, J = 7.9 Hz, 2H), 3.78 (m, 1H), 3.51 (m, 2H), 3.49(s,2H), 3.03(m,1H), 2.84 (q, J = 15.7 Hz,7.8Hz, 4H), 2.80(m,1H), 2.75-2.72 (m, 4H), 1.78 (m, 4H), 1.51 (m, 3H), 1.17 (m, 3H).

++





 26


embedded image


(R)-4-(2-(1-(2-(6- methylpyridin-3- yl)propan-2-yl)-3- ((2,2,2- trifluoroethoxy) methyl)pyrrolidin-3- yl)ethyl)benzonitrile
450

1H NMR (300 MHz, MeOD) δ 8.69 (s, 1H), 8.08 (d, J = 6.8 Hz, 1H), 7.63 (d, J = 7.3 Hz, 2H), 7.39 (dd, J = 16.3, 7.2 Hz, 3H), 3.95 (dd, J = 17.8, 9.3 Hz, 2H), 3.68 − 3.53 (m, 2H), 3.27 − 3.19 (m, 2H), 3.15 (d, J = 11.3 Hz, 1H), 2.96 (d, J = 11.5 Hz, 1H), 2.82 (dd, J = 33.8, 15.5 Hz, 8H), 2.69 − 2.59 (m, 2H), 2.56 (s, 3H), 2.05 − 1.88 (m, 2H), 1.80 (s, 6H), 1.75 − 1.56 (m, 2H).

+





 27


embedded image


(S)-4-(2-(1- (di(pyridin-3- yl)methyl)-3- (ethoxymethyl) pyrrolidin-3- yl)ethyl) benzonitrile
427

1H NMR (300 MHz, MeOD) δ 8.67 (s, 2H), 8.43 (d, J = 4.4 Hz, 2H), 8.00 (d, J = 7.6 Hz, 2H), 7.62 (d, J = 8.1 Hz, 2H), 7.47 − 7.34 (m, 4H), 4.51 (s, 1H), 3.51 (q, J = 7.0 Hz, 2H), 3.39 (dd, J = 16.1, 9.8 Hz, 2H), 2.84 (dd, J = 35.7, 15.6 Hz, 7H), 2.72 − 2.64 (m, 2H), 2.59 − 2.48 (m, 3H), 2.27 (d, J = 9.6 Hz, 1H), 1.87 − 1.67 (m, 4H), 1.18 (t, J = 7.0 Hz, 3H).

+





 28


embedded image


(R)-4-(2-(3-((2,2,2- trifluoroethoxy) methyl)-1-(2-(6- (trifluoromethyl) pyridin-3-yl)propan- 2-yl)pyrrolidin-3- yl)ethyl) benzonitrile
500

1H NMR (300 MHz, MeOD) δ 8.97 (s, 1H), 8.29 (d, J = 7.8 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 8.1 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 3.95 (q, J = 8.9 Hz, 2H), 3.64 − 3.55 (m, 2H), 3.09 − 2.94 (m, 3H), 2.93 − 2.71 (m, 14H), 2.70 − 2.62 (m, 2H), 1.91 − 1.74 (m, 5H), 1.70 (s, 6H).

+





 29


embedded image


2-isopropyl-4-(2- ((R)-3-(4- (methylsulfonyl)ph enethyl)-3-((R or S)-tetrahydrofuran- 2-yl)pyrrolidin-1- yl)propan-2- yl)thiazole
491

1H NMR (300 MHz, MeOD) δ 7.85 (d, J = 4.4 Hz, 2H), 7.65 (s, 1H), 7.45 (d, J = 4.4 Hz, 2H), 4.04-3.91 (m, 1H), 3.09 (s, 3H), 3.40 (m, 4H), 2.84 (q, J = 15.7 Hz,7.8Hz, 4H), 2.73 − 2.63 (m, 3H), 2.01 (m, 4H), 1.81 (s, 6H), 1.60 (m, 2H), 1.35 (m, 6H).

++





 30


embedded image


4-(2-((R)-1-(2-(2- isopropylthiazol-4- yl)propan-2-yl)-3- ((R or S)- tetrahydrofuran-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
438

1H NMR (300 MHz, MeOD) δ 7.63 (d, J = 4.0 Hz, 2H), 7.36 (d, J = 4.0 Hz, 2H), 4.04-3.71 (m, 3H), 3.55-3.40 (m, 3H), 3.01 (m, 1H),2.84 (q, J = 15.7 Hz,7.8Hz, 4H), 2.73 − 2.63 (m, 2H), 2.20 (m, 1 H), 2.01 (m, 5H), 1.81 (s, 6H), 1.75 (m, 2H), 1.60 (m, 1 H), 1.35 (d, J = 4.4 Hz, 6H).

+





 31


embedded image


4-(2-((R)-3-((R or S)- ethoxy(phenyl) methyl)-1-(2- phenylpropan-2- yl)pyrrolidin-3- yl)ethyl)benzonitrile
453

1H NMR (300 MHz, MeOD) δ 7.70 (d, J = 7.0 Hz, 2H), 7.61 (d, J = 7.9 Hz, 2H), 7.58 − 7.48 (m, 3H), 7.40 − 7.21 (m, 7H), 4.42 (s, 1H), 3.55 − 3.43 (m, 1H), 3.41 − 3.35 (m, 1H), 3.18 (d, J = 14.2 Hz, 2H), 2.82 (dd, J = 33.2, 15.6 Hz, 12H), 2.71 − 2.26 (m, 4H), 2.22 − 1.94 (m, 2H), 1.85 (d, J = 6.1 Hz, 6H), 1.77 − 1.62 (m, 2H), 1.13 (t, J = 6.9 Hz, 3H).

+





 32


embedded image


4-(2-((R)-3-((R or S)- ethoxy(phenyl) methyl)-1-(2- phenylpropan-2- yl)pyrrolidin-3- yl)ethyl)benzonitrile
453

1H NMR (300 MHz, MeOD) δ 7.74 (d, J = 7.7 Hz, 2H), 7.63 − 7.47 (m, 6H), 7.39 − 7.33 (m, 3H), 7.29 − 7.23 (m, 3H), 4.43 (s, 1H), 3.58 (t, J = 12.9 Hz, 2H), 3.49 − 3.38 (m, 2H), 2.92 − 2.73 (m, 9H), 2.71 − 2.57 (m, 1H), 2.39 − 1.95 (m, 3H), 1.89 (d, J = 3.6 Hz, 6H), 1.08 (s, 3H).

+





 33


embedded image


(R)-3- ((benzyloxy) methyl)-3-(4- fluorophenethyl)-1- (2-(4- (methylsulfonyl) phenyl)propan-2- yl)pyrrolidine
510

1H NMR (300 MHz, MeOD) δ 8.04 (d, J = 7.9 Hz, 2H), 7.88 (d, J = 7.9 Hz, 2H), 7.35 (m, 5H), 7.12 (dd, J = 8.4, 5.4 Hz, 2H), 6.96 (t, J = 8.6 Hz, 2H), 4.50 (s, 2H), 3.45 − 3.37 (m, 2H), 3.20 (d, J = 11.2 Hz, 1H), 3.12 (s, 3H), 2.82 (m, 8H), 2.54 − 2.40 (m, 2H), 2.02 (d, J = 6.0 Hz, 2H), 1.80 (s, 6H).

+





 34


embedded image


(3R)-3- ((benzyloxy) methyl)-3-(4- fluorophenethyl)-1- (2-(4- (methylsulfonyl) phenyl)butan-2- yl)pyrrolidine
524

1H NMR (300 MHz, MeOD) δ 8.06 (t, J = 6.9 Hz, 2H), 7.86 (d, J = 8.2 Hz, 2H), 7.47 − 7.27 (m, 5H), 7.11 (d, J = 4.2 Hz, 2H), 6.96 (t, J = 8.6 Hz, 2H), 4.60 − 4.54 (m, 2H), 3.53 − 3.34 (m, 2H), 3.17 (d, J = 21.1 Hz, 6H), 2.83 (q, J = 15.6 Hz, 4H), 2.47 (m, 2H), 2.17 − 1.97 (m, 2H), 1.78 (m, 6H).

+





 35


embedded image


(R)-(1-(2-(4- chlorophenyl) propan-2-yl)-3-(4- (methylsulfonyl) phenethyl) pyrrolidin- 3-yl)methanol
436

1H NMR (300 MHz, MeOD) δ 7.85 (d, J = 8.1 Hz, 2H), 7.71 (d, J = 8.3 Hz, 2H), 7.52 (d, J = 8.3 Hz, 2H), 7.45 (d, J = 8.1 Hz, 2H), 3.48 (dd, J = 12.8, 5.7 Hz, 2H), 3.09 (s, 3H), 3.00 (d, J = 11.7 Hz, 1H), 2.82 (q, J = 15.6 Hz, 4H), 2.69 − 2.57 (m, 2H), 2.03 (m, 2H), 1.85 (s, 6H), 1.73 (m, 2H).

+





 36


embedded image


(R)-(3-(4- fluorophenethyl)-1- (2-(4- (methylsulfonyl)ph enyl)propan-2- yl)pyrrolidin-3- yl)methanol
420

1H NMR (300 MHz, MeOD) δ 8.07 (d, J = 8.4 Hz, 2H), 7.98 (d, J = 8.4 Hz, 2H), 7.18 (m, 2H), 6.97 (t, J = 8.7 Hz, 2H), 3.52 (s, 2H), 3.21 (m, 4H), 3.14 (s, 3H), 2.93 (d, J = 12.3 Hz, 1H), 2.81 (q, J = 15.6 Hz, 4H), 2.58 − 2.47 (m, 2H), 2.01 (m, 1H), 1.86 (s, 6H), 1.73 (m, 2H).

+





 37


embedded image


(R)-3- ((benzyloxy) methyl)-1-(2-(4- chlorophenyl) propan-2-yl)-3-(4- (methylsulfonyl) phenethyl) pyrrolidine
526

1H NMR (300 MHz, MeOD) δ 7.84 (d, J = 8.2 Hz, 2H), 7.62 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 8.6 Hz, 2H), 7.35 (m, 7H), 4.45 (s, 2H), 3.44 − 3.32 (m, 2H), 3.21 (d, J = 11.9 Hz, 1H), 3.08 (s, 3H), 2.78 (q, J = 15.6 Hz, 4H), 2.65 − 2.49 (m, 2H), 1.96 (m, 3H), 1.77 (s, 6H), 1.30 (d, J = 2.3 Hz, 3H).

+





 38


embedded image


(R or S)-1-((R)-3- (4- fluorophenethyl)-1- (2-(4- (methylsulfonyl) phenyl)propan-2- yl)pyrrolidin-3- yl)ethan-1-ol
434

1H NMR (300 MHz, MeOD) δ 8.08 (d, J = 8.6 Hz, 2H), 8.00 (d, J = 8.6 Hz, 2H), 7.22 − 7.12 (m, 2H), 6.97 (t, J = 8.8 Hz, 2H), 3.90 (d, J = 6.3 Hz, 1H), 3.50 − 3.36 (m, 3H), 3.13 (s, 3H), 2.89 (s, 2H), 2.85 − 2.71 (q, J = 15.6 Hz, 4H), 2.59 − 2.46 (m, 2H), 2.25 − 2.12 (m, 1H), 2.05 (m, 1H), 1.90 (s, 6H), 1.72 (m, 3H), 1.13 (d, J = 6.3 Hz, 3H).

+





 39


embedded image


(R or S)-1-((R)-3- (4- fluorophenethyl)-1- (2-(4- (methylsulfonyl) phenyl)propan-2- yl)pyrrolidin-3- yl)ethan-1-ol
434

1H NMR (300 MHz, MeOD) δ 8.06 (d, J = 7.3 Hz, 2H), 7.95 (d, J = 8.2 Hz, 2H), 7.16 (s, 2H), 6.97 (t, J = 8.4 Hz, 2H), 3.87 (m, 1H), 3.35(m, 4H), 3.13 (s, 3H), 2.80 (q, J = 15.6 Hz, 4H), 2.53 (m, 2H), 2.14 (m, 1H), 1.98 (m, 1H), 1.85 (s, 6H), 1.70 (m, 2H), 1.13 (d, J = 5.9 Hz, 3H).

+





 40


embedded image


(R)-3- ((benzyloxy) methyl)-3-(4- fluorophenethyl)-1- (2-(4- (methylthio) phenyl)propan-2- yl)pyrrolidine
478

1H NMR (300 MHz, MeOD) δ 7.52 (d, J = 7.3 Hz, 2H), 7.43 − 7.26 (m, 7H), 7.08 (m, 2H), 6.96 (t, J = 8.7 Hz, 2H), 4.47 (s, 2H), 3.35 (m, 2H), 3.25 (d, J = 12.2 Hz, 2H), 2.99 (d, J = 12.0 Hz, 2H), 2.82 (q, J = 15.6 Hz, 4H), 2.49 (s, 3H), 2.44 (m, 2H), 2.06 (m, 2H), 1.79 (s, 6H), 1.73 − 1.51 (m, 2H).

+





 41


embedded image


4-(2-((S)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((S)- tetrahydrofuran-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
390

+





 42


embedded image


2-(2-((S)-3- ((benzyloxy) methyl)-3- ((R or S)- tetrahydrofuran-2- yl)pyrrolidin-1- yl)propan-2- yl)pyridine
381

+





 43


embedded image


(S)-1-(2-(4- chlorophenyl) propan-2-yl)-3- (methoxymethyl)- 3-(4- (methylsulfonyl) phenethyl) pyrrolidine
450

1H NMR (300 MHz, MeOD) δ 7.88 (d, J = 8.1 Hz, 2H), 7.71 (d, J = 7.7 Hz, 2H), 7.55 (d, J = 7.9 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 3.30 − 3.21 (m, 5H), 3.14 − 3.07 (m, 4H), 3.05 − 2.98 (m, 1H), 2.82 (q, J = 15.5 Hz, 7H), 2.66 (t, J = 7.7 Hz, 2H), 2.11 − 1.90 (m, 3H), 1.85 (s, 6H), 1.79 − 1.66 (m, 3H).

+





 44


embedded image


(S)-(1-(2-(4- chlorophenyl) propan-2-yl)-3-(4- (methylsulfonyl) phenethyl) pyrrolidin- 3-yl)methanol
436

1H NMR (300 MHz, MeOD) δ 7.86 (s, 2H), 7.72 (d, J = 8.7 Hz, 2H), 7.55 (d, J = 8.1 Hz, 2H), 7.43 (d, J = 8.1 Hz, 2H), 3.53 (s, 2H), 3.29 − 3.18 (m, 3H), 3.01 − 2.97 (d, J = 12.1 Hz, 1H), 2.80 (q, J = 30.3, 15.6 Hz, 6H), 2.71 (t, J = 4.5 Hz, 3H), 2.03-1.98 (m, 3H), 1.96 (s, 6H), 1.93 − 1.85 (m, 2H).

+





 45


embedded image


(S)-5-chloro-2-(2- (3- (methoxymethyl)- 3-(4- (methylsulfonyl) phenethyl) pyrrolidin- 1-yl)propan-2- yl)pyridine
451

1H NMR (300 MHz, MeOD) δ 8.71 (s, 1H), 8.01 (d, J = 8.6 Hz, 1H), 7.93 (d, J = 8.2 Hz, 2H), 7.69 (d, J = 8.3 Hz, 3H), 6.71 (d, J = 16.4 Hz, 1H), 6.54 (d, J = 16.6 Hz, 1H), 3.60 − 3.39 (m, 11H), 3.28 − 3.22 (m, 1H), 3.14 (s, 3H), 3.12 − 3.07 (m, 1H), 2.82 (q, J = 15.5 Hz, 7H), 2.39 − 2.28 (m, 2H), 1.79 (s, 6H).

+





 46


embedded image


4-(2-((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)- tetrahydrofuran-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
390

1H NMR (300 MHz, MeOD) δ 8.69 (d, J = 1.6 Hz, 2H), 8.0 (m, 1H), 7.68 (m, 3H), 7.48 (m, 3H), 4.04- 4.00(m, 2H), 3.98-3.80 (m, 2H), 3.60-3.40 (m, 2H), 3.1 (m, 2H), 2.84 (q, J = 15.7 Hz, 7.8Hz, 4H), 2.37 − 2.15 (m, 3H), 2.14-2.00 (m, 4 H), 1.98-1.85 (m, 2H), 1.67 (d, J = 4.4 Hz, 6H).

+





 47


embedded image


2-(2-((S)-3-(4- (methylsulfonyl) phenethyl)-3-((R or S)-tetrahydrofuran- 2-yl)pyrrolidin-1- yl)propan-2- yl)pyridine
443

1H NMR (300 MHz, MeOD) δ 8.68 (s, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.84 (d, J = 8.2 Hz, 2H), 7.62 (d, J = 7.7 Hz, 1H), 7.48 (m, 3H), 4.01-3.81 (m, 2H), 3.20 (d, J = 11.6 Hz, 2H), 2.86 (m, 9H), 2.49 (s, 3H), 2.26 -2.11 (m, 2H), 1.90 (dd, J = 21.4, 12.6 Hz, 6H), 1.75 (d, J = 10.2 Hz, 6H).

+





 48


embedded image


2-(2-((S)-3-(4- (methylsulfonyl) phenethyl)-3-((R or S)-tetrahydrofuran- 2-yl)pyrrolidin-1- yl)propan-2- yl)pyridine
443

1H NMR (300 MHz, MeOD) δ 8.68 (s, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.84 (d, J = 8.2 Hz, 2H), 7.62 (d, J = 7.7 Hz, 1H), 7.48 (m, 3H), 4.01-3.81 (m, 2H), 3.20 (d, J = 11.6 Hz, 2H), 2.98 (m, 2H), 2.86 (m, 7H), 2.49 (s, 3H), 2.26 − 2.11 (m, 2H), 1.90 (m, 6H), 1.75 (d, J = 10.2 Hz, 6H).

+





 49


embedded image


(S)-4-(2-(1- (di(pyridin-3- yl)methyl)-3- (hydroxymethyl) pyrrolidin-3- yl)ethyl) benzonitrile
399

1H NMR (300 MHz, MeOD) δ 8.70 (s, 2H), 8.46 (d, J = 4.5 Hz, 2H), 8.04 (s, 2H), 7.64 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 7.9 Hz, 4H), 4.57 (s, 1H), 3.57 − 3.51 (m, 2H), 3.36 (s, 2H), 2.87 (q, J = 15.6 Hz, 4H), 2.77 − 2.66 (m, 2H), 2.56 − 2.51 (m, 2H), 2.32 (d, J = 9.3 Hz, 1H), 1.76 − 1.69 (m, 3H).

+





 50


embedded image


(R or S)-2,2,2- trifluoro-1-((R)-3- (4- fluorophenethyl)-1- (2-(4- (methylsulfonyl) phenyl)propan-2- yl)pyrrolidin-3- yl)ethan-1-ol
488

1H NMR (300 MHz, MeOD) δ 8.05 (d, J = 7.6 Hz, 2H), 7.96 (d, J = 7.6 Hz, 2H), 7.15 (m, 2H), 7.01 (t, J = 8.5 Hz, 2H), 4.13 (m, 2H), 3.36 (d, J = 4.7 Hz, 2H), 3.17 (m, 2H), 3.14 (s, 3H), 2.84 (q, J = 15.6 Hz, 4H), 2.61 (m, 2H), 2.40 (m, 1H), 2.12 (m, 2H), 1.77 (d, J = 7.0 Hz, 6H).

+





 51


embedded image


(S)-1-(2-(4- chlorophenyl) propan-2-yl)-3- (ethoxymethyl)-3- (4- (methylsulfonyl) phenethyl) pyrrolidine
464

1H NMR (300 MHz, MeOD) δ 7.85 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.2 Hz, 2H), 7.50 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 3.46 (dd, J = 14.0, 7.0 Hz, 2H), 3.33 (m, 2H), 3.19 (d, J = 11.4 Hz, 1H), 3.09 (s, 3H), 3.01 (d, J = 11.4 Hz, 1H), 2.77 (q, J = 15.4 Hz, 4H), 2.65 (t, J = 8.6 Hz, 2H), 1.95 (m, 4H), 1.81 (s, 6H), 1.73 (m, 2H), 1.15 (t, J = 7.0 Hz, 3H).

++





 52


embedded image


4-(2-((R)-3-((R or S)-1-ethoxy-2,2,2- trifluoroethyl)-1-(2- (pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl)benzonitrile
446

1H NMR (300 MHz, MeOD) δ 8.67 (s, 1H), 7.96 (d, J = 6.9 Hz, 1H), 7.67 (d, J = 7.7 Hz, 3H), 7.52 − 7.44 (m, 1H), 7.40 (d, J = 7.5 Hz, 1H), 4.22 − 3.94 (m, 2H), 3.79 (m, 2H), 3.46 (m, 2H), 3.25 − 3.14 (m, 2H), 2.80 (q, J = 15.5 Hz, 4H), 2.50 (m, 2H), 1.99 (m, 4H), 1.80 (s, 6H), 1.33 (t, J = 7.0 Hz, 3H).

+





 53


embedded image


(R)-(3-(4- (methylsulfonyl) phenethyl)-1-(2- (pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)methanol
403

1H NMR (300 MHz, MeOD) δ 8.70 (d, J = 3.6 Hz, 1H), 7.96 (t, J = 7.0 Hz, 1H), 7.89 (d, J = 8.3 Hz, 2H), 7.64 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 8.3 Hz, 2H), 7.47 − 7.42 (m, 1H), 3.67 − 3.65 (m, 2H), 3.46 (t, J = 7.3 Hz, 2H), 3.12 (s, 3H), 2.82 (q, J = 15.5 Hz, 4H), 2.74 (d, J = 5.6 Hz, 2H), 2.18 − 2.09 (m, 2H), 2.07 − 1.98 (m, 2H), 1.92 − 1.84 (m, 2H), 1.79 (d, J = 5.9 Hz, 6H).

+





 54


embedded image


(R)-4-(2-(3- (hydroxymethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
350

1H NMR (300 MHz, MeOD) δ 8.68 (s, 1H), 7.94 − 7.92 (m, 1H), 7.63 (t, J = 8.3 Hz, 3H), 7.42 (d, J = 8.3 Hz, 3H), 3.64 (s, 2H), 3.43 − 3.37 (m, 2H), 2.82 (q, J = 15.6 Hz, 4H), 2.70 − 2.67 (m, 2H), 2.24 − 2.04 (m, 4H), 1.82 − 1.79 (m, 2H), 1.77 (d, J = 4.9 Hz, 6H).

++





 55


embedded image


4-(2-((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
418

1H NMR (300 MHz, MeOD) δ 8.69 (s, 1H), 8.02 7.92 (m, 1H), 7.65 (m, 3H), 7.42 (m, 3H), 4.32 (s, 1H), 3.51 (m, 3H), 3.21 (s, 2H), 2.83 (q, J = 15.6 Hz, 4H), 2.01 (m, 5H), 1.79 (s, 6H).

++





 56


embedded image


4-(2-((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
418

1H NMR (300 MHz, MeOD) δ 8.69 (s, 1H), 8.02 − 7.92 (m, 1H), 7.65 − 7.62 (m, 3H), 7.42 − 7.38 (m, 3H), 4.32 (s, 1H), 3.51 − 3.40 (m, 3H), 3.21 (s, 2H), 2.83 (q, J = 15.6 Hz, 4H), 2.01 − 1.82 (m, 5H), 1.79 (s, 6H).

++





 57


embedded image


4-(2-((R)-3-((R or S)-hydroxy (phenyl)methyl)- 1-(2-(pyridin- 2-yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
426

++





 58


embedded image


4-(2-((3S)-1-((4- fluorophenyl) (pyridin-3- yl)methyl)- 3-((R or S)-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
430

1H NMR (300 MHz, MeOD) δ 8.66 (s, 1H), 8.43 (s, 1H), 8.00 (s, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.53 (s, 2H), 7.46 − 7.30 (m, 3H), 7.08 (t, J = 8.5 Hz, 2H), 4.58 (d, J = 12.5 Hz, 1H), 3.82 − 3.79 (m, 1H), 2.84 (q, J = 15.6 Hz, 4H), 2.70 −2.58 (m, 4H), 2.52 − 2.41 (m, 2H), 2.01-1.77 (m, 4H), 1.18 (d, J = 5.4 Hz, 3H).

+





 59


embedded image


(R)-4-(2-(3- (methoxymethyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl)benzonitrile
364

1H NMR (300 MHz, MeOD) δ 8.69 (s, 1H), 7.94 − 7.85 (m, 1H), 7.64 − 7.59 (m, 3H), 7.41 − 7.32 (m, 3H), 3.46 (s, 6H), 3.11 (d, J = 12.3 Hz, 1H), 2.78 (q, J = 15.6 Hz, 4H), 2.69 − 2.61 (m, 4H), 2.09 (d, J = 20.9 Hz, 2H), 1.83 − 1.79 (m, 2H), 1.75 (s, 6H).

+





 60


embedded image


4-(2-((3S)-3- (ethoxymethyl)-1- ((4- fluorophenyl) (pyridin-3- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile
444

1H NMR (300 MHz, MeOD) δ 8.64 (s, 1H), 8.42 (s, 1H), 7.97 (s, 1H), 7.62 (d, J = 7.4 Hz, 2H), 7.52 − 7.49 (m, 2H), 7.39 − 7.32 (m, 3H), 7.07 − 7.02 (m, 2H), 4.52 (s, 1H), 3.51 − 3.50 (m, 2H), 3.38 − 3.32 (m, 3H), 2.84 (q, J = 15.6 Hz, 4H), 2.65 − 2.57 (m, 4H), 2.38 − 2.35 (m, 1H), 1.74 − 1.69 (m, 4H), 1.19 (t, J = 7.0 Hz, 3H).

+





 61


embedded image


4-(2-((R)-3-((R or S)-1-hydroxy-2- methylpropyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
392

1H NMR (300 MHz, MeOD) δ 8.68 (d, J = 3.9 Hz, 1H), 7.95 (t, J = 7.9 Hz, 1H), 7.65 (t, J = 9.3 Hz, 3H), 7.44 (t, J = 9.6 Hz, 3H), 3.63 (s, 1H), 3.48 − 3.34 (m, 3H), 3.28 − 3.19 (m, 1H), 2.85 − 2.72 (q, J = 15.6 Hz, 4H), 2.68 − 2.66 (m, 2H), 2.53 − 2.50 (m, 1H), 1.97 − 1.86 (m, 4H), 1.77 (d, J = 7.4 Hz, 6H), 1.05 (d, J = 6.8 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H).

+





 62


embedded image


4-(2-((R)-3-((R or S)-1-hydroxy-2- methylpropyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
392

1H NMR (300 MHz, MeOD) δ 8.67 (s, 1H), 7.93 − 7.88 (m, 1H), 7.64 − 7.58 (m, 3H), 7.42 − 7.40 (m, 3H), 3.60 − 3.52 (m, 3H), 3.41 − 3.38 (m, 2H), 2.92 (d, J = 12.2 Hz, 1H), 2.78 (q, J = 15.6 Hz, 4H), 2.25 (s, 2H), 1.97 − 1.89 (m, 2H), 1.85 − 1.80 (m, 2H), 1.76 (s, 6H), 1.04 (d, J = 6.2 Hz, 3H), 0.82 − 0.80 (m, 3H).

+





 63


embedded image


(S)-4-(2-(1- (di(pyridin-3- yl)methyl)-3-(2- hydroxypropan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
427

1H NMR (300 MHz, MeOD) δ 8.72 (d, J = 8.2 Hz, 2H), 8.44 (s, 2H), 8.03 (s, 2H), 7.94 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.50 − 7.32 (m, 4H), 4.51 (s, 1H), 2.84 (q, J = 15.6 Hz, 4H), 2.69 − 2.58 (m, 1H), 2.49 − 2.41 (m, 3H), 2.10 − 2.02 (m, 2H), 1.75 − 1.64 (m, 4H), 1.18 (d, J = 15.6 Hz, 6H).

+





 64


embedded image


4-(2-((3S)-1-((4- fluorophenyl) (pyridin-3-yl) methyl)-3- (hydroxymethyl) pyrrolidin-3- yl)ethyl) benzonitrile
416

1H NMR (300 MHz, MeOD) δ 8.65 (s, 1H), 8.42 (d, J = 4.0 Hz, 1H), 8.02 − 7.96 (m, 1H), 7.62 (d, J = 7.9 Hz, 2H), 7.53 −7.48 (m, 2H), 7.40 (d, J = 8.0 Hz, 2H), 7.07 (t, J = 8.3 Hz, 2H), 4.58 (s, 1H), 3.55 − 3.49 (m, 2H) , 3.35 (s, 2H), 2.84 (q, J = 15.7 Hz, 4H), 2.68 − 2.59 (m, 4H), 2.42 − 2.33 (m, 1H), 1.76 − 1.69 (m, 4H).

+





 65


embedded image


(R)-4-(2-(3- (methoxymethyl)- 1-(2-(6- methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
378

1H NMR (300 MHz, MeOD) δ 8.69 (s, 1H), 8.05 (d, J = 8.2 Hz, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.39 − 7.35 (m, 3H), 3.34 − 3.29 (m, 3H), 3.27 − 3.17 (m, 3H), 3.11 (d, J = 11.3 Hz, 2H), 2.90 (d, J = 15.6 Hz, 1H), 2.85 − 2.69 (q, J = 15.6 Hz, 4H), 2.62 (t, J = 8.4 Hz, 2H), 2.56 (s, 3H), 2.04 − 1.84 (m, 2H), 1.78 (s, 6H), 1.76 − 1.59 (m, 2H).

+





 66


embedded image


(S)-(1-((6- methylpyridin-3- yl)amino)-3- phenethylpyrrolidin- 3-yl)methanol
312

1H NMR (300 MHz, MeOD) δ 8.01 (s, 1H), 7.45 − 7.36 (m, 1H), 7.32 − 7.05 (m, 6H), 4.88 − 4.75 (m, 2H), 3.38 (s, 5H), 2.89 − 2.83 (m, 2H), 2.77 (q, J = 15.6 Hz, 4H), 2.63 − 2.55 (m, 2H), 2.46 (d, J = 3.0 Hz, 3H), 1.80 − 1.64 (m, 4H).

+





 67


embedded image


2-(2-((R)-3-(4- (methylsulfonyl) phenethyl)-3-((R or S)-tetrahydrofuran- 2-yl)pyrrolidin-1- yl)propan-2- yl)pyridine
443

1H NMR (300 MHz, MeOD) δ 8.68 (s, 1H), 7.95 (m, 1H), 7.88 (d, J = 8.2 Hz, 2H), 7.62 (d, J = 7.7 Hz, 1H), 7.50 (m, 2H), 4.03 (m, 2H), 3.83 (m, 2H), 3.53 (m, 2H), 3.09 (s, 3H), 3.00 (m, 1H), 2.80 (q, J = 15.6 Hz, 4H), 2.39-2.19 (m, 2H), 2.02 (m, 4H), 1.82 (m, 4H), 1.81 − 1.69 (m, 4H).

+





 68


embedded image


(S)-(1-(methyl(6- methylpyridin-3- yl)amino)-3- phenethylpyrrolidin- 3-yl)methanol
326

1H NMR (300 MHz, MeOD) δ 8.17 (s, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 8.2 Hz, 1H), 7.24 (s, 4H), 7.17 − 7.07 (m, 1H), 3.57 − 3.53 (m, 2H), 2.92 (s, 3H), 2.88 − 2.73 (q, J = 15.6 Hz, 4H), 2.71 − 2.59 (m, 4H), 2.51 (s, 3H), 1.76 − 1.74 (m, 4H).

+





 69


embedded image


(S)-N-(3- (methoxymethyl)- 3- phenethylpyrrolidin- 1-yl)-N,6- dimethylpyridin-3- amine
340

1H NMR (300 MHz, MeOD) δ 8.17 (s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 7.35 (d, J = 8.8 Hz, 1H), 7.29 − 7.10 (m, 5H), 3.39 (s, 5H), 2.95 − 2.93 (m, 3H), 2.92 − 2.82 (q, J = 8.8 Hz, 4H), 2.76 − 2.75 (m, 2H), 2.74 − 2.58 (m, 4H), 2.49 (s, 3H), 1.88 − 1.69 (m, 4H).

+





 70


embedded image


4-(2-((R)-1-((6- methoxypyridin-3- yl)methyl)-3-((R or S)-2,2,2-trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
420

1H NMR (300 MHz, MeOD) δ 8.25 (s, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.70 − 7.59 (m, 2H), 7.45 − 7.34 (m, 2H), 6.87 − 6.84 (m, 1H), 4.37 − 4.17 (m, 3H), 3.92 (s, 3H), 3.58 (d, J = 11.7 Hz, 1H), 3.37 (d, J = 7.4 Hz, 2H), 3.22 − 3.06 (m, 2H), 2.78 (q, J = 15.5 Hz, 4H), 2.40 − 2.10 (m, 2H), 1.94 (s, 3H).

+








embedded image


(R)-4-(2-(3-(2- hydroxypropan-2- yl)-1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
378

1H NMR (300 MHz, MeOD) δ 8.67 (s, 1H), 7.94 (d, J = 8.2 Hz, 3H), 7.64 (d, J = 8.1 Hz, 1H), 7.52 − 7.34 (m, 3H), 3.55 (d, J = 11.8 Hz, 1H), 3.35 − 3.31 (m, 3H), 3.17 (d, J = 11.8 Hz, 1H), 2.78 (q, J = 15.5 Hz, 4H), 2.58 (s, 3H), 2.51 − 2.41 (m, 1H), 2.11 − 2.07 (m, 1H), 1.79 (d, J = 7.6 Hz, 6H), 1.26 (d, J = 11.5 Hz, 6H).

+





 71


embedded image


4-(2-((3S)-1-((4- fluorophenyl) (pyridin- 3-yl)methyl)-3- (2-hydroxypropan- 2-yl)pyrrolidin-3- yl)ethyl) benzonitrile
444

1H NMR (300 MHz, MeOD) δ 8.68 (d, J = 6.4 Hz, 1H), 8.42 (s, 1H), 8.04 − 7.88 (m, 3H), 7.54 − 7.50 (m, 2H), 7.37 (d, J = 8.1 Hz, 3H), 7.08 (t, J = 8.2 Hz, 2H), 3.14 − 3.07 (m, 1H), 2.90 (q, J = 15.6 Hz, 5H), 2.59 − 2.47 (m, 5H), 2.21- 2.11 (m, 2H), 1.73 − 1.69 (m, 2H), 1.24 − 1.08 (d, J = 5.7 Hz, 6H).

+





 72


embedded image


(S)-4-(2-(3- ((benzyloxy) methyl)- 1-(di(pyridin-3- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile
489

1H NMR (300 MHz, MeOD) δ 8.64 (s, 2H), 8.42 (d, J = 4.0 Hz, 2H), 7.96 (s, 2H), 7.60 (d, J = 7.6 Hz, 2H), 7.36 − 7.28 (m, 9H), 4.50 (d, J = 10.6 Hz, 3H), 3.44 − 3.35 (m, 2H), 2.84 (q, J = 15.6 Hz, 4H), 2.55 − 2.41 (m, 5H), 2.24 (d, J = 9.7 Hz, 1H), 1.82 − 1.68 (m, 4H).

+





 73


embedded image


4-(2-((R)-1-(2-(6- methylpyridin-3- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
432

1H NMR (300 MHz, MeOD) δ 8.68 (s, 1H), 8.03 (s, 1H), 7.64 (d, J = 7.9 Hz, 2H), 7.47 − 7.27 (m, 3H), 4.13 − 4.08 (m, 2H), 3.21 (s, 6H), 2.81 (q, J = 15.6 Hz, 4H), 2.54 (s, 3H), 2.35 − 2.27 (m, 1H), 2.17 − 2.09 (m, 1H), 2.04 − 1.93 (m, 1H), 1.75 (d, J = 8.6 Hz, 6H).

++





 74


embedded image


4-((((S)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)- tetrahydrofuran-2- yl)pyrrolidin-3- yl)methoxy)methyl) benzonitrile
406

1H NMR (300 MHz, MeOD) δ 8.57 (s, 1H), 7.93 (t, J = 7.7 Hz, 1H), 7.74 (d, J = 8.0 Hz, 2H), 7.60 − 7.51 (m, 3H), 7.48 − 7.38 (m, 1H), 4.65 (s, 2H), 3.97 − 3.82 (m, 3H), 3.54 (s, 2H), 3.41 − 3.30 (m, 3H), 3.23 (s, 1H), 2.83 (q, J = 15.6 Hz, 4H), 2.22 − 2.18 (m, 1H), 2.08 − 2.02 (m, 1H), 1.94 − 1.83 (m, 3H), 1.74 (d, J = 4.1 Hz, 6H), 1.60 −

+






1.43 (m, 1H).






 75


embedded image


4-(2-((((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((S)- tetrahydrofuran-2- yl)pyrrolidin-3- yl)methyl)amino) propan-2- yl)benzonitrile
433

1H NMR (300 MHz, MeOD) δ 8.69 (s, 1H), 7.95 (d, J = 7.5 Hz, 1H), 8.69 (s, 4H), 7.62 (d, J = 7.9 Hz, 1H), 7.48 (s, 1H), 3.89 − 3.63 (m, 3H), 3.21 − 3.03 (m, 5H), 2.81 (q, J = 15.6 Hz, 4H), 2.35 (s, 2H), 2.20 − 1.95 (m, 3H), 1.83 − 1.79 (m, 2H), 1.76 (d, J = 10.9 Hz, 6H), 1.59 (s, 6H).

+





 76


embedded image


(S)-4-(2-(3- (methoxymethyl)- 1-(2-phenylpropan- 2-yl)pyrrolidin-3- yl)ethyl)benzonitrile
363

1H NMR (300 MHz, MeOD) δ 7.69 (d, J = 7.2 Hz, 2H), 7.61 (d, J = 8.1 Hz, 2H), 7.50 − 7.42 (m, 3H), 7.35 (d, J = 7.9 Hz, 2H), 3.43 − 3.33 (m, 2H), 3.29 − 3.16 (m, 9H), 2.96 (d, J = 12.2 Hz, 1H), 2.78 (q, J = 15.4 Hz, 5H), 2.59 (t, J = 8.3 Hz, 2H), 2.06 − 1.89 (m, 2H), 1.84 (s, 6H).

+





 77


embedded image


(S)-4-(2-(3- (hydroxymethyl)-1- (2-phenylpropan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
349

1H NMR (300 MHz, MeOD) δ 7.69 (d, J = 7.1 Hz, 2H), 7.61 (d, J = 8.0 Hz, 2H), 7.50 (d, J = 7.6 Hz, 3H), 7.35 (d, J = 7.9 Hz, 2H), 3.49 (s, 2H), 3.43 − 3.33 (m, 3H), 3.28 − 3.18 (m, 2H), 2.95 (d, J = 11.8 Hz, 1H), 2.79 (q, J = 15.4 Hz, 4H), 2.65 − 2.54 (m, 2H), 2.08 − 1.87 (m, 2H), 1.85 (s, 6H).

+





 78


embedded image


(R or S)-2,2,2- trifluoro-1-((R)-3- (4- fluorophenethyl)-1- (2-(6- methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)ethan-1-ol
425

1H NMR (300 MHz, MeOD) δ 8.68 (s, 1H), 8.03 (s, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.13 − 7.00 (m, 2H), 6.98 (t, J = 8.7 Hz, 2H), 4.12 − 4.08 (m, 1H), 3.31 − 3.20 (m, 1H), 3.18 (d, J = 10.1 Hz, 2H), 3.08 (d, J = 8.4 Hz, 1H), 2.91 (d, J = 13.2 Hz, 1H), 2.80 (q, J = 15.5 Hz, 4H), 2.60 − 2.58 (m, 2H), 2.54 (s, 3H), 2.33 − 2.26 (m, 1H), 2.16 − 2.07 (m, 1H), 2.04 − 1.89 (m, 1H), 1.75 (d, J = 8.3 Hz, 6H).

++





 79


embedded image


(R or S)-2,2,2- trifluoro-1-((R)-1- (2-(6- methylpyridin-3- yl)propan-2-yl)-3- (4- (methylsulfonyl) phenethyl) pyrrolidin- 3-yl)ethan-1-ol
485

1H NMR (300 MHz, MeOD) δ 8.67 (s, 1H), 8.02 (s, 1H), 7.86 (d, J = 8.0 Hz, 2H), 7.49 − 7.32 (m, 3H), 4.26 − 4.01 (m, 1H), 3.18 − 3.13 (m, 2H), 3.09 (s, 3H), 2.81 (q, J = 15.6 Hz, 4H), 2.54 (s, 3H), 2.36 − 2.23 (m, 1H), 2.18 − 2.09 (m, 1H), 2.04 − 1.93 (m, 1H), 1.82 − 1.80 (m, 2H), 1.73 (d, J = 9.1 Hz, 6H), 1.19 (s, 3H).

+





 80


embedded image


(R)-6-(2-(3- ((benzyloxy) methyl)- 1-(2-(6- methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile
455

1H NMR (300 MHz, MeOD) δ 8.79 (s, 1H), 8.64 (s, 1H), 8.01 (dd, J = 23.5, 7.5 Hz, 2H), 7.49 − 7.23 (m, 7H), 4.47 (s, 2H), 3.25 − 3.02 (m, 4H), 2.90 − 2.79 (m, 4H), 2.77 (q, J = 15.6 Hz, 4H), 2.54 (s, 3H), 1.88- 1.78 (m, 4H), 1.73 (s, 6H).







 81


embedded image


(R)-6-(2-(3- (hydroxymethyl)-1- (2-(6- methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile
365

1H NMR (300 MHz, MeOD) δ 8.80 (s, 1H), 8.68 (s, 1H), 8.06 (t, J = 7.7 Hz, 2H), 7.44 (dd, J = 19.5, 8.4 Hz, 2H), 3.50 (s, 2H), 3.26 − 3.18 (m, 3H), 3.13 (d, J = 11.9 Hz, 1H), 2.90 (d, J = 12.3 Hz, 2H), 2.85 − 2.70 (q, J = 15.6 Hz, 4H), 2.56 (s, 3H), 1.90 − 1.85 (m, 4H), 1.80 (s, 6H).

++





 82


embedded image


4-(2-((S)-1-(2- phenylpropan-2- yl)-3-((R or S)- 2,2,2-trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
417

1H NMR (300 MHz, MeOD) δ 7.76 − 7.59 (m, 4H), 7.49 − 7.36 (m, 3H), 7.27 (d, J = 7.4 Hz, 2H), 4.11 − 4.08 (m, 1H), 3.21 − 3.13 (m, 2H), 3.06 − 2.96 (m, 2H), 2.79 (q, J = 15.6 Hz, 4H), 2.62 − 2.53 (m, 2H), 2.45 − 2.34 (m, 1H), 1.82 (s, 6H), 1.72 − 1.62 (m, 2H).

+





 83


embedded image


(R)-4-(2-(1-((2,4- dimethylpyridin-3- yl)methyl)-3- (hydroxymethyl) pyrrolidin-3- yl)ethyl) benzonitrile
350

1H NMR (300 MHz, MeOD) δ 8.26 (s, 1H), 7.63 (d, J = 7.7 Hz, 2H), 7.39 (d, J = 7.7 Hz, 2H), 7.25 (s, 1H), 4.12 (s, 2H), 3.55 (s, 2H), 3.00 (s, 4H), 2.81 (q, J = 15.7 Hz, 4H), 2.66 (s, 4H), 2.51 (s, 3H), 1.86 − 1.73 (m, 4H).

+





 84


embedded image


(R)-4-(2-(1-((2,4- dimethylpyridin-3- yl)methyl)-3- (ethoxymethyl) pyrrolidin-3- yl)ethyl) benzonitrile
378

1H NMR (300 MHz, MeOD) δ 8.26 (d, J = 4.9 Hz, 1H), 7.62 (d, J = 7.9 Hz, 2H), 7.37 (d, J = 7.9 Hz, 2H), 7.24 (d, J = 4.9 Hz, 1H), 4.08 (s, 2H), 3.52 (dd, J = 13.9, 6.9 Hz, 2H), 3.40 (s, 2H), 3.08 − 2.97 (m, 4H), 2.90 − 2.73 (q, J = 15.6 Hz, 4H), 2.69 (d, J = 9.4 Hz, 2H), 2.66 (s, 3H), 2.50 (s, 3H), 1.83 − 1.75 (m, 4H), 1.19 (t, J = 7.0 Hz, 3H).

+





 85


embedded image


(R)-N-(3- (ethoxymethyl)-3- phenethylpyrrolidin- 1-yl)-N,6- dimethylpyridin-3- amine
354

1H NMR (300 MHz, MeOD) δ 8.15 (s, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.36 (d, J = 9.0 Hz, 1H), 7.25 − 7.14 (m, 5H), 3.55 − 3.53 (m, 2H), 3.43 − 3.42 (m, 2H), 2.93 − 2.91 (m, 5H), 2.88 − 2.77 (m, 4H), 2.72 − 2.61 (m, 4H), 2.49 (s, 3H), 1.83 − 1.73 (m, 4H), 1.24 (t, J = 6.9 Hz, 3H).

+





 86


embedded image


(R)-N-(3- (methoxymethyl)- 3- phenethylpyrrolidin- 1-yl)-6- methylpyridin-3- amine
326

1H NMR (300 MHz, MeOD) δ 8.02 (s, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.38-7.11 (m, 6H), 3.52 (dd, J = 13.9, 6.9 Hz, 2H), 3.42- 3.31 (m, 2H), 2.97-2.91 (m, 2H), 2.90 − 2.73 (q, J = 15.6 Hz, 4H), 2.69-2.61 (m, 4H), 2.48 (s, 3H), 1.79- 1.72 (m, 4H), 1.19 (t, J = 7.0 Hz, 3H).

+





 87


embedded image


4-(2-((S)-1-(2- phenylpropan-2- yl)-3-((R or S)- 2,2,2-trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
417

1H NMR (300 MHz, MeOD) δ 7.66 (dd, J = 16.7, 7.9 Hz, 4H), 7.46 (dt, J = 14.5, 6.9 Hz, 3H), 7.31 (d, J = 7.9 Hz, 2H), 4.27 − 4.12 (m, 1H), 3.61 − 3.38 (m, 2H), 2.97 − 2.87 (m, 1H), 2.79 (dd, J = 29.0, 15.5 Hz, 5H), 2.70 − 2.61 (m, 2H), 2.36 − 1.96 (m, 3H), 1.89 − 1.70 (m, 8H).

+





 88


embedded image


6-(2-((R)-1-(2-(6- methylpyridin-3- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) nicotinonitrile
433

1H NMR (300 MHz, MeOD) δ 8.82 (s, 1H), 8.65 (s, 1H), 8.16 − 7.94 (m, 2H), 7.40 (dd, J = 14.7, 8.9 Hz, 2H), 4.15 − 3.97 (m, 1H), 3.13 − 3.03 (m, 3H), 2.98 − 2.91 (m, 2H), 2.81 (dd, J = 32.3, 15.6 Hz, 6H), 2.54 (s, 3H), 2.41 − 2.24 (m, 1H), 2.06 − 1.77 (m, 4H), 1.70 (s, 6H).

++





 89


embedded image


6-(2-((R)-1-(2-(6- methylpyridin-3- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) nicotinonitrile
433

1H NMR (300 MHz, MeOD) δ 8.83 (s, 1H), 8.66 (s, 1H), 8.05 (dd, J = 15.8, 7.2 Hz, 2H), 7.40 (dd, J = 11.7, 8.3 Hz, 2H), 4.21 − 4.06 (m, 1H), 3.18 − 3.02 (m, 4H), 3.01 − 2.90 (m, 2H), 2.81 (dd, J = 32.9, 15.5 Hz, 7H), 2.54 (s, 3H), 2.21 − 2.08 (m, 1H), 2.04 − 1.88 (m, 3H), 1.73 (s, 6H).

++





 90


embedded image


(R)-4-(2-(3- (hydroxymethyl)-1- (2-(6- (trifluoromethyl) pyridin-3-yl)propan- 2-yl)pyrrolidin-3- yl)ethyl) benzonitrile
418

1H NMR (300 MHz, MeOD) δ 8.97 (s, 1H), 8.28 (d, J = 7.8 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 3.52 (s, 2H), 3.08 − 2.92 (m, 3H), 2.82 (dd, J = 33.3, 15.6 Hz, 6H), 2.72 − 2.61 (m, 3H), 1.87 − 1.73 (m, 4H), 1.69 (s, 6H).

+





 91


embedded image


(R)-4-(2-(3- (ethoxymethyl)-1- (2-(6- (trifluoromethyl) pyridin-3-yl)propan- 2-yl)pyrrolidin-3- yl)ethyl) benzonitrile
446

1H NMR (300 MHz, MeOD) δ 8.99 (s, 1H), 8.30 (d, J = 4.8 Hz, 1H), 7.87 (d, J = 6.9 Hz, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 7.8 Hz, 2H), 3.46 (dd, J = 14.0, 7.0 Hz, 3H), 3.36 (s, 2H), 3.06 (s, 2H), 2.95 (d, J = 9.6 Hz, 1H), 2.82 (dd, J = 33.4, 15.5 Hz, 6H), 2.70 − 2.60 (m, 2H), 1.93 − 1.76 (m, 4H), 1.72 (s, 6H), 1.17 − 1.12 (m, 3H).

+





 92


embedded image


4-(2-((R)-3-((R or S)-2,2,2-trifluoro- 1-hydroxyethyl)-1- (2-(6- (trifluoromethyl) pyridin-3- yl)propan- 2-yl)pyrrolidin-3- yl)ethyl) benzonitrile
486

1H NMR (300 MHz, MeOD) δ 8.95 (s, 1H), 8.22 (d, J = 8.1 Hz, 1H), 7.82 (d, J = 7.9 Hz, 1H), 7.64 (d, J = 7.8 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H), 4.10 − 4.00 (m, 1H), 3.02 − 2.65 (m, 10H), 2.34 − 2.14 (m, 2H), 1.95- 1.71 (m, 4H), 1.61 (s, 6H).

+





 93


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxamide
363

1H NMR (300 MHz, MeOD) δ 8.65 (d, J = 4.1 Hz, 1H), 7.91 (t, J = 7.2 Hz, 1H), 7.62 (d, J = 8.0 Hz, 3H), 7.46 − 7.31 (m, 3H), 3.72 (d, J = 11.7 Hz, 1H), 3.34 (s, 2H), 3.01 (d, J = 12.0 Hz, 1H), 2.77 (q, J = 15.5 Hz, 4H), 2.68 − 2.45 (m, 3H), 2.24 − 2.11 (m, 1H), 2.09 − 1.93 (m, 2H), 1.72 (d, J = 4.9 Hz, 6H).

++





 94


embedded image


(S)-5-chloro-2-(2- (3- (methoxymethyl)- 3-(4- (methylsulfonyl)ph enethyl)pyrrolidin- 1-yl)propan-2- yl)pyridine
451

1H NMR (300 MHz, MeOD) δ 8.70 (s, 1H), 7.99 (d, J = 6.8 Hz, 1H), 7.87 (d, J = 7.9 Hz, 2H), 7.64 (d, J = 8.3 Hz, 1H), 7.49 (d, J = 7.8 Hz, 2H), 3.56 − 3.39 (m, 7H), 3.39 − 3.35 (m, 1H), 3.18 − 3.05 (m, 4H), 2.93 − 2.66 (m, 7H), 2.22 − 1.97 (m, 3H), 1.93 − 1.83 (m, 2H), 1.76 (s, 6H).







 95


embedded image


4-(2-((R)-3-((Ror S)-2,2,2-trifluoro- 1-hydroxyethyl)-1- (2-(6- (trifluoromethyl)py ridin-3-yl)propan- 2-yl)pyrrolidin-3- yl)ethyl)benzonitril e
486

1H NMR (300 MHz, MeOD) δ 8.95 (s, 1H), 8.23 (d, J = 8.1 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.3 Hz, 2H), 4.09 (dd, J = 16.0, 8.1 Hz, 1H), 3.10 (d, J = 9.8 Hz, 1H), 2.97 − 2.73 (m, 9H), 2.73 − 2.61 (m, 2H), 2.13 − 1.77 (m, 5H), 1.63 (s, 6H).

+





 96


embedded image


(R or S)-2,2,2- trifluoro-1-((R)-3- (4- fluorophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethan-1-ol
411

1H NMR (300 MHz, MeOD) δ 8.68 (d, J = 4.2 Hz, 1H), 7.95 (t, J = 6.8 Hz, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.45 (dd, J = 7.6, 4.6 Hz, 1H), 7.19 (dd, J = 7.9, 5.7 Hz, 2H), 7.00 (t, J = 8.7 Hz, 2H), 4.36 − 4.22 (m, 1H), 3.58 − 3.36 (m, 4H), 2.77 (dd, J = 31.9, 15.5 Hz, 4H), 2.67 − 2.52 (m, 3H), 2.01 − 1.85 (m, 3H), 1.78 (s, 6H).

+





 97


embedded image


(R or S)-2,2,2- trifluoro-1-((R)-3- (4- fluorophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethan-1-ol
411

1H NMR (300 MHz, MeOD) δ 8.67 (s, 1H), 7.93 (t, J = 7.1 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.52 − 7.40 (m, 1H), 7.29 − 7.14 (m, 2H), 7.01 (t, J = 8.7 Hz, 2H), 4.29 (q, J = 7.8 Hz, 1H), 3.65 (d, J = 11.9 Hz, 1H), 3.51 (t, J = 7.3 Hz, 2H), 3.02 (d, J = 12.0 Hz, 1H), 2.88 − 2.54 (m, 6H), 2.44 − 2.15 (m, 2H), 1.99 − 1.83 (m, 2H), 1.78 (d, J = 2.4 Hz, 6H).

+





 98


embedded image


(R or S)-1-((S)-1- (2-(4- chlorophenyl)propa n-2-yl)-3-(4- (methylsulfonyl) phenethyl) pyrrolidin- 3-yl)-2,2,2- trifluoroethan-1-ol
504

1H NMR (300 MHz, MeOD) δ 7.86 (d, J = 7.8 Hz, 2H), 7.68 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 7.5 Hz, 2H), 7.38 (d, J = 7.7 Hz, 2H), 4.13 (dd, J = 15.3, 8.6 Hz, 1H), 3.49 (dd, J = 13.9, 6.9 Hz, 2H), 3.09 (s, 3H), 3.07 − 2.97 (m, 1H), 2.90 − 2.64 (m, 8H), 2.49 − 2.32 (m, 1H), 1.95 − 1.83 (m, 1H), 1.83 − 1.66 (m, 9H).

++





 99


embedded image


(R or S)-1-((S)-1- (2-(4- chlorophenyl) propan-2- yl)-3-(4- (methylsulfonyl) phenethyl) pyrrolidin- 3-yl)-2,2,2- trifluoroethan-1-ol
504

1H NMR (300 MHz, MeOD) δ 7.86 (d, J = 7.7 Hz, 2H), 7.70 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 7.6 Hz, 2H), 4.22 (dd, J = 15.6, 7.9 Hz, 1H), 3.60 − 3.43 (m, 3H), 3.40 − 3.34 (m, 2H), 3.09 (s, 3H), 2.94 (d, J = 12.2 Hz, 1H), 2.80 (dd, J = 31.2, 15.5 Hz, 8H), 2.71 − 2.62 (m, 1H), 2.34 − 1.98 (m, 3H), 1.82 (s, 6H).

++





100


embedded image


(R)-4-(2-(1-(2- (pyridin-2- yl)propan-2-yl)-3- (2,2,2- trifluoroacetyl) pyrrolidin-3- yl)ethyl) benzonitrile
416

1H NMR (300 MHz, MeOD) δ 8.67 (d, J = 3.0 Hz, 1H), 7.95 (t, J = 8.2 Hz, 1H), 7.72 − 7.58 (m, 3H), 7.54 − 7.43 (m, 1H), 7.38 (d, J = 8.0 Hz, 2H), 3.62 (d, J = 11.7 Hz, 1H), 3.51 − 3.42 (m, 2H), 3.09 (d, J = 11.7 Hz, 2H), 2.81 (q, J = 15.6 Hz, 4H), 2.70 − 2.55 (m, 1H), 2.08 − 1.89 (m, 4H), 1.77 (s, 6H).

+





101


embedded image


4-(2-((R)-1-((2,4- dimethylpyridin-3- yl)methyl)-3-((R or S)-1-ethoxy-2,2,2- trifluoroethyl) pyrrolidin-3- yl)ethyl) benzonitrile
446

1H NMR (500 MHz, MeOD) δ 8.23 (d, J = 5.4 Hz, 1H), 7.61 (d, J = 8.2 Hz, 2H), 7.30 (d, J = 8.2 Hz, 2H), 7.27 (d, J = 5.3 Hz, 1H), 3.96 − 3.88 (m, 1H), 3.83 (dd, J = 15.2, 7.6 Hz, 1H), 3.78 (s, 2H), 3.65 (dq, J = 14.1, 7.0 Hz, 1H), 2.91 − 2.75 (m, 8H), 2.70 (dt, J = 8.6, 5.5 Hz, 2H), 2.66 (s, 3H), 2.63 (d, J = 9.7 Hz, 1H), 2.58 (dd, J = 16.0, 8.1 Hz, 1H), 2.52 (s, 3H), 2.16 − 2.11 (m, 1H), 2.03 (dd, J = 12.2, 6.4 Hz, 1H), 1.87 (td, J = 13.0, 4.6 Hz, 1H), 1.80 − 1.68 (m,

+






2H), 1.64 − 1.56 (m, 1H),







1.23 (t, J = 7.0 Hz, 3H).






102


embedded image


4-(2-((R)-1-((2,4- dimethylpyridin-3- yl)methyl)-3-((R or S)-1-ethoxy-2,2,2- trifluoroethyl) pyrrolidin-3- yl)ethyl) benzonitrile
446

1H NMR (500 MHz, MeOD) δ 8.25 (d, J = 5.2 Hz, 1H), 7.61 (d, J = 8.1 Hz, 2H), 7.31 (d, J = 8.0 Hz, 3H), 3.90 (dd, J = 15.5, 7.8 Hz, 2H), 3.82 (dd, J = 25.1, 13.5 Hz, 2H), 3.60 − 3.54 (m, 1H), 2.92 − 2.74 (m, 10H), 2.70 (d, J = 4.8 Hz, 1H), 2.67 (s, 3H), 2.63 (d, J = 9.4 Hz, 1H), 2.56 − 2.49 (m, 3H), 2.06 − 1.96 (m, 2H), 1.93 − 1.84 (m, 1H), 1.82 − 1.71 (m, 2H), 1.66 − 1.56 (m, 1H), 1.16 (t, J = 7.0 Hz, 3H).

+





103


embedded image


2-fluoro-4-(2-((R)- 1-(2-(pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
436

1H NMR (500 MHz, MeOD) δ 8.69 − 8.65 (m, 1H), 7.95 (td, J = 7.8, 1.8 Hz, 1H), 7.71 − 7.62 (m, 2H), 7.45 (ddd, J = 7.6, 4.8, 0.8 Hz, 1H), 7.25 − 7.19 (m, 2H), 4.29 (q, J = 7.5 Hz, 1H), 3.54 − 3.43 (m, 4H), 3.32 (d, J = 4.6 Hz, 1H), 2.85 − 2.72 (m, 7H), 2.60 (dt, J = 13.9, 9.1 Hz, 1H), 2.01 − 1.89 (m, 3H), 1.79 (d, J = 2.6 Hz, 6H).

+





104


embedded image


2-fluoro-4-(2-((R)- 1-(2-(pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
436

1H NMR (500 MHz, MeOD) δ 8.66 (ddd, J = 4.8, 1.6, 0.8 Hz, 1H), 7.93 (td, J = 7.8, 1.8 Hz, 1H), 7.68 (dd, J = 8.0, 6.9 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.44 (ddd, J = 7.6, 4.8, 0.9 Hz, 1H), 7.25 − 7.20 (m, 2H), 4.29 (q, J = 7.8 Hz, 1H), 3.65 (d, J = 12.2 Hz, 1H), 3.54 − 3.46 (m, 2H), 3.06 (d, J = 12.2 Hz, 1H), 2.87 − 2.71 (m, 7H), 2.40 − 2.31 (m, 1H), 2.28 − 2.18 (m, 1H), 1.99 − 1.88 (m, 2H), 1.78 (d, J = 2.2 Hz, 6H).

+





105


embedded image


(R)-2-fluoro-4-(2- (1-(2-(pyridin-2- yl)propan-2-yl)-3- (2,2,2- trifluoroacetyl) pyrrolidin-3- yl)ethyl) benzonitrile
434

1H NMR (500 MHz, MeOD) δ 8.66 (s, 1H), 7.94 (t, J = 7.5 Hz, 1H), 7.70 − 7.61 (m, 2H), 7.48 − 7.40 (m, 1H), 7.24 − 7.17 (m, 2H), 3.64 − 3.58 (m, 1H), 3.49 (q, J = 7.0 Hz, 1H), 3.44 − 3.37 (m, 1H), 3.34 − 3.31 (m, 1H), 3.10 − 3.00 (m, 1H), 2.93 − 2.72 (m, 8H), 2.64 (ddd, J = 23.0, 14.4, 9.6 Hz, 1H), 2.09 − 1.86 (m, 3H), 1.82 − 1.71 (m, 6H).

+





106


embedded image


4-(2-((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
418

1H NMR (500 MHz, MeOD) δ 8.67 (dd, J = 9.1, 4.1 Hz, 1H), 7.98 − 7.90 (m, 1H), 7.69 − 7.61 (m, 3H), 7.48 − 7.42 (m, 1H), 7.39 (d, J = 8.2 Hz, 2H), 4.35 − 4.25 (m, 1H), 3.65 (d, J = 12.2 Hz, 0.5H), 3.55 − 3.44 (m, 4H), 3.04 (d, J = 12.2 Hz, 0.5H), 2.86 − 2.71 (m, 7H), 2.61 (dt, J = 17.0, 8.7 Hz, 1H), 2.42 − 2.17 (m, 1H), 2.03 − 1.89 (m, 3H), 1.83 − 1.75 (m, 6H).

++





107


embedded image


(R)-4-(2-(3-(1H- imidazol-2-yl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
386

1H NMR (500 MHz, MeOD) δ 8.64 (d, J = 4.5 Hz, 1H), 7.91 (td, J = 7.8, 1.7 Hz, 1H), 7.59 (dd, J = 8.1, 3.4 Hz, 3H), 7.42 (dd, J = 7.4, 4.9 Hz, 1H), 7.27 (d, J = 8.2 Hz, 2H), 7.15 (s, 2H), 3.74 (d, J = 11.7 Hz, 1H), 3.47 − 3.40 (m, 1H), 3.36 − 3.33 (m, 3H), 3.32 (s, 1H), 2.79 (dd, J = 41.6, 15.5 Hz, 5H), 2.66 − 2.57 (m, 1H), 2.51 − 2.44 (m, 1H), 2.40 − 2.32 (m, 1H), 2.28 − 2.15 (m, 3H), 1.67 (s, 3H), 1.62 (s, 3H).

+





108


embedded image


(R)-4-(2-(1-(2- (pyridin-2- yl)propan-2-yl)-3- (5- (trifluoromethyl)- 1H-imidazol-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
454

1H NMR (500 MHz, MeOD) δ 8.64 − 8.61 (m, 1H), 7.91 (td, J = 7.8, 1.8 Hz, 1H), 7.62 − 7.55 (m, 4H), 7.44 − 7.39 (m, 1H), 7.27 (d, J = 8.2 Hz, 2H), 3.90 (d, J = 11.9 Hz, 1H), 3.50 − 3.42 (m, 1H), 3.38 − 3.33 (m, 2H), 2.78 (dd, J = 42.2, 15.5 Hz, 5H), 2.68 − 2.61 (m, 1H), 2.54 − 2.46 (m, 1H), 2.45 − 2.37 (m, 1H), 2.33 − 2.17 (m, 3H), 1.70 (d, J = 9.6 Hz, 6H).

+





109


embedded image


(R)-4-(2-(3- ((benzyloxy)methyl )-1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-3- fluorobenzonitrile
458

1H NMR (500 MHz, MeOD) δ 8.51 (d, J = 2.8 Hz, 1H), 7.91 (td, J = 7.8, 1.8 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.51 − 7.47 (m, 2H), 7.46 − 7.30 (m, 7H), 4.65 − 4.56 (m, 2H), 3.57 (dd, J = 21.9, 9.0 Hz, 2H), 3.42 (t, J = 7.5 Hz, 2H), 3.38 (d, J = 12.1 Hz, 1H), 3.14 (d, J = 11.9 Hz, 1H), 2.85 − 2.62 (m, 7H), 2.22 − 2.12 (m, 1H), 2.09 − 2.00 (m, 1H), 1.94 − 1.73 (m, 2H), 1.71 (d, J = 3.8 Hz, 6H).

+





110


embedded image


(R)-2-fluoro-4-(2- (3- (hydroxymethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
368

1H NMR (500 MHz, MeOD) δ 8.68 − 8.65 (m, 1H), 7.93 (td, J = 7.8, 1.7 Hz, 1H), 7.64 (dt, J = 9.5, 5.1 Hz, 2H), 7.51 − 7.47 (m, 1H), 7.44 (ddd, J = 7.6, 4.8, 0.8 Hz, 1H), 7.25 (dd, J = 13.8, 5.9 Hz, 2H), 3.62 (qd, J = 10.7, 3.4 Hz, 2H), 3.45 (t, J = 7.4 Hz, 2H), 3.37 (d, J = 11.8 Hz, 1H), 3.13 (dd, J = 11.8, 9.1 Hz, 1H), 2.85 − 2.63 (m, 7H), 2.15 − 1.97 (m, 2H), 1.92 − 1.80 (m, 2H), 1.78 (d, J = 7.8 Hz, 6H).

++





111


embedded image


(R)-3-fluoro-4-(2- (3- (hydroxymethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
368

1H NMR (500 MHz, MeOD) δ 8.67 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 7.93 (td, J = 7.8, 1.8 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.52 − 7.46 (m, 3H), 7.44 (ddd, J = 7.6, 4.8, 0.9 Hz, 1H), 3.64 (q, J = 10.6 Hz, 2H), 3.48 − 3.41 (m, 2H), 3.37 (d, J = 11.8 Hz, 1H), 3.12 (d, J = 11.9 Hz, 1H), 2.84 − 2.70 (m, 7H), 2.19 − 2.10 (m, 1H), 2.03 (dt, J = 13.4,

+






8.0 Hz, 1H), 1.89 − 1.79







(m, 2H), 1.77 (d, J =







9.8 Hz, 6H).






112


embedded image


(R)-4-(2-(3- ((benzyloxy)methyl )-1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl)-2- fluorobenzonitrile
458

1H NMR (500 MHz, MeOD) δ 8.50 (s, 1H), 7.91 (td, J = 7.8, 1.8 Hz, 1H), 7.64 (t, J = 7.4 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.43 − 7.31 (m, 6H), 7.20 (dd, J = 13.4, 5.7 Hz, 2H), 4.65 − 4.56 (m, 2H), 3.56 (dd, J = 25.2, 8.6 Hz, 2H), 3.45 − 3.35 (m, 3H), 3.15 (d, J = 11.9 Hz, 1H), 2.79 (dd, J = 44.4, 15.5 Hz, 6H), 2.72- 2.60 (m, 2H), 2.21 − 2.11 (m, 1H), 2.08 − 1.99 (m, 2H), 1.93 − 1.79 (m, 2H), 1.72 (d, J = 3.1 Hz, 6H).

+





113


embedded image


(R)-6-(2-(3- ((benzyloxy)methyl )-1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile
441

1H NMR (500 MHz, MeOD) δ 8.81 (d, J = 1.9 Hz, 1H), 8.51 (s, 1H), 8.07 (dd, J = 8.1, 2.2 Hz, 1H), 7.92 (td, J = 7.8, 1.7 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.43 − 7.30 (m, 6H), 4.61 (q, J = 11.6 Hz, 2H), 3.56 (dd, J = 25.1, 8.7 Hz, 2H), 3.45 − 3.36 (m, 3H), 3.17 (d, J = 11.9 Hz, 1H), 2.89 − 2.73 (m, 11H), 2.21 − 2.11 (m, 1H), 2.08 − 1.92 (m, 4H), 1.72 (s, 6H).

+





114


embedded image


(R)-6-(2-(3- (hydroxymethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile
351

1H NMR (500 MHz, MeOD) δ 8.83 (d, J = 1.6 Hz, 1H), 8.67 (dd, J = 4.8, 0.8 Hz, 1H), 8.09 (dd, J = 8.1, 2.2 Hz, 1H), 7.93 (td, J = 7.8, 1.8 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.46 − 7.42 (m, 1H), 3.62 (q, J = 10.7 Hz, 2H), 3.44 (t, J = 7.5 Hz, 2H), 3.36 (d, J = 5.5 Hz, 1H), 3.15 (d, J = 11.9 Hz, 1H), 2.92 − 2.84 (m, 2H), 2.77 (dd, J = 39.0, 15.4 Hz, 5H), 2.21 − 2.08 (m, 1H), 2.04 − 1.91 (m, 3H), 1.77 (d, J = 4.8 Hz, 7H).

+





115


embedded image


(S)-4-(2-(3- (aminomethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
349

1H NMR (500 MHz, MeOD) δ 8.59 (d, J = 4.0 Hz, 1H), 7.85 (td, J = 7.8, 1.8 Hz, 1H), 7.63 (d, J = 8.2 Hz, 2H), 7.55 (d, J = 8.1 Hz, 1H), 7.40 (d, J = 8.2 Hz, 2H), 7.33 (dd, J = 6.8, 4.9 Hz, 1H), 3.24 − 3.21 (m, 1H), 3.09 (q, J = 13.1 Hz, 2H), 2.93 (dd, J = 16.9, 9.3 Hz, 1H), 2.85 − 2.70 (m, 6H), 2.70 − 2.61 (m, 3H), 2.06 − 1.96 (m, 1H), 1.96 − 1.88 (m, 1H), 1.77 (t, J = 8.7 Hz, 2H), 1.53 (d, J = 15.9 Hz, 6H).

+





116


embedded image


3-fluoro-4-(2-((R)- 1-(2-(pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
436

1H NMR (500 MHz, MeOD) δ 8.67 (d, J = 4.2 Hz, 1H), 7.95 (td, J = 7.8, 1.5 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 8.7 Hz, 2H), 7.49 − 7.42 (m, 2H), 4.28 (q, J = 7.5 Hz, 1H), 3.54 (d, J = 11.9 Hz, 1H), 3.46 (dd, J = 8.0, 6.6 Hz, 2H), 3.30 − 3.28 (m, 1H), 2.85 − 2.70 (m, 7H), 2.64 − 2.54 (m, 1H), 1.99 − 1.90 (m, 3H), 1.79 (s, 6H).

+





117


embedded image


3-fluoro-4-(2-((R)- 1-(2-(pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
436

1H NMR (500 MHz, MeOD) δ 8.65 (d, J = 4.7 Hz, 1H), 7.92 (td, J = 7.8, 1.7 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 8.9 Hz, 2H), 7.48 − 7.41 (m, 2H), 4.30 (q, J = 7.8 Hz, 1H), 3.64 (d, J = 12.1 Hz, 1H), 3.49 (t, J = 7.3 Hz, 2H), 3.05 (d, J = 12.2 Hz, 1H), 2.90 − 2.70 (m, 6H), 2.42 − 2.33 (m, 1H), 2.28 − 2.16 (m, 1H), 1.92 (t, J =

+






8.4 Hz, 2H), 1.78 (d, J =







4.3 Hz, 6H).






118


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- carbohydrazide
378

1H NMR (500 MHz, MeOD) δ 8.66 (d, J = 4.0 Hz, 1H), 7.92 (td, J = 7.8, 1.8 Hz, 1H), 7.62 (d, J = 8.2 Hz, 3H), 7.46 − 7.41 (m, 1H), 7.37 (d, J = 8.2 Hz, 2H), 3.75 (d, J = 11.9 Hz, 1H), 3.46 − 3.37 (m, 1H),3.35 − 3.32 (m, 1H), 3.07 (d, J = 12.0 Hz, 1H), 2.79 (dd, J = 42.1, 15.5 Hz, 6H), 2.67 − 2.47 (m, 3H), 2.21-2.09 (m, 1H), 2.07 − 1.96 (m, 2H), 1.73 (d, J = 7.3 Hz, 6H).

+





119


embedded image


(R)-4-(2-(3- (1,1,1,3,3,3- hexafluoro-2- hydroxypropan-2- yl)-1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
486

1H NMR (500 MHz, MeOD) δ 8.64 (d, J = 4.8 Hz, 1H), 7.92 (td, J = 7.8, 1.8 Hz, 1H), 7.67 (d, J = 8.2 Hz, 3H), 7.46 − 7.38 (m, 3H), 3.67 (d, J = 12.2 Hz, 1H), 3.42 − 3.33 (m, 2H), 3.20 − 3.16 (m, 1H), 2.90 (dd, J = 12.8, 4.8 Hz, 1H), 2.87 − 2.73 (m, 7H), 2.73 -2.64 (m, 1H), 2.27 − 2.19 (m, 1H), 2.09 − 1.89 (m, 3H), 1.76 (d, J = 18.1 Hz, 6H).

+





120


embedded image


6-(2-((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) nicotinonitrile
419

1H NMR (500 MHz, MeOD) δ 8.86 (d, J = 1.8 Hz, 1H), 8.71 − 8.66 (m, 1H), 8.10 (dd, J = 8.1, 2.2 Hz, 1H), 7.95 (td, J = 7.8, 1.7 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.49 − 7.43 (m, 2H), 4.28 (q, J = 7.7 Hz, 1H), 3.52 (d, J = 12.0 Hz, 1H), 3.49 − 3.44 (m, 2H), 3.36 − 3.32 (m, 1H), 3.01 − 2.87 (m, 2H), 2.78 (dd, J = 41.9, 15.5 Hz, 6H), 2.64 − 2.54 (m, 1H), 2.09 (t, J = 8.3 Hz, 2H), 2.00 − 1.92 (m, 1H), 1.79 (d, J = 10.1 Hz, 6H).

+





121


embedded image


6-(2-((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) nicotinonitrile
419

1H NMR (500 MHz, MeOD) δ 8.85 (d, J = 1.7 Hz, 1H), 8.68 − 8.65 (m, 1H), 8.10 (dd, J = 8.1, 2.2 Hz, 1H), 7.93 (td, J = 7.8, 1.8 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.48 − 7.41 (m, 2H), 4.29 (q, J = 7.8 Hz, 1H), 3.66 (d, J = 12.3 Hz, 1H), 3.55 − 3.46 (m, 2H), 3.11 (d, J = 12.3 Hz, 1H), 3.02 − 2.96 (m, 2H), 2.79 (dd, J = 42.1, 15.5 Hz, 5H), 2.38 − 2.31 (m, 1H), 2.25-2.16 (m, 1H), 2.14 − 2.02 (m, 2H), 1.79 (d, J = 2.2 Hz, 6H).

+





122


embedded image


(R)-6-(2-(3- (1,1,1,3,3,3- hexafluoro-2- hydroxypropan-2- yl)-1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile
487

1H NMR (500 MHz, MeOD) δ 8.88 (s, 1H), 8.63 (d, J = 4.5 Hz, 1H), 8.11 (dd, J = 8.0, 1.6 Hz, 1H), 7.92 (t, J = 7.7 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.41 (dd, J = 7.4, 4.9 Hz, 1H), 3.67 (d, J = 12.2 Hz, 1H), 3.34 (d, J = 6.9 Hz, 2H), 3.12 − 2.96 (m, 2H), 2.79 (dd, J = 43.5, 15.5 Hz, 5H), 2.71 − 2.63 (m, 1H), 2.24 − 2.07 (m, 4H), 1.75 (d, J = 23.3 Hz, 6H).







123


embedded image


(S)-4-(2-(1- (di(pyridin-3- yl)methyl)-3- (hydroxymethyl) pyrrolidin-3- yl)ethyl) benzonitrile
399

1H NMR (500 MHz, MeOD) δ 8.72 − 8.65 (m, 2H), 8.42 (d, J = 3.9 Hz, 2H), 8.03 − 7.97 (m, 2H), 7.62 (d, J = 8.2 Hz, 2H), 7.45 − 7.37 (m, 4H), 4.51 (s, 1H), 3.54 (q, J = 10.8 Hz, 2H), 2.84 (dd, J = 55.3, 15.7 Hz, 5H), 2.73 − 2.66 (m, 2H), 2.61 − 2.48 (m, 3H), 2.28 (d, J = 9.6 Hz, 1H), 1.83 − 1.68 (m, 4H).







124


embedded image


(R)-4-(2-(3-(1,3,4- oxadiazol-2-yl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
388

1H NMR (500 MHz, MeOD) δ 8.97 (s, 1H), 8.61 (d, J = 4.1 Hz, 1H), 7.90 (td, J = 7.9, 1.6 Hz, 1H), 7.61 (dd, J = 10.8, 8.2 Hz, 3H), 7.41 (dd, J = 7.2, 5.1 Hz, 1H), 7.32 (d, J = 8.2 Hz, 2H), 3.87 (d, J = 12.2 Hz, 1H), 3.54 − 3.39 (m, 4H), 2.81 (dd, J = 47.7, 15.5 Hz, 9H), 2.66 − 2.57 (m, 1H), 2.52 − 2.45 (m, 1H), 2.36 − 2.25 (m, 3H), 2.02 (dt, J = 17.9, 8.8 Hz, 1H), 1.71 (s, 6H).

+





125


embedded image


(R)-3-(2-(3- ((benzyloxy) methyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
440

1H NMR (500 MHz, MeOD) δ 8.50 (d, J = 3.1 Hz, 1H), 7.91 (td, J = 7.8, 1.7 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.56 − 7.49 (m, 3H), 7.46 (d, J = 7.9 Hz, 1H), 7.44 − 7.31 (m, 6H), 4.66 − 4.57 (m, 2H), 3.57 (dd, J = 25.7, 9.0 Hz, 2H), 3.40 (t, J = 7.5 Hz, 2H), 3.35 (d, J = 11.8 Hz, 1H), 3.12 (d, J = 11.8 Hz, 1H), 2.76 (dd, J = 37.9, 15.4 Hz, 4H), 2.63 (pd, J = 13.6, 5.8 Hz, 2H), 2.22 − 2.10 (m,

+






1H), 2.08 − 2.00 (m,







1H), 1.92 − 1.78 (m, 2H),







1.71 (d, J = 4.3 Hz, 6H).






126


embedded image


(R)-2-(2-(3- ((benzyloxy) methyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
440

1H NMR (500 MHz, MeOD) δ 8.51 (s, 1H), 7.91 (td, J = 7.8, 1.7 Hz, 1H), 7.68 (dd, J = 7.7, 0.9 Hz, 1H), 7.62 − 7.56 (m, 2H), 7.46 − 7.30 (m, 8H), 4.63 (q, J = 11.5 Hz, 2H), 3.62 (dd, J = 25.6, 8.9 Hz, 2H), 3.47 − 3.38 (m, 3H), 3.19 (d, J = 12.6 Hz, 1H), 2.87 − 2.70 (m, 6H), 2.23 − 2.06 (m, 2H), 1.94 − 1.80 (m, 2H), 1.71 (d, J = 2.8 Hz, 6H).

+





127


embedded image


(R)-3-(2-(3- (hydroxymethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
350

1H NMR (500 MHz, MeOD) δ 8.67 (d, J = 4.8 Hz, 1H), 7.93 (td, J = 7.8, 1.8 Hz, 1H), 7.62 (d, J = 8.1 Hz, 2H), 7.57 − 7.53 (m, 2H), 7.49 − 7.42 (m, 2H), 3.64 (q, J = 10.6 Hz, 2H), 3.43 (t, J = 7.3 Hz, 2H), 3.38 − 3.33 (m, 2H), 3.12 (d, J = 11.8 Hz, 1H), 2.77 (dd, J = 38.9, 15.4 Hz, 4H), 2.71 − 2.63 (m, 2H), 2.22- 2.08 (m, 1H), 2.06 − 1.98 (m, 1H), 1.90 − 1.79 (m,

+






2H), 1.77 (d, J = 8.9 Hz,







6H).






128


embedded image


(R)-3-(2-(3- (ethoxymethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
378

1H NMR (500 MHz, MeOD) δ 8.67 (d, J = 4.1 Hz, 1H), 7.95 (td, J = 7.8, 1.7 Hz, 1H), 7.64 − 7.59 (m, 2H), 7.55 (dd, J = 8.6, 4.4 Hz, 2H), 7.49 − 7.44 (m, 2H), 3.70 − 3.49 (m, 4H), 3.41 (ddd, J = 21.2, 10.4, 6.7 Hz, 3H), 3.16 (d, J = 11.6 Hz, 1H), 2.83 − 2.62 (m, 6H), 2.21 − 2.12 (m, 1H), 2.10 − 2.01 (m, 1H), 1.91 − 1.80 (m, 2H), 1.76 (d, J = 11.9 Hz, 6H), 1.33 (t, J = 6.8 Hz, 3H).

+





129


embedded image


(R)-2-(2-(3- (hydroxymethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
350

1H NMR (500 MHz, MeOD) δ 8.68 (d, J = 4.1 Hz, 1H), 7.93 (td, J = 7.8, 1.8 Hz, 1H), 7.68 (dd, J = 7.7, 1.0 Hz, 1H), 7.64 − 7.58 (m, 2H), 7.44 (ddd, J = 8.1, 5.6, 4.1 Hz, 2H), 7.38 (td, J = 7.7, 1.0 Hz, 1H), 3.68 (dd, J = 21.4, 10.5 Hz, 2H), 3.48 − 3.38 (m, 3H), 2.87-2.71 (m, 8H), 2.22 − 2.00 (m, 3H), 1.89 − 1.82 (m, 2H), 1.78 (d, J = 8.7 Hz, 6H).

+





130


embedded image


(R)-2-(2-(3- (ethoxymethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
378

1H NMR (500 MHz, MeOD) δ 8.67 (d, J = 4.7 Hz, 1H), 7.94 (td, J = 7.8, 1.7 Hz, 1H), 7.68 (dd, J = 7.7, 0.9 Hz, 1H), 7.61 (ddd, J = 12.2, 6.3, 2.5 Hz, 2H), 7.45 (dd, J = 7.3, 4.5 Hz, 2H), 7.38 (td, J = 7.7, 0.8 Hz, 1H), 3.70 − 3.52 (m, 4H), 3.49 − 3.38 (m, 3H), 2.90 − 2.71 (m, 7H), 2.24 − 2.07 (m, 2H), 1.94 − 1.81 (m, 2H), 1.77 (d, J = 11.0 Hz, 6H), 1.36 − 1.31 (m, 3H).

+





131


embedded image


(R)-4-(2-(3- ((benzyloxy) methyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
440

1H NMR (500 MHz, MeOD) δ 8.50 (s, 1H), 7.91 (td, J = 7.8, 1.7 Hz, 1H), 7.63 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 8.0 Hz, 1H), 7.45 − 7.30 (m, 8H), 4.67 − 4.57 (m, 2H), 3.65 − 3.51 (m, 2H), 3.36 (d, J = 11.0 Hz, 1H), 3.12 (d, J = 11.9 Hz, 1H), 2.79 (dd, J = 41.9, 15.5 Hz, 5H), 2.71 − 2.60 (m, 2H), 2.22 − 2.12 (m, 2H), 2.07 − 2.00 (m, 3H), 1.95 − 1.79 (m, 2H), 1.71 (d, J = 4.5 Hz, 6H).

+





132


embedded image


(R)-4-(2-(3- (ethoxymethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
378

1H NMR (500 MHz, MeOD) δ 8.67 (d, J = 4.3 Hz, 1H), 7.95 (td, J = 7.8, 1.7 Hz, 1H), 7.63 (dd, J = 13.5, 8.1 Hz, 3H), 7.46 (dd, J = 7.5, 4.8 Hz, 1H), 7.41 (d, J = 8.2 Hz, 2H), 3.68 − 3.51 (m, 4H), 3.42 − 3.36 (m, 3H), 3.15 (d, J = 11.6 Hz, 1H), 2.85 − 2.65 (m, 7H), 2.22 − 2.13 (m, 1H), 2.10 − 1.98 (m, 1H), 1.93 − 1.80 (m, 3H), 1.76 (d, J = 12.5 Hz, 6H), 1.35 (d, J = 16.6 Hz, 3H).

+





133


embedded image


3-(2-((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((S)-2,2, 2-trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
418

1H NMR (500 MHz, MeOD) δ 8.68 (d, J = 4.2 Hz, 1H), 7.95 (td, J = 7.8, 1.7 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.59 − 7.56 (m, 2H), 7.54 − 7.44 (m, 3H), 4.29 (q, J = 7.7 Hz, 1H), 3.50 (d, J = 11.9 Hz, 1H), 3.45 (dd, J = 8.5, 6.2 Hz, 2H), 2.85 − 2.66 (m, 7H), 2.65 − 2.55 (m, 1H), 2.00 − 1.90 (m, 3H), 1.78 (s, 6H).

+





134


embedded image


3-(2-((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
418

1H NMR (500 MHz, MeOD) δ 8.66 (d, J = 4.0 Hz, 1H), 7.93 (td, J = 7.8, 1.8 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.60 − 7.55 (m, 2H), 7.54 − 7.46 (m, 2H), 7.43 (ddd, J = 7.6, 4.8, 0.7 Hz, 1H), 4.29 (q, J = 7.8 Hz, 1H), 3.64 (d, J = 12.2 Hz, 1H), 3.50 (t, J = 7.3 Hz, 2H), 3.04 (d, J = 12.2 Hz, 1H), 2.86 − 2.71 (m, 7H), 2.41 − 2.32 (m, 1H), 2.29 − 2.20 (m, 1H), 1.97 −

+






1.88 (m, 2H), 1.78 (d, J =







3.2 Hz, 6H).






135


embedded image


2-(2-((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
418

1H NMR (500 MHz, MeOD) δ 8.68 (d, J = 4.1 Hz, 1H), 7.94 (td, J = 7.9, 1.7 Hz, 1H), 7.70 (d, J = 7.2 Hz, 1H), 7.63 (dd, J = 15.4, 7.7 Hz, 2H), 7.47-7.38 (m, 3H), 4.28 (dd, J = 15.3, 7.6 Hz, 1H), 3.55 (d, J = 11.9 Hz, 1H), 3.50-3.44 (m, 2H), 3.35 (d, J = 2.9 Hz, 1H), 2.93-2.86 (m, 2H), 2.78 (dd, J = 40.4, 15.5 Hz, 5H), 2.66-2.56 (m, 1H), 2.05-1.90 (m, 3H), 1.79 (d, J = 10.3 Hz, 6H).

+





136


embedded image


2-(2-((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
418

1H NMR (500 MHz, MeOD) δ 8.67 (dd, J = 9.9, 4.6 Hz, 1H), 7.97 − 7.90 (m, 1H), 7.73 − 7.68 (m, 1H), 7.66 − 7.59 (m, 2H), 7.47 − 7.37 (m, 3H), 4.35 − 4.26 (m, 1H), 3.68 (d, J = 12.3 Hz, 1H), 3.53 (t, J = 7.3 Hz, 2H), 3.08 (d, J = 12.4 Hz, 1H), 3.02 − 2.87 (m, 2H), 2.79 (dd, J = 42.5, 15.5 Hz, 5H), 2.43 (dt, J = 14.7, 7.5 Hz, 1H), 2.34 (dt, J = 13.9, 7.1 Hz, 1H), 2.06 − 1.89 (m, 3H),

+






1.78 (d, J = 3.4 Hz, 6H).






137


embedded image


(R)-4-(2-(3-(2- ethoxy-1,1,1,3,3,3- hexafluoropropan- 2-yl)-1-(2-(pyridin- 2-yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
514

1H NMR (500 MHz, MeOD) δ 8.61 (d, J = 4.3 Hz, 1H), 7.92 (td, J = 7.9, 1.6 Hz, 1H), 7.68 (dd, J = 8.0, 6.6 Hz, 3H), 7.42 (t, J = 7.7 Hz, 3H), 4.09 (q, J = 6.6 Hz, 2H), 3.54 (d, J = 11.2 Hz, 1H), 3.37 − 3.31 (m, 2H), 3.20 − 3.14 (m, 1H), 3.00 − 2.87 (m, 2H), 2.86 − 2.73 (m, 5H), 2.69 − 2.58 (m, 1H), 2.29 − 2.14 (m, 1H), 2.07 − 1.95 (m, 2H), 1.73 (d, J = 25.3 Hz, 6H), 1.35 (t, J = 7.0 Hz, 3H).

+





138


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxylic acid
364

1H NMR (500 MHz, MeOD) δ 8.67 (d, J = 4.7 Hz, 1H), 7.92 (td, J = 7.8, 1.6 Hz, 1H), 7.60 (t, J = 7.8 Hz, 3H), 7.44 (dd, J = 7.6, 4.8 Hz, 1H), 7.39 (d, J = 8.1 Hz, 2H), 3.71 (d, J = 11.7 Hz, 1H), 3.43 − 3.36 (m, 1H), 3.34 − 3.32 (m, 1H), 3.06 (d, J = 11.8 Hz, 1H), 2.83 (dd, J = 50.8, 15.6 Hz, 4H), 2.75 − 2.69 (m, 1H), 2.67 − 2.59 (m, 1H), 2.57 − 2.45 (m, 1H), 2.21 − 2.05 (m, 1H), 1.98 − 1.88 (m, 2H),

+






1.75 (d, J = 20.0 Hz, 6H).






139


embedded image


ethyl (R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxylate
392

1H NMR (500 MHz, MeOD) δ 8.64 (d, J = 4.2 Hz, 1H), 7.91 (t, J = 7.0 Hz, 1H), 7.63 (d, J = 8.2 Hz, 3H), 7.42 (dd, J = 7.6, 4.9 Hz, 1H), 7.36 (d, J = 8.2 Hz, 2H), 4.26 − 4.20 (m, 2H), 3.66 (d, J = 12.1 Hz, 1H), 3.41 − 3.34 (m, 1H), 3.09 (d, J = 11.9 Hz, 1H), 2.78 (dd, J = 40.7, 15.5 Hz, 4H), 2.70 − 2.62 (m, 1H), 2.62 − 2.54 (m, 2H), 2.22 − 1.96 (m, 4H), 1.70 (d, J = 2.3 Hz, 6H), 1.32 (t, J = 7.1 Hz, 3H).

+





140


embedded image


(R)-4-(2-(3-(2- hydroxypropan-2- yl)-1-(2-(6- (trifluoromethyl) pyridin-3-yl)propan- 2-yl)pyrrolidin-3- yl)ethyl) benzonitrile
446

1H NMR (500 MHz, MeOD) δ 9.03 (s, 1H), 8.31 (d, J = 7.2 Hz, 1H), 7.90 (dd, J = 11.7, 8.3 Hz, 3H), 7.31 (d, J = 8.1 Hz, 2H), 3.09 − 3.00 (m, 1H), 2.91 − 2.72 (m, 12H), 2.65 − 2.59 (m, 1H), 2.58 (s, 3H), 2.31 − 2.22 (m, 1H), 1.95 − 1.86 (m, 1H), 1.79 (d, J = 5.2 Hz, 6H), 1.74 − 1.69 (m, 2H), 1.22 (s, 3H), 1.17 (s, 3H).

+





141


embedded image


(R)-5-(2-(3- ((benzyloxy) methyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl)thiophene- 2-carbonitrile
446

1H NMR (500 MHz, MeOD) δ 8.51 (s, 1H), 7.91 (td, J = 7.8, 1.8 Hz, 1H), 7.59 − 7.56 (m, 2H), 7.43 − 7.31 (m, 6H), 6.94 (d, J = 3.8 Hz, 1H), 4.64 − 4.57 (m, 2H), 3.54 (dd, J = 22.6, 8.8 Hz, 2H), 3.39 (t, J = 7.5 Hz, 2H), 3.12 (d, J = 11.9 Hz, 1H), 2.91 − 2.84 (m, 2H), 2.83 − 2.71 (m, 4H), 2.14 (dt, J = 13.6, 7.4 Hz, 2H), 2.03 − 1.91 (m, 3H), 1.70 (d, J = 2.8 Hz, 6H).

++





142


embedded image


(R)-4-(2-(3- (hydroxymethyl)-1- (2-(3- methoxyphenyl) propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
379

1H NMR (500 MHz, MeOD) δ 7.61 (d, J = 8.2 Hz, 2H), 7.42 (t, J = 8.0 Hz, 1H), 7.36 (d, J = 8.2 Hz, 2H), 7.23 (dd, J = 7.9, 5.0 Hz, 2H), 7.03 (dd, J = 8.2, 2.2 Hz, 1H), 3.84 (s, 3H), 3.50 (s, 2H), 3.44 − 3.33 (m, 2H), 3.24 (d, J = 12.2 Hz, 1H), 2.97 (d, J = 12.2 Hz, 1H), 2.79 (dd, J = 43.3, 15.4 Hz, 4H), 2.64 − 2.58 (m, 2H), 2.06 − 1.97 (m, 1H), 1.94 − 1.86 (m, 1H), 1.82 (d, J = 5.4 Hz, 6H), 1.79 − 1.65 (m, 2H).

+





143


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(3- methoxyphenyl)pro pan-2- yl)pyrrolidine-3- carboxylic acid
393

1H NMR (500 MHz, MeOD) δ 7.58 (d, J = 8.2 Hz, 2H), 7.41 (t, J = 8.0 Hz, 1H), 7.34 (d, J = 8.2 Hz, 2H), 7.20 − 7.16 (m, 2H), 7.03 (dd, J = 8.2, 1.8 Hz, 1H), 3.84 (s, 3H), 3.61 (d, J = 11.7 Hz, 1H), 3.40 − 3.32 (m, 2H), 3.27 (dd, J = 11.1, 8.8 Hz, 1H), 2.90 − 2.74 (m, 4H), 2.72 − 2.63 (m, 1H), 2.61 − 2.53 (m, 1H), 2.49 − 2.41 (m, 1H), 2.12 − 2.00 (m, 1H), 1.94 − 1.82 (m, 2H), 1.79 (d, J = 1.3 Hz, 6H).

+





144


embedded image


(R)-4-(2-(3- (hydroxymethyl)-1- (2-(6- methylpyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
364

1H NMR (500 MHz, MeOD) δ 7.80 (t, J = 7.8 Hz, 1H), 7.64 (d, J = 8.2 Hz, 2H), 7.42 (d, J = 8.2 Hz, 2H), 7.39 (d, J = 7.9 Hz, 1H), 7.30 (d, J = 7.7 Hz, 1H), 3.65 (dd, J = 25.9, 10.3 Hz, 2H), 3.43 (t, J = 7.6 Hz, 2H), 3.39 − 3.33 (m, 1H), 3.15 (d, J = 11.6 Hz, 1H), 2.83 − 2.71 (m, 4H), 2.71 − 2.64 (m, 2H), 2.57 (s, 3H), 2.20 − 2.10 (m, 1H), 2.08 − 2.00 (m, 1H), 1.90 − 1.78 (m, 2H), 1.75 (d, J = 11.5 Hz, 6H).

+





145


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(6- methylpyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxylic acid
378

1H NMR (500 MHz, MeOD) δ 7.79 (t, J = 7.8 Hz, 1H), 7.61 (d, J = 8.2 Hz, 2H), 7.38 (t, J = 8.2 Hz, 3H), 7.29 (d, J = 7.7 Hz, 1H), 3.69 (d, J = 11.6 Hz, 1H), 3.45 − 3.35 (m, 2H), 3.06 (d, J = 11.7 Hz, 1H), 2.82 (dd, J = 49.5, 15.6 Hz, 4H), 2.74 − 2.69 (m, 1H), 2.68 − 2.61 (m, 1H), 2.59 (s, 3H), 2.55 − 2.44 (m, 1H), 2.21 − 2.10 (m, 1H), 2.01 − 1.88 (m, 2H), 1.74 (d, J = 17.3 Hz, 6H).

+





146


embedded image


(R)-(3-(3,4- difluorophenethyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)methanol
361

1H NMR (500 MHz, MeOD) δ 8.67 (d, J = 4.7 Hz, 1H), 7.93 (td, J = 7.8, 1.7 Hz, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.44 (dd, J = 8.0, 4.5 Hz, 1H), 7.18 − 7.11 (m, 2H), 7.03 − 6.98 (m, 1H), 3.61 (t, J = 11.9 Hz, 2H), 3.43 (t, J = 7.1 Hz, 2H), 3.10 (d, J = 11.8 Hz, 1H), 2.80 (dd, J = 43.9, 15.5 Hz, 4H), 2.62 − 2.57 (m, 2H), 2.20 − 2.16 (m, 1H), 2.12 (dt, J = 13.6, 6.9 Hz, 1H), 2.05 − 1.98 (m, 2H), 1.81 (dd, J = 11.2, 3.9 Hz, 1H), 1.76 (d, J = 9.6 Hz, 6H).

+





147


embedded image


(R)-5-(2-(3- (hydroxymethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl)thiophene- 2-carbonitrile
356

1H NMR (500 MHz, MeOD) δ 8.67 (d, J = 3.9 Hz, 1H), 7.94 (t, J = 7.8 Hz, 1H), 7.65 − 7.58 (m, 2H), 7.45 (dd, J = 7.5, 4.7 Hz, 1H), 6.99 (d, J = 3.8 Hz, 1H), 3.64 − 3.57 (m, 2H), 3.43 (t, J = 7.3 Hz, 2H), 3.13 (d, J = 11.9 Hz, 1H), 2.95 − 2.90 (m, 2H), 2.86 − 2.72 (m, 4H), 2.12 (dd, J = 13.4, 7.0 Hz, 1H), 2.04 − 1.98 (m, 2H), 1.98 − 1.93 (m, 2H), 1.80 − 1.74 (m, 6H).

+





148


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(3- methoxyphenyl) propan-2- yl)pyrrolidine-3- carboxamide
392

1H NMR (500 MHz, MeOD) δ 7.59 (d, J = 8.2 Hz, 2H), 7.41 − 7.36 (m, 1H), 7.33 (d, J = 8.2 Hz, 2H), 7.18 (dd, J = 4.2, 2.0 Hz, 2H), 7.00 (dd, J = 8.2, 1.9 Hz, 1H), 3.84 (s, 3H), 3.62 (d, J = 11.9 Hz, 1H), 3.37-3.32 (m, 1H), 3.25 − 3.16 (m, 1H), 2.88 − 2.72 (m, 5H), 2.67 − 2.58 (m, 1H), 2.57 − 2.48 (m, 1H), 2.48 − 2.40 (m, 1H), 2.14 − 2.05 (m, 1H), 2.05 − 1.89 (m, 2H), 1.75 (s, 6H).

+





149


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(6- methylpyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxamide
377

1H NMR (500 MHz, MeOD) δ 7.79 (t, J = 7.8 Hz, 1H), 7.61 (d, J = 8.3 Hz, 2H), 7.38 (t, J = 8.0 Hz, 3H), 7.29 (d, J = 7.7 Hz, 1H), 3.77 (d, J = 11.9 Hz, 1H), 3.51 − 3.43 (m, 1H), 3.39 − 3.35 (m, 1H), 3.05 (d, J = 12.0 Hz, 1H), 2.77 (dd, J = 39.1, 15.4 Hz, 4H), 2.70 − 2.64 (m, 1H), 2.63 − 2.59 (m, 1H), 2.58 (s, 3H), 2.56 − 2.50 (m, 1H), 2.24 − 2.15 (m, 1H), 2.11 − 1.98 (m, 2H), 1.73 (d, J = 7.4 Hz, 6H).

+





150


embedded image


(R or S)-1-((R)-3- (3,4- difluorophenethyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3-yl)- 2,2,2- trifluoroethan-1-ol
429

1H NMR (500 MHz, MeOD) δ 8.68 (d, J = 4.7 Hz, 1H), 7.95 (dt, J = 7.8, 3.9 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.46 (dd, J = 6.9, 4.9 Hz, 1H), 7.20 − 7.08 (m, 2H), 6.99 (dd, J = 6.7, 2.7 Hz, 1H), 4.27 (d, J = 7.6 Hz, 1H), 3.52 − 3.47 (m, 2H), 3.45 (d, J = 8.7 Hz, 2H), 2.79 (dd, J = 42.5, 15.5 Hz, 4H), 2.70 − 2.57 (m, 3H), 1.94 (dd, J = 17.0, 8.2 Hz, 3H), 1.79 (s, 6H).

++





151


embedded image


(R or S)-1-((R)-3- (3,4- difluorophenethyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3-yl)- 2,2,2- trifluoroethan-1-ol
429

1H NMR (500 MHz, MeOD) δ 8.66 (d, J = 4.8 Hz, 1H), 7.93 (td, J = 7.8, 1.7 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.46 − 7.41 (m, 1H), 7.20 − 7.07 (m, 2H), 6.99(d, J = 8.4 Hz, 1H), 4.27 (dd, J = 15.7, 7.8 Hz, 1H), 3.64 (d, J = 12.1 Hz, 1H), 3.49 (t, J = 7.2 Hz, 2H), 3.02 (d, J = 12.2 Hz, 1H), 2.78 (dd, J = 40.7, 15.5 Hz, 4H), 2.68 (dt, J = 13.3, 6.6 Hz, 2H), 2.39 − 2.30 (m, 1H), 2.26 − 2.17 (m, 1H), 1.94 − 1.86 (m, 2H), 1.77 (d, J = 3.7 Hz, 6H).

+





152


embedded image


5-(2-((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl)pyrro lidin-3- yl)ethyl)thiophene- 2-carbonitrile
424

1H NMR (500 MHz, MeOD) δ 8.67 (d, J = 4.0 Hz, 1H), 7.97 − 7.92 (m, 1H), 7.63 (dd, J = 15.8, 5.9 Hz, 2H), 7.45 (dd, J = 7.5, 4.8 Hz, 1H), 6.97 (d, J = 3.7 Hz, 1H), 4.26 (d, J = 7.2 Hz, 1H), 3.47 (dd, J = 16.0, 10.2 Hz, 3H), 3.01 − 2.94 (m, 2H), 2.85 − 2.71 (m, 4H), 2.58 (dd, J = 22.0, 7.9 Hz, 1H), 2.22 − 2.13 (m, 1H), 2.09 − 2.01 (m, 2H), 1.98 − 1.92 (m, 1H), 1.78 (d, J = 2.1 Hz, 6H).

++





153


embedded image


5-(2-((R)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl)pyrro lidin-3- yl)ethyl)thiophene- 2-carbonitrile
424

1H NMR (500 MHz, MeOD) δ 8.66 (d, J = 4.4 Hz, 1H), 7.96 − 7.87 (m, 1H), 7.61 (dd, J = 14.7, 10.6 Hz, 2H), 7.43 (dd, J = 14.4, 9.4 Hz, 1H), 6.96 (d, J = 8.5 Hz, 1H), 4.26 (d, J = 7.6 Hz, 1H), 3.61 (dd, J = 20.8, 9.3 Hz, 1H), 3.48 (d, J = 6.0 Hz, 2H), 3.09 − 3.02 (m, 2H), 2.84 − 2.69 (m, 4H), 2.34 − 2.27 (m, 1H), 2.19 (dd, J = 17.7, 6.3 Hz, 2H), 2.03 (d, J = 8.7 Hz, 2H), 1.76 (d, J = 9.9 Hz, 6H).

+





154


embedded image


(R)-5-(2-(1-(2- (pyridin-2- yl)propan-2-yl)-3- (2,2,2- trifluoroacetyl)pyrr olidin-3- yl)ethyl)thiophene- 2-carbonitrile
422

1H NMR (500 MHz, MeOD) δ 8.66 (s, 1H), 7.97 − 7.91 (m, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.60 (d, J = 3.8 Hz, 1H), 7.44 (d, J = 5.3 Hz, 1H), 6.95 (d, J = 3.0 Hz, 1H), 3.59 (dd, J = 11.9, 5.7 Hz, 1H), 3.48 − 3.38 (m, 2H), 3.06 (dd, J = 13.9, 7.0 Hz, 3H), 2.85 − 2.73 (m, 4H), 2.70 − 2.58 (m, 1H), 2.07 − 1.95 (m, 3H), 1.80 − 1.72 (m, 6H).

+





155


embedded image


(R)-3-(4- cyanophenethyl)- N-methyl-1-(2- (pyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxamide
377

1H NMR (500 MHz, MeOD) δ 8.68 − 8.65 (m, 1H), 7.92 (dd, J = 7.8, 1.8 Hz, 1H), 7.62 (d, J = 8.1 Hz, 3H), 7.45 − 7.42 (m, 1H), 7.36 (d, J = 8.2 Hz, 2H), 3.78 (d, J = 12.0 Hz, 1H), 3.47 − 3.41 (m, 1H), 3.34 − 3.31 (m, 1H), 3.08 (d, J = 12.1 Hz, 1H), 2.85 − 2.72 (m, 7H), 2.64 − 2.48 (m, 3H), 2.19 − 2.11 (m, 1H), 2.09 − 1.99 (m, 2H), 1.74 (d, J = 6.7 Hz, 6H).

++





156


embedded image


5-(2-((R)-3-((R or S)-1-ethoxy-2,2,2- trifluoroethyl)-1-(2- (pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl)thiophene- 2-carbonitrile
452

1H NMR (500 MHz, MeOD) δ 8.67 (d, J = 4.1 Hz, 1H), 7.98 − 7.91 (m, 1H), 7.68 − 7.63 (m, 1H), 7.62 (d, J = 3.8 Hz, 1H), 7.46 (dd, J = 12.9, 5.3 Hz, 1H), 6.98 (d, J = 3.7 Hz, 1H), 4.22 (dt, J = 13.9, 7.0 Hz, 1H), 4.12 (dd, J = 14.3, 7.0 Hz, 1H), 3.99 (dd, J = 15.0, 7.7 Hz, 1H), 3.78 (dt, J = 14.3, 7.1 Hz, 1H), 3.53 (dd, J = 22.2, 10.1 Hz, 1H), 3.39 (d, J = 12.4 Hz, 1H), 3.11 − 3.05 (m, 1H), 3.04 − 2.97 (m, 1H), 2.80 (dd, J = 44.9, 15.5 Hz,

++






4H), 2.45 (dd, J = 22.5, 9.0







Hz, 1H), 2.30 − 2.17 (m,







2H), 2.04 (dd, J = 16.7,







12.0 Hz, 2H), 1.78 (t, J =







4.0 Hz, 6H), 1.30 − 1.27







(m, 3H).






157


embedded image


(R)-4-(2-(3- (hydroxymethyl)-1- (2-(6- methoxypyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
380

1H NMR (500 MHz, MeOD) δ 7.81 − 7.76 (m, 1H), 7.64 (d, J = 8.2 Hz, 2H), 7.41 (d, J = 8.2 Hz, 2H), 7.15 (d, J = 7.4 Hz, 1H), 6.85 (d, J = 8.3 Hz, 1H), 3.96 (s, 3H), 3.73 (d, J = 9.2 Hz, 1H), 3.64 (d, J = 9.6 Hz, 1H), 3.48 (d, J = 11.2 Hz, 1H), 3.40 (t, J = 7.4 Hz, 2H), 3.21 (d, J = 11.3 Hz, 1H), 2.78 (dd, J = 40.1, 15.5 Hz, 4H), 2.70 (d, J = 5.1 Hz, 2H), 2.16 (d, J = 8.3 Hz, 1H), 2.09 (s, 1H), 1.90 − 1.80 (m, 2H), 1.76 (d, J = 15.5 Hz, 6H).

++





158


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(6- methoxypyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxylic acid
394

1H NMR (500 MHz, MeOD) δ 7.79 − 7.75 (m, 1H), 7.60 (d, J = 8.1 Hz, 2H), 7.39 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 7.4 Hz, 1H), 6.84 (d, J = 8.3 Hz, 1H), 4.00 (s, 3H), 3.68 (d, J = 10.7 Hz, 1H), 3.45 (s, 1H), 3.39 (d, J = 8.4 Hz, 1H), 3.06 (d, J = 11.1 Hz, 1H), 2.83 (dd, J = 50.8, 15.6 Hz, 4H), 2.73 (d, J = 4.3 Hz, 1H), 2.69 − 2.60 (m, 1H), 2.43 (s, 1H), 2.28 − 2.15 (m, 1H), 1.98 (d, J = 12.7 Hz, 1H), 1.87 (s, 1H), 1.76 (d, J = 10.8 Hz, 6H).

+





159


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(6- methoxypyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxamide
393

1H NMR (500 MHz, MeOD) δ 7.77 (dd, J = 8.3, 7.5 Hz, 1H), 7.61 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.2 Hz, 2H), 7.15 (d, J = 7.4 Hz, 1H), 6.84 (d, J = 8.3 Hz, 1H), 4.00 (s, 3H), 3.78 (d, J = 11.7 Hz, 1H), 3.56- 3.48 (m, 1H), 3.45 − 3.37 (m, 1H), 3.04 (d, J = 11.7 Hz, 1H), 2.78 (dd, J = 40.4, 15.4 Hz, 4H), 2.71 − 2.66 (m, 1H), 2.65 − 2.56 (m, 1H), 2.52 − 2.41 (m, 1H), 2.27 − 2.17 (m, 1H), 2.11 − 1.96 (m, 2H), 1.76 (d, J = 2.0 Hz, 6H).

++





160


embedded image


(R)-5-(2-(3- (1,1,1,3,3,3- hexafluoro-2- hydroxypropan-2- yl)-1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl)thiophene- 2-carbonitrile
492

1H NMR (500 MHz, MeOD) δ 8.63 (d, J = 4.0 Hz, 1H), 7.94 − 7.89 (m, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 3.8 Hz, 1H), 7.42 (dd, J = 6.8, 4.8 Hz, 1H), 7.02 − 6.98 (m, 1H), 3.63 (d, J = 12.3 Hz, 1H), 3.35 (s, 1H), 3.17 − 3.10 (m, 2H), 3.05 (dd, J = 21.2, 9.8 Hz, 1H), 2.82 (dd, J = 49.0, 15.6 Hz, 4H), 2.66 (dd, J = 14.8, 7.4 Hz, 1H), 2.22 − 2.07 (m, 4H), 1.74 (d, J = 16.2 Hz, 6H).

+





161


embedded image


(R)-5-(2-(3-(2- ethoxy-1,1,1,3,3,3- hexafluoropropan- 2-yl)-1-(2-(pyridin- 2-yl)propan-2- yl)pyrrolidin-3- yl)ethyl)thiophene- 2-carbonitrile
520

1H NMR (500 MHz, MeOD) δ 8.60 (d, J = 4.4 Hz, 1H), 7.93 − 7.88 (m, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 3.8 Hz, 1H), 7.40 (dd, J = 7.1, 5.0 Hz, 1H), 7.02 − 6.99 (m, 1H), 4.10 − 4.03 (m, 2H), 3.53 − 3.43 (m, 1H), 3.26 (d, J = 7.6 Hz, 1H), 3.19 − 3.06 (m, 4H), 2.81 (dd, J = 47.5, 15.6 Hz, 4H), 2.59 (dd, J = 14.3, 6.9 Hz, 1H), 2.16 − 2.09 (m, 3H), 1.70 (d, J = 20.1 Hz, 6H), 1.32 (d, J = 6.9 Hz, 3H).

+





162


embedded image


(R)-4-(2-(3- ((methylsulfonyl) methyl)-1-(2- (pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
412

1H NMR (500 MHz, MeOD) δ 8.66 (dd, J = 4.8, 0.7 Hz, 1H), 7.93 (td, J = 7.8, 1.8 Hz, 1H), 7.66 − 7.62 (m, 3H), 7.47 − 7.41 (m, 3H), 3.69 (d, J = 13.9 Hz, 2H), 3.59 (d, J = 14.3 Hz, 1H), 3.52 (t, J = 7.2 Hz, 2H), 3.27 (d, J = 12.5 Hz, 1H), 3.07 (s, 3H), 2.89 (dd, J = 12.9, 4.5 Hz, 1H), 2.86 − 2.73 (m, 4H), 2.29 − 2.08 (m, 4H), 1.95 (td, J = 13.3, 4.5 Hz, 1H), 1.77 (t,

+






J = 6.7 Hz, 6H).






163


embedded image


(R)-5-(2-(3- ((benzyloxy) methyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl)benzo[c] [1,2,5]oxadiazole
457

1H NMR (500 MHz, MeOD) δ 8.50 (s, 1H), 7.91 (td, J = 7.9, 1.6 Hz, 1H), 7.82 (d, J = 9.3 Hz, 1H), 7.63 (s, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.44 − 7.31 (m, 7H), 4.63 (s, 2H), 3.61 (d, J = 17.2 Hz, 2H), 3.41 (dd, J = 17.5, 10.1 Hz, 3H), 3.21 − 3.15 (m, 1H), 2.85 − 2.72 (m, 4H), 2.72 (d, J = 7.5 Hz, 2H), 2.23 − 2.14 (m, 1H), 2.08 (dd, J = 14.5, 6.7 Hz, 1H), 2.00 − 1.86

+






(m, 2H), 1.72 (d, J = 2.8 Hz,







6H).






164


embedded image


(R)-2-(2-(3-(2- (benzofuran-6- yl)ethyl)-3- ((benzyloxy) methyl)pyrrolidin- 1- yl)propan-2- yl)pyridine
453

1H NMR (500 MHz, MeOD) δ 8.47 (s, 1H), 7.89 (td, J = 7.9, 1.4 Hz, 1H), 7.68 (d, J = 1.9 Hz, 1H), 7.52 (dd, J = 30.1, 8.0 Hz, 2H), 7.43 − 7.31 (m, 7H), 7.06 (d, J = 7.9 Hz, 1H), 6.77 (d, J = 1.0 Hz, 1H), 4.68 − 4.57 (m, 2H), 3.60 (dd, J = 29.4, 8.4 Hz, 2H), 3.46 − 3.32 (m, 3H), 3.09 (d, J = 11.8 Hz, 1H), 2.78 (dd, J = 39.8, 15.4 Hz, 4H), 2.71 − 2.62 (m, 2H),

+






2.21 − 2.12 (m, 1H), 2.09 −







2.00 (m, 1H), 1.98 − 1.85 (m,







2H), 1.69 (d, J = 8.4 Hz, 6H).






165


embedded image


(R)-4-(2-(3- (1,1,1,3,3,3- hexafluoro-2- hydroxypropan-2- yl)-1-(2-(6- methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
500

1H NMR (500 MHz, MeOD) δ 8.60 (d, J = 2.2 Hz, 1H), 7.95 (dd, J = 8.2, 2.3 Hz, 1H), 7.66 (d, J = 8.2 Hz, 2H), 7.35 (t, J = 8.0 Hz, 3H), 3.16 (dd, J = 3.4, 1.7 Hz, 1H), 2.91 − 2.76 (m, 4H), 2.73 (d, J = 9.9 Hz, 3H), 2.53 (s, 3H), 2.50 − 2.45 (m, 1H), 1.98 − 1.83 (m, 4H), 1.62 (dd, J = 13.4, 5.0 Hz, 1H), 1.55 (d, J = 3.0 Hz, 6H).

++





166


embedded image


(R)-4-(2-(1-(2-(6- methylpyridin-3- yl)propan-2-yl)-3- (2,2,2- trifluoroacetyl) pyrrolidin-3- yl)ethyl) benzonitrile
430

1H NMR (500 MHz, MeOD) δ 8.64 (d, J = 14.4 Hz, 1H), 8.02 − 7.94 (m, 1H), 7.64 − 7.60 (m, 2H), 7.41 − 7.38 (m, 1H), 7.32 − 7.28 (m, 2H), 3.39 − 3.35 (m, 1H), 3.15 − 3.00 (m, 2H), 2.82 (dd, J = 50.3, 15.6 Hz, 4H), 2.73 − 2.58 (m, 3H), 2.54 (d, J = 2.2 Hz, 3H), 2.51 − 2.42 (m, 2H), 1.91 − 1.80 (m, 2H), 1.71 (d, J = 25.8 Hz, 6H).

++





167


embedded image


(R)-(3-(2- (benzo[c][1,2,5] oxadiazol-5- yl)ethyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)methanol
367

1H NMR (500 MHz, MeOD) δ 8.67 (d, J = 4.1 Hz, 1H), 7.95 − 7.91 (m, 1H), 7.84 (d, J = 9.2 Hz, 1H), 7.68 (s, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.44 (t, J = 7.0 Hz, 2H), 3.67 (d, J = 11.3 Hz, 2H), 3.46 (t, J = 7.3 Hz, 2H), 3.38 (d, J = 11.7 Hz, 1H), 3.17 (d, J = 11.8 Hz, 1H), 2.87 − 2.72 (m, 5H), 2.21 − 2.12 (m, 1H), 2.09 − 2.02 (m, 1H), 1.98 − 1.82 (m, 3H), 1.78 (d, J = 8.1 Hz, 6H).

++





168


embedded image


(R)-(3-(2- (benzofuran-6- yl)ethyl)-1-(2- (pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)methanol
365

1H NMR (500 MHz, MeOD) δ 8.65 (d, J = 4.1 Hz, 1H), 7.94 − 7.90 (m, 1H), 7.68 (d, J = 2.2 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.43 (dd, J = 7.3, 5.1 Hz, 1H), 7.36 (s, 1H), 7.10 (dd, J = 8.0, 1.1 Hz, 1H), 6.79 − 6.76 (m, 1H), 3.65 (dd, J = 23.6, 10.5 Hz, 2H), 3.42 (t, J = 7.6 Hz, 2H), 3.08 (d, J = 11.8 Hz, 1H), 2.82 − 2.71 (m, 5H), 2.21 − 1.99 (m, 3H),

++






1.96 − 1.80 (m, 3H), 1.75 (d,







J = 13.0 Hz, 6H).






169


embedded image


(R)-5-(2-(3- ((methylsulfonyl) methyl)-1-(2- (pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl)benzo[c] [1,2,5]oxadiazole
429

1H NMR (500 MHz, MeOD) δ 8.66 (d, J = 4.0 Hz, 1H), 7.94 − 7.90 (m, 1H), 7.84 (d, J = 9.2 Hz, 1H), 7.70 (s, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.51 (dd, J = 9.3, 1.2 Hz, 1H), 7.42 (dd, J = 7.6, 4.8 Hz, 1H), 3.70 (dd, J = 22.2, 13.4 Hz, 2H), 3.62 (d, J = 14.2 Hz, 1H), 3.51 (t, J = 7.4 Hz, 2H), 3.09 (s, 3H), 2.96 − 2.89 (m, 1H), 2.84 − 2.82 (m, 1H), 2.85 − 2.72 (m, 4H), 2.25 (t, J = 6.8 Hz, 2H), 2.21 − 2.15 (m, 1H),

+






2.07 − 1.97 (m, 2H), 1.78 (d,







J = 3.5 Hz, 6H).






170


embedded image


4-(2-((R)-3-((R or S)-1-ethoxy-2,2,2- trifluoroethyl)-1-(2- (6-methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
460

1H NMR (500 MHz, MeOD) δ 8.64 (d, J = 2.1 Hz, 1H), 8.00 (dd, J = 8.2, 2.4 Hz, 1H), 7.65 (d, J = 8.2 Hz, 2H), 7.35 (dd, J = 14.2, 8.2 Hz, 3H), 3.88 (dd, J = 15.8, 8.8 Hz, 2H), 3.61 (dd, J = 8.9, 7.1 Hz, 1H), 3.05 − 2.98 (m, 1H), 2.97 − 2.90 (m, 1H), 2.87 (s, 1H), 2.88 − 2.74 (m, 4H), 2.81 (dd, J = 15.0, 7.2 Hz, 2H), 2.72 − 2.66 (m, 1H), 2.53 (s, 3H), 2.16 (dd, J =13.8, 7.1 Hz, 1H), 1.82 (dd, J = 13.1,

+






6.5 Hz, 2H), 1.69 (d, J = 13.9







Hz, 1H), 1.64 (s, 6H), 1.26







(t, J = 9.0 Hz, 3H).






171


embedded image


4-(2-((R)-3-((R or S)-1-ethoxy-2,2,2- trifluoroethyl)-1-(2- (6-methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
460

1H NMR (500 MHz, MeOD) δ 8.66 (d, J = 2.1 Hz, 1H), 8.01 (dd, J = 8.2, 2.4 Hz, 1H), 7.64 (d, J = 8.2 Hz, 2H), 7.36 (dd, J = 18.7, 8.2 Hz, 3H), 4.03 (dd, J = 15.3, 7.7 Hz, 1H), 3.87 (dd, J = 16.2, 6.7 Hz, 1H), 3.65 − 3.58 (m, 1H), 3.15 (d, J = 11.3 Hz, 2H), 2.99 − 2.93 (m, 1H), 2.88 − 2.73 (m, 4H), 2.82 − 2.78 (m, 1H), 2.70 − 2.63 (m, 1H), 2.54 (s, 3H), 2.08 − 2.02 (m, 1H), 1.96 (dd, J = 14.1, 7.2

+






Hz, 1H), 1.89 − 1.74 (m, 3H),







1.69 (d, J = 4.7 Hz, 6H),







1.26 (t, J = 9.0 Hz, 3H).






172


embedded image


(R or S)-1-((R)-3- (2-(benzofuran-6- yl)ethyl)-1-(2- (pyridin-2- yl)propan-2- yl)pyrrolidin-3-yl)- 2,2,2- trifluoroethan-1-ol
433

1H NMR (500 MHz, MeOD) δ 8.66 (d, J = 4.4 Hz, 1H), 7.94 (t, J = 7.7 Hz, 1H), 7.70 (s, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.46 − 7.42 (m, 1H), 7.33 (s, 1H), 7.08 (d, J = 7.9 Hz, 1H), 6.79 (s, 1H), 4.31 (d, J = 7.3 Hz, 1H), 3.45 (d, J = 10.4 Hz, 3H), 3.22 (dd, J = 40.8, 16.7 Hz, 2H), 2.76 (dd, J = 37.5, 15.4 Hz, 4H), 2.76 (d, J = 8.8 Hz, 1H), 2.61 (d, J = 13.7 Hz, 1H), 2.04 − 1.98 (m, 2H),

+






1.95 − 1.88 (m, 1H), 1.77 (d,







J = 4.3 Hz, 6H).






173


embedded image


(R or S)-1-((R)-3- (2-(benzofuran-6- yl)ethyl)-1-(2- (pyridin-2- yl)propan-2- yl)pyrrolidin-3-yl)- 2,2,2- trifluoroethan-1-ol
433

1H NMR (500 MHz, MeOD) δ 8.65 (d, J = 4.4 Hz, 1H), 7.93 (t, J = 7.5 Hz, 1H), 7.69 (d, J = 1.9 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.43 (dd, J = 7.4, 4.9 Hz, 1H), 7.33 (s, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.79 (s, 1H), 4.34 − 4.28 (m, 1H), 3.64 (d, J = 11.8 Hz, 1H), 3.51 (t, J = 5.9 Hz, 2H), 3.01 (d, J = 11.8 Hz, 1H), 2.81 (s, 1H), 2.79 (t, J = 19.8 Hz, 4H), 2.39 (dd, J = 13.2, 6.4

+






Hz, 1H), 2.29 (dd, J = 14.2,







7.8 Hz, 1H), 2.05 − 1.93 (m,







3H), 1.77 (d, J = 6.0 Hz, 6H).






174


embedded image


(R)-3-(2- (benzofuran-6- yl)ethyl)-1-(2- (pyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxamide
378

1H NMR (500 MHz, MeOD) δ 8.63 (d, J = 3.9 Hz, 1H), 7.90 (t, J = 7.7 Hz, 1H), 7.69 (s, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.43 − 7.38 (m, 1H), 7.31 (s, 1H), 7.06 (d, J = 7.8 Hz, 1H), 6.77 (s, 1H), 3.78 (d, J = 11.9 Hz, 1H), 3.44 (s, 1H), 3.02 (d, J = 12.0 Hz, 1H), 2.78 (dd, J = 41.3, 15.5 Hz, 4H), 2.70 − 2.50 (m, 3H), 2.26 − 2.18 (m, 1H), 2.15 − 1.99 (m, 3H), 1.73 (d, J = 13.8 Hz, 6H).

++





175


embedded image


(R)-3-(3,4- difluorophenethyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- carbonitrile
356

1H NMR (500 MHz, MeOD) δ 8.56 (d, J = 4.8 Hz, 1H), 7.88 − 7.83 (m, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.35 (dd, J = 7.0, 5.4 Hz, 1H), 7.16 (dd, J = 18.9, 8.4 Hz, 2H), 7.03 (d, J = 4.6 Hz, 1H), 3.29 − 3.22 (m, 2H), 3.17 − 3.13 (m, 1H), 2.91 (d, J = 11.1 Hz, 1H), 2.89 − 2.75 (m, 4H), 2.84 − 2.80 (m, 1H), 2.73 (d, J = 8.1 Hz, 1H), 2.46 − 2.40 (m, 1H), 2.05 − 1.98 (m,

+






3H), 1.60 (d, J = 14.8







Hz, 6H).






176


embedded image


(R or S)-1-((R)-3- (2- (benzo[c][1,2,5] oxadiazol-5- yl)ethyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3-yl)- 2,2,2- trifluoroethan-1-ol
435

1H NMR (500 MHz, MeOD) δ 8.68 (d, J = 4.3 Hz, 1H), 7.95 (t, J = 7.8 Hz, 1H), 7.86 (d, J = 9.2 Hz, 1H), 7.65 (d, J = 8.3 Hz, 2H), 7.47 − 7.39 (m, 2H), 4.33 (d, J = 7.4 Hz, 1H), 3.54 (d, J = 11.6 Hz, 1H), 3.51 − 3.44 (m, 2H), 3.36 (s, 1H), 2.81 (s, 1H), 2.78 (dd, J = 41.0, 15.5 Hz, 4H), 2.66 − 2.58 (m, 1H), 2.09-1.95 (m, 4H), 1.80 (d, J = 2.7 Hz, 6H).

+





177


embedded image


(R or S)- 1-((R)-3- (2- (benzo[c][1,2,5] oxadiazol-5- yl)ethyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidin- 3-yl)- 2,2,2- trifluoroethan- 1-ol
435

1H NMR (500 MHz, MeOD) δ 8.66 (d, J = 4.3 Hz, 1H), 7.93 (t, J = 7.7 Hz, 1H), 7.86 (d, J = 9.2 Hz, 1H), 7.68 − 7.62 (m, 2H), 7.45 − 7.39 (m, 2H), 4.37 − 4.29 (m, 1H), 3.67 (d, J = 12.2 Hz, 1H), 3.52 (t, J = 6.0 Hz, 2H), 3.09 (d, J = 12.2 Hz, 1H), 2.96 − 2.85 (m, 2H), 2.78 (dd, J = 40.7, 15.5 Hz, 4H), 2.43 − 2.34 (m, 1H), 2.32 − 2.24 (m, 1H), 2.04 − 1.97 (m, 2H), 1.79 (s, 6H).

+





178


embedded image


(R)-3-(2- (benzo[c][1,2,5] oxadiazol-5- yl)ethyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- carbonitrile
362

1H NMR (500 MHz, MeOD) δ 8.56 (d, J = 4.4 Hz, 1H), 7.85 (t, J = 9.2 Hz, 2H), 7.72 (d, J = 7.5 Hz, 2H), 7.45 (d, J = 9.1 Hz, 1H), 7.34 (dd, J = 7.1, 4.8 Hz, 1H), 3.41 (d, J = 10.7 Hz, 1H), 3.29 − 3.25 (m, 1H), 3.20 − 3.15 (m, 1H), 3.03 − 2.91 (m, 3H), 2.82 (dd, J = 51.4, 15.6 Hz, 4H), 2.48 (s, 1H), 2.14 (t, J = 8.3 Hz, 2H), 2.09 − 2.01 (m, 1H), 1.62 (d, J = 14.4 Hz, 6H).

+





179


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- carbonitrile
345

1H NMR (500 MHz, MeOD) δ 8.56 (d, J = 3.9 Hz, 1H), 7.86 (t, J = 7.5 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 7.7 Hz, 2H), 7.43 (d, J = 7.8 Hz, 2H), 7.37 − 7.32 (m, 1H), 3.26 − 3.21 (m, 1H), 3.19 − 3.07 (m, 2H), 2.93 (dd, J = 14.9, 8.3 Hz, 2H), 2.82 (dd, J = 49.6, 15.5 Hz, 4H), 2.46 − 2.40 (m, 1H), 2.10- 1.96 (m, 4H), 1.59 (d, J = 13.0 Hz, 6H).

+





180


embedded image


(R)-3-(2- (benzofuran-6- yl)ethyl)-1-(2- (pyridin-2- yl)propan-2- yl)pyrrolidine-3- carbonitrile
360

1H NMR (500 MHz, MeOD) δ 8.55 (d, J = 4.0 Hz, 1H), 7.86 (t, J = 7.5 Hz, 1H), 7.68 (dd, J = 9.7, 4.9 Hz, 2H), 7.51 (d, J = 7.9 Hz, 1H), 7.39 − 7.33 (m, 2H), 7.12 (d, J = 7.8 Hz, 1H), 6.78 (s, 1H), 3.32 (d, 1H), 3.25 (s, 1H), 2.99 − 2.93 (m, 2H), 2.91 (d, J = 7.4 Hz, 1H), 2.82 (dd, J = 49.9, 15.6 Hz, 4H), 2.49 − 2.42 (m, 1H), 2.14 − 1.99 (m, 4H), 1.62 (d, J = 20.7 Hz, 6H).

+





181


embedded image


(R)-5-(2-(1-(2- (pyridin-2- yl)propan-2-yl)-3- (2H-tetrazol-5- yl)pyrrolidin-3- yl)ethyl) benzo[c] [1,2,5]oxadiazole
405

1H NMR (500 MHz, MeOD) δ 8.64 (d, J = 4.6 Hz, 1H), 7.90 (t, J = 7.6 Hz, 1H), 7.76 (d, J = 9.3 Hz, 1H), 7.58 (d, J = 7.7 Hz, 1H), 7.54 (s, 1H), 7.41 (dd, J = 7.4, 4.8 Hz, 1H), 7.28 (d, J = 9.3 Hz, 1H), 3.90 (d, J = 11.5 Hz, 1H), 3.57 (s, 1H), 3.52 (d, J = 12.5 Hz, 1H), 3.43 (d, J = 11.8 Hz, 1H), 2.84 (dd, J = 55.4, 15.6 Hz, 4H), 2.59 − 2.55 (m, 1H), 2.42 − 2.38 (m, 1H), 2.31 − 2.26 (m, 2H), 2.20 − 2.17 (m, 1H), 2.04 − 2.00 (m, 1H), 1.65 (d, J =

+






32.5 Hz, 6H).






182


embedded image


(R)-4-(2-(1-(2- (pyridin-2- yl)propan-2-yl)-3- (2H-tetrazol-5- yl)pyrrolidin-3- yl)ethyl) benzonitrile
388

1H NMR (500 MHz, MeOD) δ 8.65 (s, 1H), 7.92 (t, J = 7.7 Hz, 1H), 7.58 (d, J = 6.4 Hz, 3H), 7.45 − 7.41 (m, 1H), 7.28 (d, J = 6.5 Hz, 2H), 3.91 − 3.85 (m, 1H), 3.56 (s, 1H), 3.48 (d, J = 11.5 Hz, 1H), 3.39 (s, 1H), 2.84 (dd, J = 56.5, 15.6 Hz, 4H), 2.50 (d, J = 6.6 Hz, 1H), 2.26 (dd, J = 15.6, 8.1 Hz, 3H), 2.21 − 2.17 (m, 1H), 2.03 (d, J = 5.0 Hz, 1H), 1.65 (d, J = 25.5 Hz, 6H).

+





183


embedded image


(R)-2-(2-(3-(2- (benzofuran-6- yl)ethyl)-3-(2H- tetrazol-5- yl)pyrrolidin-1- yl)propan-2- yl)pyridine
403

+





184


embedded image


(R)-(1-(2-(pyridin- 2-yl)propan-2-yl)- 3-(2-(quinoxalin-2- yl)ethyl) pyrrolidin- 3-yl)methanol
377

1H NMR (500 MHz, MeOD) δ 8.85 (s, 1H), 8.66 (d, J = 4.4 Hz, 1H), 8.05 (dd, J = 23.8, 8.0 Hz, 2H), 7.93 (t, J = 7.6 Hz, 1H), 7.86 − 7.79 (m, 2H), 7.62 (d, J = 7.9 Hz, 1H), 7.43 (dd, J = 7.4, 4.9 Hz, 1H), 3.69 (dd, J = 23.0, 10.6 Hz, 2H), 3.48 (t, J = 7.2 Hz, 2H), 3.40 (d, J = 11.8 Hz, 1H), 3.21 (d, J = 11.8 Hz, 1H), 3.06 (dd, J = 15.7, 8.6 Hz, 2H), 2.78 (dd, J = 40.2, 15.4 Hz, 4H), 2.20 − 2.13 (m,

+






1H), 2.12 − 2.05 (m, 3H),







1.79 (d, J = 7.5 Hz, 6H).






185


embedded image


(S,E)-4-(2-(1-(2- (pyridin-2- yl)propan-2-yl)-3- (2H-tetrazol-5- yl)pyrrolidin-3- yl)vinyl) benzonitrile
386

1H NMR (500 MHz, MeOD) δ 8.67 (s, 1H), 7.92 (s, 1H), 7.63 (dd, J = 20.4, 6.7 Hz, 3H), 7.58 − 7.41 (m, 3H), 6.72 (d, J = 15.4 Hz, 1H), 6.27 (d, J = 14.8 Hz, 1H), 4.11 − 4.01 (m, 1H), 3.82 − 3.72 (m, 1H), 3.64 (t, J = 14.0 Hz, 1H), 3.51 − 3.37 (m, 2H), 2.84 (dd, J = 55.7, 15.3 Hz, 4H), 2.65 − 2.54 (m, 1H), 1.69 (d, J = 29.0 Hz, 6H).

+





186


embedded image


(S,E)-5-(2-(3-(2- ethoxy-1,1, 1,3,3,3- hexafluoropropan- 2-yl)-1-(2-(6- methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)vinyl)benzo[c] [1,2,5]oxadiazole
543

1H NMR (500 MHz, MeOD) δ 8.57 (d, J = 2.0 Hz, 1H), 7.92 (dd, J = 12.0, 5.9 Hz, 2H), 7.77 (s, 1H), 7.72 (d, J = 9.5 Hz, 1H), 7.28 (d, J = 8.2 Hz, 1H), 6.77 (s, 1H), 6.45 (s, 1H), 4.06 − 4.01 (m, 2H), 3.37 (d, J = 10.1 Hz, 1H), 3.16 (s, 1H), 3.03 (d, J = 9.5 Hz, 1H), 2.92 (d, J = 8.5 Hz, 1H), 2.82 (dd, J = 51.7, 15.6 Hz, 4H), 2.56 − 2.51 (m, 1H), 2.44 (s, 3H), 2.24 (s, 1H), 1.55 (d, J = 4.7 Hz, 6H), 1.28 (d, J = 6.8 Hz, 3H).

++





187


embedded image


(S,E)-2-(2-(3-(2- ethoxy-1,1,1,3,3,3- hexafluoropropan- 2-yl)-1-(2-(6- methylpyridin-3- yl)propan-2- yl)pyrrolidin-3- yl)vinyl)quinoxaline
553

1H NMR (500 MHz, MeOD) δ 8.98 (s, 1H), 8.55 (d, J = 2.1 Hz, 1H), 8.10 − 8.06 (m, 2H), 7.95 (dd, J = 8.2, 2.4 Hz, 1H), 7.87 − 7.80 (m, 2H), 7.26 (d, J = 8.2 Hz, 1H), 7.11 (d, J = 16.1 Hz, 1H), 6.95 (d, J = 16.2 Hz, 1H), 4.06 (dd, J = 13.6, 6.6 Hz, 2H), 3.38 (d, J = 10.1 Hz, 1H), 3.08 (d, J = 9.6 Hz, 1H), 2.96 − 2.91 (m, 1H), 2.89 − 2.75 (m, 4H), 2.57 (dd, J = 15.1, 6.3 Hz, 1H), 2.40 (s, 3H), 2.29 − 2.22 (m,

+






2H), 1.55 (d, J = 8.0 Hz, 6H),







1.30 (d, J = 7.0 Hz, 3H).






188


embedded image


(S,E)-2-(2-(3- ((benzyloxy) methyl)- 3-(2-(5- (trifluoromethyl) furan-2- yl)vinyl)pyrrolidin- 1-yl)propan-2- yl)pyridine
471

1H NMR (500 MHz, MeOD) δ 8.51 (s, 1H), 7.93 − 7.88 (m, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.42 − 7.30 (m, 6H), 6.96 (dd, J = 3.5, 1.2 Hz, 1H), 6.50 (d, J = 16.5 Hz, 2H), 6.38 (d, J = 16.5 Hz, 1H), 4.65 − 4.59 (m, 2H), 3.61 (dd, J = 18.6, 8.9 Hz, 2H), 3.54 (d, J = 12.0 Hz, 1H), 3.47 − 3.43 (m, 2H), 2.79 (dd, J = 43.1, 15.5 Hz, 4H), 2.36 − 2.22 (m, 3H), 1.72 (s, 6H).

+





189


embedded image


(R)-(1-(2-(pyridin- 2-yl)propan-2-yl)- 3-(2-(5- (trifluoromethyl) furan-2- yl)ethyl)pyrrolidin- 3-yl)methano
383

1H NMR (500 MHz, MeOD) δ 8.67 (d, J = 4.2 Hz, 1H), 7.93 (td, J = 7.8, 1.8 Hz, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.44 (dd, J = 6.7, 4.8 Hz, 1H), 6.85 (d, J = 2.1 Hz, 1H), 6.26 (d, J = 2.9 Hz, 1H), 3.59 (t, J = 10.7 Hz, 2H), 3.46 − 3.39 (m, 2H), 3.09 (d, J = 11.8 Hz, 1H), 2.81 (dd, J = 47.5, 15.6 Hz, 4H), 2.72 (s, 1H), 2.23 − 2.16 (m, 1H), 2.15 − 2.08 (m, 1H), 2.03 − 1.89 (m, 4H), 1.76 (d, J = 9.3 Hz, 6H).

+





190


embedded image


(R)-(1-(2-(pyridin- 2-yl)propan-2-yl)- 3-(2-(2- (trifluoromethyl) pyrimidin-5- yl)ethyl)pyrrolidin- 3-yl)methanol
395

1H NMR (500 MHz, MeOD) δ 8.87 (s, 2H), 8.69 − 8.67 (m, 1H), 7.96 − 7.92 (m, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.47 − 7.42 (m, 1H), 3.66 (dd, J = 23.2, 10.6 Hz, 2H), 3.46 (t, J = 7.9 Hz, 2H), 3.39 (d, J = 11.8 Hz, 1H), 3.18 (d, J = 11.9 Hz, 1H), 2.79 − 2.76 (m, 1H), 2.85 − 2.72 (m, 4H), 2.74 (d, J = 3.3 Hz, 1H), 2.15 (dd, J = 13.5, 6.9 Hz, 1H), 2.09 − 2.02 (m, 1H), 1.91 − 1.83 (m, 2H), 1.78 (d, J = 6.2 Hz, 6H).

+





191


embedded image


(R)-2-(2-(3-(2- (benzofuran-6- yl)ethyl)-3-(1H- 1,2,3-triazol-4- yl)pyrrolidin-1- yl)propan-2- yl)pyridine
402

1H NMR (500 MHz, MeOD) δ 8.62 (d, J = 4.1 Hz, 1H), 7.99 − 7.85 (m, 2H), 7.66 (d, J = 2.2 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.43 − 7.39 (m, 1H), 7.23 (s, 1H), 6.97 (d, J = 9.2 Hz, 1H), 6.77 − 6.73 (m, 1H), 3.79 (d, J = 12.3 Hz, 1H), 3.57 (s, 1H), 3.49 − 3.43 (m, 1H), 3.40 (d, J = 12.6 Hz, 1H), 2.84 (dd, J = 55.5, 15.7 Hz, 4H), 2.67 (s, 1H), 2.60 − 2.53 (m, 1H), 2.46 − 2.35 (m, 1H), 2.30 − 2.20 (m, 2H), 2.03 (d, J = 5.9 Hz, 1H), 1.34 (d, 6H).

+





192


embedded image


4-(2-((R)-3-((R or S)-3,3- dimethyloxetan-2- yl)-1-(pyridin-2- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile
376

1H NMR (500 MHz, MeOD) δ 8.63 (d, J = 4.9 Hz, 1H), 7.88 (t, J = 6.7 Hz, 1H), 7.66 (d, J = 7.8 Hz, 2H), 7.50 (d, J = 6.9 Hz, 1H), 7.42 (d, J = 7.5 Hz, 3H), 4.58 (s, 1H), 4.55 − 4.39 (m, 2H), 4.37 (dd, J = 11.1, 5.7 Hz, 1H), 4.23 (dd, J = 17.5, 5.6 Hz, 1H), 3.51 (s, 1H), 3.47 − 3.39 (m, 2H), 3.34 (s, 1H), 3.22 − 3.13 (m, 1H), 2.78 (dd, J = 42.8, 15.5 Hz, 4H), 2.72 (s, 1H), 2.14 − 2.02 (m, 1H), 1.97 − 1.82 (m, 2H), 1.38 (s, 3H), 1.32 (s, 3H), 1.24 (s, 1H).

++





193


embedded image


4-(2-((R)-3-((R or S)-3,3- dimethyloxetan-2- yl)-1-(pyridin-3- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile
376

1H NMR (500 MHz, MeOD) δ 8.68 (d, J = 16.8 Hz, 1H), 8.60 (s, 1H), 8.03 (d, 1H), 7.64 (d, J = 7.5 Hz, 2H), 7.52 (s, 1H), 7.41 (d, J = 7.2 Hz, 2H), 4.57 (s, 1H), 4.43 − 4.05 (m, 4H), 3.43 − 3.33 (m, 3H), 3.27 (d, 1H), 2.94 (d, J = 10.3 Hz, 1H), 2.79 (dd, J = 48.1, 15.5 Hz, 4H), 2.69 (d, J = 5.6 Hz, 2H), 2.06 − 1.95 (m, 1H), 1.94 − 1.87 (m, 1H), 1.85 − 1.76 (m, 1H), 1.32 (dd, J = 48.3, 22.0 Hz, 6H).

++





194


embedded image


4-(2-((R)-3-((R or S)-3,3- dimethyloxetan-2- yl)-1-((6- methylpyridin-3- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile
390

1H NMR (500 MHz, MeOD) δ 8.53 (d, J = 15.8 Hz, 1H), 7.91 (dd, J = 19.0, 6.3 Hz, 1H), 7.64 (d, J = 7.7 Hz, 2H), 7.40 (dd, J = 11.1, 7.5 Hz, 3H), 4.56 (s, 1H), 4.38 − 4.27 (m, 2H), 4.22 (d, J = 5.3 Hz, 2H), 3.42 − 3.34 (m, 1H), 3.25 (d, J = 11.6 Hz, 2H), 2.92 (d, J = 11.3 Hz, 1H), 2.78 (dd, J = 46.2, 15.5 Hz, 4H), 2.71 − 2.63 (m, 2H), 2.56 (s, 3H), 2.18 − 2.08 (m, 1H), 2.04 − 1.94 (m, 1H), 1.94 − 1.86 (m, 1H),

++






1.86 − 1.77 (m, 1H), 1.33







(dd, J = 35.0, 7.7 Hz, 6H).






195


embedded image


4-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-3,3- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
409

1H NMR (500 MHz, MeOD) δ 7.68 − 7.61 (m, 2H), 7.54 (dd, J = 16.4, 7.7 Hz, 2H), 7.47 (d, 2H), 7.41 (d, J = 6.7 Hz, 2H), 4.57 (s, 1H), 4.42 − 4.26 (m, 3H), 4.22 (d, J = 5.5 Hz, 1H), 3.48 − 3.34 (m, 3H), 3.03 (d, J = 10.2 Hz, 1H), 2.78 (dd, J = 46.8, 15.5 Hz, 4H), 2.71 − 2.59 (m, 3H), 2.09 − 1.98 (m, 1H), 1.97 − 1.88 (m, 1H), 1.87 − 1.79 (m, 1H), 1.33 (dd, J = 37.4, 8.0 Hz, 6H).

++





196


embedded image


4-(2-((R)-3-((R or S)-3,3- difluorooxetan-2- yl)-1-(pyridin-2- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile
384

1H NMR (500 MHz, MeOD) δ 8.66 (d, J = 4.5 Hz, 1H), 7.89 (d, J = 6.9 Hz, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.52 (d, J = 8.2 Hz, 1H), 7.42 (d, J = 7.9 Hz, 3H), 5.32 − 5.13 (m, 1H), 5.06 (d, J = 17.8 Hz, 1H), 4.56 (d, J = 9.4 Hz, 1H), 4.49 (d, J = 5.7 Hz, 1H), 3.80 (d, J = 12.5 Hz, 1H), 3.59 − 3.39 (m, 3H), 2.91 − 2.74 (m, 4H), 2.75 − 2.68 (m, 1H), 2.28 − 2.19 (m, 1H), 2.02 − 1.90 (m, 2H), 1.31 (d, J = 16.4 Hz, 3H).

++





197


embedded image


4-(2-((R)-3-((R or S)-3,3- difluorooxetan-2- yl)-1-(pyridin-3- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile
384

1H NMR (500 MHz, MeOD) δ 8.64 (d, J = 14.3 Hz, 1H), 8.60 − 8.52 (m, 1H), 7.99 (dd, J = 16.7, 7.8 Hz, 1H), 7.64 (dd, J = 8.2, 1.9 Hz, 2H), 7.50 (dd, J = 12.6, 7.6 Hz, 1H), 7.39 (dd, J = 8.1, 1.8 Hz, 2H), 5.22 − 5.06 (m, 1H), 4.78 − 4.66 (m, 2H), 4.19 (s, 1H), 4.10 (s, 1H), 3.22 − 3.14 (m, 1H), 3.10 (d, J = 11.2 Hz, 1H), 3.06 − 2.93 (m, 1H), 2.81 (dd, J = 50.8, 15.5 Hz, 4H), 2.75 − 2.68 (m, 2H), 2.42 − 2.31 (m, 1H), 2.12 − 2.03 (m, 1H), 2.02 − 1.95 (m, 1H), 1.94 −

++






1.84 (m, 2H).






198


embedded image


4-(2-((R)-3-((R or S)-3,3- difluorooxetan-2- yl)-1-((6- methylpyridin-3- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile
398

1H NMR (500 MHz, MeOD) δ 8.49 (d, J = 13.8 Hz, 1H), 7.87 (dd, J = 15.7, 7.6 Hz, 1H), 7.64 (dd, J = 8.2, 1.7 Hz, 2H), 7.38 (dd, J = 16.1, 7.9 Hz, 3H), 5.23 − 5.08 (m, 1H), 4.80 − 4.64 (m, 2H), 4.16 (s, 1H), 4.07 (s, 1H), 3.23 − 3.15 (m, 1H), 3.11 (d, J = 11.1 Hz, 1H), 3.06 − 2.94 (m, 1H), 2.80 (dd, J = 48.8, 15.5 Hz, 4H), 2.74 − 2.69 (m, 2H), 2.55 (d, J = 2.1 Hz, 3H), 2.44 − 2.33 (m, 1H), 2.14 − 2.04 (m, 1H), 2.02 − 1.94 (m, 1H), 1.94 − 1.84 (m, 2H).

++





199


embedded image


4-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-3,3- difluorooxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
417

1H NMR (500 MHz, MeOD) δ 7.65 (d, J = 7.9 Hz, 2H), 7.56 − 7.44 (m, 4H), 7.40 (d, J = 8.1 Hz, 2H),5.28 − 5.12 (m, 1H), 5.04 (s, 1H), 4.78 − 4.70 (m, 1H), 4.33 (d, J = 9.3 Hz, 1H), 4.26 (d, J = 8.8 Hz, 1H), 3.55 (d, J = 12.4 Hz, 1H), 3.46 − 3.38 (m, 1H), 3.19 − 3.13 (m, 1H), 2.80 (dd, 4H), 2.73 − 2.67 (m, 2H), 2.54 − 2.44 (m, 1H), 2.20 − 2.11 (m, 1H), 2.10 − 2.02 (m, 1H), 1.97 − 1.89 (m, 2H).

++





200


embedded image


(S)-3- (ethoxymethyl)-3- (4- (methylsulfonyl) phenethyl)-1-(2- phenylpropan-2- yl)pyrrolidine
430

1H NMR (500 MHz, MeOD) δ 7.84 (d, J = 8.3 Hz, 2H), 7.71 (d, J = 7.5 Hz, 2H), 7.51 (t, J = 7.4 Hz, 2H), 7.47 (d, J = 7.1 Hz, 1H), 7.43 (d, J = 8.2 Hz, 2H), 3.45 (dd, J = 6.9 Hz, 2H), 3.40 − 3.32 (m, 3H), 3.28 (d, J = 12.3 Hz, 2H), 3.09 (s, 3H), 3.05 (d, J = 12.2 Hz, 1H), 2.78 (dd, J = 42.2, 15.4 Hz, 4H), 2.63 (t, J = 8.5 Hz, 2H), 2.05 − 1.97 (m, 1H), 1.96 − 1.89 (m, 1H), 1.86 (s, 6H), 1.83 − 1.75 (m, 1H), 1.75 − 1.67 (m, 1H), 1.15 (t, J = 7.0 Hz, 3H).

++





201


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (1- (trifluoromethyl) cyclopropyl) pyrrolidine- 3-carboxamide
471

1H NMR (500 MHz, MeOD) δ 8.66 (d, J = 3.9 Hz, 1H), 7.92 (t, J = 7.8, 1.6 Hz, 1H), 7.69 − 7.58 (m, 3H), 7.44 (dd, J = 7.4, 4.8 Hz, 1H), 7.33 (d, J = 8.1 Hz, 2H), 3.73 (d, J = 12.0 Hz, 1H), 3.44 − 3.37 (m, 1H), 3.26 − 3.18 (m, 1H), 3.03 (d, J = 12.1 Hz, 1H), 2.79 (dd, J = 43.3, 15.5 Hz, 4H), 2.61 − 2.51 (m, 2H), 2.50 − 2.42 (m, 1H), 2.24 − 2.13 (m, 1H), 2.11 − 1.97 (m, 2H), 1.72 (s, 6H), 1.36

++






(dd, 2H), 1.13 (dd, J =







22.8, 10.7 Hz, 2H).






202


embedded image


(S)-4-(2-(1-(2- (pyridin-2- yl)propan-2-yl)-3- (((3- (trifluoromethyl) oxetan-3- yl)amino)methyl) pyrrolidin-3- yl)ethyl) benzonitrile
473

1H NMR (500 MHz, MeOD) δ 8.70 (d, J = 4.2 Hz, 1H), 7.95 (t, J = 7.3 Hz, 1H), 7.65 (d, J = 7.8 Hz, 3H), 7.49 − 7.38 (m, 3H), 4.83 − 4.70 (m, 3H), 4.61 (d, J = 6.5 Hz, 1H), 3.46 (d, J = 9.4 Hz, 3H), 3.21 (d, J = 11.7 Hz, 1H), 2.90 (d, J = 12.3 Hz, 1H), 2.77 (dd, J = 40.2, 15.5 Hz, 4H), 2.73 − 2.65 (m, 3H), 2.19 − 2.03 (m, 2H), 1.95 − 1.83 (m, 2H), 1.82 (s, 6H).

+





203


embedded image


(S)-4-(2-(1-(2- (pyridin-2- yl)propan-2-yl)-3- (((1- (trifluoromethyl) cyclopropyl) amino)methyl) pyrrolidin-3- yl)ethyl) benzonitrile
457

1H NMR (500 MHz, MeOD) δ 8.68 (d, J = 4.0 Hz, 1H), 7.94 (td, J = 7.8, 1.7 Hz, 1H), 7.69 − 7.59 (m, 3H), 7.46 (dd, J = 7.5, 4.9 Hz, 1H), 7.42 (d, J = 8.2 Hz, 2H), 3.46 − 3.33 (m, 2H), 3.25 (d, J = 40.0 Hz, 1H), 3.12 (d, J = 11.8 Hz, 1H), 3.02 (d, J = 12.5 Hz, 1H), 2.89 (d, J = 12.5 Hz, 1H), 2.76 (dd, J = 37.9, 15.4 Hz, 4H), 2.70 − 2.63 (m, 2H), 2.09 − 1.96 (m, 2H), 1.87 − 1.78 (m, 2H), 1.73 (dd, J = 21.3, 8.3 Hz, 6H), 1.16 − 1.05 (m, 3H), 0.95 (d, J = 5.5 Hz, 1H).

+





204


embedded image


4-(2-((R)-1-(4- cyanobenzyl)-3-((R or S)-3,3- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
400

1H NMR (500 MHz, MeOD) δ 7.78 (d, J = 7.9 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 7.64 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 4.55 (s, 1H), 4.33 (d, J = 5.6 Hz, 1H), 4.27 − 4.15 (m, 3H), 3.36 − 3.32 (m, 1H), 3.21 (t, J = 5.7 Hz, 1H), 3.15 (dd, J = 14.3, 9.0 Hz, 1H), 2.86 − 2.82 (m, 1H), 2.77 (dd, J = 48.0, 15.4 Hz, 4H), 2.73 − 2.64 (m, 3H), 1.99 − 1.86 (m, 2H), 1.84 − 1.75 (m, 1H), 1.37 (s, 3H), 1.30 (s, 3H).

++





205


embedded image


4-(2-((R)-3-((R or S)-3,3- dimethyloxetan-2- yl)-1-(4- methoxybenzyl)pyr rolidin-3- yl)ethyl) benzonitrile
405

1H NMR (500 MHz, MeOD) δ 7.64 (d, 2H), 7.42 (dd, J = 13.9, 8.2 Hz, 4H), 6.98 (d, J = 8.2 Hz, 2H), 4.56 (s, 1H), 4.34 (d, J = 5.6 Hz, 1H), 4.31 − 4.15 (m, 3H), 3.81 (s, 3H), 3.46 − 3.33 (m, 3H), 3.00 (d, J = 12.1 Hz, 1H), 2.83 − 2.69 (m, 4H), 2.74 − 2.60 (m, 3H), 2.06 − 1.95 (m, 1H), 1.94 − 1.86 (m, 1H), 1.86 − 1.75 (m, 1H), 1.37 (s, 3H), 1.29 (s, 3H).

++





206


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (3- (trifluoromethyl)ox etan-3- yl)pyrrolidine-3- carboxamide
487

1H NMR (500 MHz, MeOD) δ 8.64 (d, J = 3.6 Hz, 1H), 7.92 (t, J = 7.2 Hz, 1H), 7.68 − 7.56 (m, 3H), 7.42 (dd, J = 7.0, 4.9 Hz, 1H), 7.34 (d, J = 8.0 Hz, 2H), 4.86 − 4.76 (m, 4H), 3.70 (d, J = 11.7 Hz, 1H), 3.43 − 3.35 (m, 1H), 3.27 − 3.19 (m, 1H), 3.01 (t, J = 5.5 Hz, 1H), 2.79 (dd, J = 43.6, 15.5 Hz, 4H), 2.65 − 2.48 (m, 3H), 2.25 − 2.15 (m, 1H), 2.12 − 1.96

++






(m, 2H), 1.72 (s, 6H).






207


embedded image


(R)-3-(4- cyanophenethyl)- N-(5-fluoropyridin- 2-yl)-1-(2-(pyridin- 2-yl)propan-2- yl)pyrrolidine-3- carboxamide
458

1H NMR (500 MHz, MeOD) δ 8.64 (d, J = 4.0 Hz, 1H), 8.24 (d, J = 3.0 Hz, 1H), 8.09 (dd, J = 9.1, 4.0 Hz, 1H), 7.95 − 7.87 (m, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.64 − 7.59 (m, 1H), 7.56 (d, J = 8.1 Hz, 2H), 7.41 (dd, J = 7.4, 4.8 Hz, 1H), 7.35 (d, J = 8.1 Hz, 2H), 3.89 (d, J = 13.7 Hz, 1H), 3.47 − 3.39 (m, 1H), 3.39 − 3.33 (m, 1H), 3.14 (d, J = 12.2 Hz, 1H), 2.80 (dd, J = 48.3, 15.6 Hz, 4H),

++






2.72 − 2.58 (m, 3H), 2.42-







2.33 (m, 1H), 2.19 − 2.08







(m, 2H), 1.75 (s, 6H).






208


embedded image


(R)-N-(3- cyanooxetan-3-yl)- 3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxamide
444

1H NMR (500 MHz, MeOD) δ 8.64 (d, J = 4.3 Hz, 1H), 7.91 (td, J = 7.8, 1.6 Hz, 1H), 7.61 (d, J = 8.1 Hz, 3H), 7.41 (dd, J = 7.4, 4.9 Hz, 1H), 7.37 (d, J = 8.1 Hz, 2H), 5.02 (t, J = 7.2 Hz, 2H), 4.79 (dd, J = 7.0, 4.5 Hz, 2H), 3.61 (d, J = 11.5 Hz, 1H), 3.37 − 3.33 (m, 1H), 3.28 − 3.21 (m, 1H), 2.99 (d, J = 11.6 Hz, 1H), 2.78 (dd, J = 42.6, 15.5 Hz, 4H), 2.68 − 2.60 (m, 1H), 2.59 − 2.48 (m, 2H), 2.25 − 2.15 (m,

++






1H), 2.11 − 1.99 (m, 2H), 1.70







(d, J = 2.4 Hz, 6H).






209


embedded image


(S)-3-(((3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)methyl)amino) oxetane-3- carbonitrile
430

1H NMR (500 MHz, MeOD) δ 8.70 (d, J = 4.0 Hz, 1H), 7.95 (td, J = 7.8, 1.5 Hz, 1H), 7.64 (t, J = 8.1 Hz, 3H), 7.45 (t, J = 6.3 Hz, 3H), 4.99 − 4.92 (m, 2H), 4.68 (d, J = 5.7 Hz, 1H), 4.60 (d, J = 6.7 Hz, 1H), 3.51 − 3.36 (m, 3H), 3.19 (d, J = 11.8 Hz, 1H), 2.88 − 2.82 (m, 1H), 2.77 (dd, J = 40.2, 15.5 Hz, 4H), 2.74 − 2.67 (m, 3H), 2.16 − 2.05 (m, 2H), 1.94 − 1.85 (m, 2H), 1.79 (s, 6H).

+





210


embedded image


4-(2-((R)-1-((5- chloropyrimidin-2- yl)methyl)-3-((R or S)-3,3- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl)benzonitrile
411

1H NMR (500 MHz, MeOD) δ 8.89 (s, 2H), 7.66 (d, J = 7.9 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 4.60 (s, 1H), 4.57 (d, J = 6.5 Hz, 2H), 4.35 (d, J = 5.6 Hz, 1H), 4.25 (d, J = 5.6 Hz, 1H), 3.59 − 3.50 (m, 2H), 3.47 (d, J = 11.7 Hz, 1H), 3.27 (d, J = 12.1 Hz, 1H), 2.84 − 2.81 (m, 1H), 2.78 (dd, J = 41.7, 15.5 Hz, 4H), 2.77 − 2.69 (m, 2H), 2.10 − 2.01 (m, 1H), 1.98 − 1.83 (m, 2H), 1.36 (d, J = 30.8 Hz, 6H).

+





211


embedded image


4-(2-((R)-1-((5- chlorothiazol-2- yl)methyl)-3-((R or S)-3,3- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl)benzonitrile
416

1H NMR (500 MHz, MeOD) δ 7.65 (d, J = 7.9 Hz, 2H), 7.61 (s, 1H), 7.41 (d, J = 7.9 Hz, 2H), 4.51 (s, 1H), 4.31 (d, J = 5.4 Hz, 1H), 4.18 (d, J = 5.5 Hz, 1H), 4.09 (s, 2H), 3.20 − 3.13 (m, 1H), 3.01 (d, J = 9.8 Hz, 1H), 2.88 − 2.83 (m, 1H), 2.82 (dd, J = 51.4, 15.5 Hz, 4H), 2.77 (d, J = 15.5 Hz, 2H), 2.67 (d, J = 9.7 Hz, 1H), 2.58 − 2.48 (m, 1H), 1.94 − 1.81 (m, 2H), 1.81 − 1.72 (m, 1H), 1.33 (d, J = 23.8 Hz, 6H).

++





212


embedded image


(R)-2,2,2-trifluoro- 1-((S)-3-(4- (methylsulfonyl) phenethyl)-1-(2- phenylpropan-2- yl)pyrrolidin-3- yl)ethan-1-ol
470

1H NMR (300 MHz, MeOD) δ 7.86 (d, J = 7.9 Hz, 2H), 7.71 (d, J = 7.6 Hz, 2H), 7.57 − 7.42 (m, 3H), 7.35 (d, J = 8.1 Hz, 2H), 4.12 (dd, J = 15.4, 8.0 Hz, 1H), 3.55 − 3.36 (m, 3H), 3.17 (d, J = 21.7 Hz, 1H), 3.09 (s, 3H), 2.80 (q, J = 15.5 Hz, 6H), 2.69 − 2.58 (m, 2H), 2.54 − 2.37 (m, 1H), 2.23 − 1.96 (m, 2H), 1.85 (s, 6H).

++





213


embedded image


(R or S)-2,2,2- trifluoro-1-((S)-3- (4- (methylsulfonyl) phenethyl)-1-(2- phenylpropan-2- yl)pyrrolidin-3- yl)ethan-1-ol
470

1H NMR (300 MHz, MeOD) δ 7.86 (d, J = 7.1 Hz, 2H), 7.70 (d, J = 6.4 Hz, 2H), 7.44 (dd, J = 28.3, 8.0 Hz, 5H), 4.21 (d, J = 7.6 Hz, 1H), 3.64 − 3.49 (m, 2H), 3.36 (s, 2H), 3.09 (s, 3H), 2.92 (dd, J = 6.9, 5.9 Hz, 1H), 2.88 − 2.62 (m, 8H), 2.39 − 1.93 (m, 3H), 1.85 (s, 6H).

++





214


embedded image


4-(2-((R)-3-((R or S)-1- hydroxyethyl)-1-(2- (6- (trifluoromethyl) pyridin-3- yl)propan- 2-yl)pyrrolidin-3- yl)ethyl) benzonitrile
432

1H NMR (300 MHz, MeOD) δ 8.96 (s, 1H), 8.24 (d, J = 6.8 Hz, 1H), 7.85 (d, J = 5.9 Hz, 1H), 7.63 (d, J = 7.5 Hz, 2H), 7.38 (d, J = 7.3 Hz, 2H), 3.90 − 3.78 (m, 1H), 3.04 − 2.92 (m, 3H), 2.81 (dd, J = 31.5, 15.7 Hz, 6H), 2.70 − 2.60 (m, 2H), 2.11 − 2.00 (m, 1H), 1.79 − 1.64 (m, 9H), 1.18 − 1.14 (m, 3H).

++





215


embedded image


(R)-(3-(4- fluorophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)methanol
343

1H NMR (300 MHz, MeOD) δ 8.68 (s, 1H), 7.94 (t, J = 7.6 Hz, 1H), 7.61 (d, J = 7.9 Hz, 1H), 7.44 (dd, J = 7.3, 4.7 Hz, 1H), 7.21 (dd, J = 8.0, 5.6 Hz, 2H), 6.98 (t, J = 8.6 Hz, 2H), 3.63 (q, J = 11.0 Hz, 2H), 3.42 (t, J = 7.0 Hz, 2H), 3.34 − 3.31 (m, 1H), 3.09 (d, J = 11.8 Hz, 1H), 2.79 (q, J = 15.5 Hz, 5H), 2.59 (t, J = 8.1 Hz, 2H), 2.21 − 1.94 (m, 2H), 1.90 − 1.70 (m, 8H).

+





216


embedded image


(R or S)-1-((R)-3- (4- fluorophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethan-1-ol
357

1H NMR (300 MHz, MeOD) δ 8.65 (d, J = 4.1 Hz, 1H), 7.94 (t, J = 7.5 Hz, 1H), 7.60 (d, J = 8.2 Hz, 1H), 7.45 (dd, J = 6.7, 4.8 Hz, 1H), 7.21 (dd, J = 7.9, 5.9 Hz, 2H), 6.99 (t, J = 8.7 Hz, 2H), 4.08 − 3.94 (m, 1H), 3.39 (d, J = 11.4 Hz, 2H), 3.25 − 3.15 (m, 2H), 2.77 (q, J = 15.4 Hz, 4H), 2.66 − 2.45 (m, 2H), 2.42 − 2.27 (m, 1H), 1.89 − 1.67 (m, 9H), 1.22 (d, J = 6.2 Hz, 3H).

+





217


embedded image


(R or S)-1-((R)-3- (4- fluorophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethan-1-ol
357

1H NMR (300 MHz, MeOD) δ 8.65 (d, J = 3.7 Hz, 1H), 7.94 (t, J = 7.2 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.44 (dd, J = 7.3, 4.8 Hz, 1H), 7.21 (dd, J = 8.1, 5.5 Hz, 2H), 6.99 (t, J = 8.6 Hz, 2H), 3.97 (d, J = 6.2 Hz, 1H), 3.51 − 3.37 (m, 3H), 2.93 (d, J = 11.4 Hz, 1H), 2.78 (q, J = 15.5 Hz, 5H), 2.66 − 2.56 (m, 2H), 2.33 − 2.10 (m, 2H), 1.75 (d, J = 4.7 Hz, 8H), 1.21 (d, J = 6.1 Hz, 3H).

+





218


embedded image


2-(2-((R)-3-((E)-4- (methylsulfonyl) styryl)- 3-((R or S)- tetrahydrofuran-2- yl)pyrrolidin-1- yl)propan-2- yl)pyridine
441

1H NMR (300 MHz, MeOD) δ 8.68 (s, 1H), 7.92 (d, J = 8.1 Hz, 3H), 7.74 − 7.59 (m, 3H), 7.44 (s, 1H), 6.73 (dd, J = 16.8, 6.6 Hz, 1H), 6.51 (dd, J = 17.0, 4.6 Hz, 1H), 4.05 − 3.76 (m, 3H), 3.65 − 3.44 (m, 4H), 3.12 (s, 3H), 2.79 (q, J = 15.5 Hz, 6H), 2.42 − 2.24 (m, 2H), 2.01 − 1.87 (m, 3H), 1.77 (d, J = 6.7 Hz, 6H).

+





219


embedded image


(R or S)-1-((R)-1- (2-(4- chlorophenyl) propan-2- yl)-3-(4- (methylsulfonyl) phenethyl) pyrrolidin- 3-yl)ethan-1-ol
450

1H NMR (300 MHz, MeOD) δ 7.84 (d, J = 8.2 Hz, 2H), 7.67 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 8.6 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H ), 3.87 (d, J = 6.5 Hz, 1H) , 3.46 − 3.66 (m, 2H), 3.17 (s, 1H) ), 3.09 (s, 4H) , 2.82 (q, J = 15.6 Hz, J = 8.7 Hz, 2H) , 2.61 (s, 2H), 2.24 (s, 1H), 1.84 (s, 6H), 1.72 (s, 3H), 1.16 (d, J = 6.2 Hz, 3H).

+





220


embedded image


(R or S)-1-((R)-1- (2-(4- chlorophenyl) propan- 2-yl)-3-(4- (methylsulfonyl) phenethyl) pyrrolidin- 3-yl)ethan-1-ol
450

1H NMR (300 MHz, MeOD) δ 7.84 (d, J = 8.1 Hz, 2H), 7.68 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 7.9 Hz, 2H), 3.89 (d, J = 5.8 Hz, 1H), 3.40 (s, 2H), 3.20 − 3.15 (m, 1H), 3.09 (s, 3H), 2.82 (q, J = 15.6 Hz, J = 8.7 Hz, 2H), 2.70 − 2.60 (m, 2H), 2.19 (s, 1H), 2.04 (s, 1H), 1.85 (s,6H), 1.72 (s, 3H), 1.14 (d, J = 5.9 Hz, 2H).

+





221


embedded image


(R)-1-(2-(4- chlorophenyl) propan-2-yl)-3- (ethoxymethyl)-3- (4- (methylsulfonyl) phenethyl) pyrrolidine
464

1H NMR (300 MHz, MeOD) δ 7.84 (d, J = 7.9 Hz, 2H), 7.71 (d, J = 8.2 Hz, 2H), 7.53 (d, J = 8.3 Hz, 2H), 7.44 (d, J = 8.2 Hz, 2H), 3.53 − 3.42 (m, 3H), 3.35 (s, 4H), 3.09 (s, 4H), 2.82 (q, J = 15.6 Hz, J = 8.7 Hz, 2H) , 2.65 (t, J = 8.6 Hz, 2H) , 2.02 (s, 2H), 1.87 (s, 6H), 1.77 (s, 2H), 1.11 − 1.21 (m, 3H).

+





222


embedded image


(R or S)-1-((R)-1- (2-(4- chlorophenyl) propan- 2-yl)-3-(4- (methylsulfonyl) phenethyl) pyrrolidin- 3-yl)-2,2,2- trifluoroethan-1-ol
504

1H NMR (300 MHz, MeOD) δ 7.87 (d, J = 7.8 Hz, 2H), 7.68 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 7.2 Hz, 2H), 7.37 (d, J = 7.6 Hz, 2H), 4.13 (s, 1H), 3.49 (d, J = 7.0 Hz, 2H), 3.09 (s,3H), 3.04 − 2.96 (m, 1H), 2.82 (q, J = 15.6 Hz, J = 8.7 Hz, 2H), 2.70 − 2.63 (m, 2H), 2.42 (s, 1H), 1.78 (s, 7H), 1.17 (t, J = 7.0 Hz, 3H).

+





223


embedded image


4-(2-((S)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
418

1H NMR (300 MHz, MeOD) δ 8.67 (d, J = 3.3 Hz, 1H), 7.95 (t, J = 7.5 Hz, 1H), 7.71 − 7.61 (m, 3H), 7.50 − 7.35 (m, 3H), 4.29 (dd, J = 14.6, 7.4 Hz, 1H), 3.56 − 3.35 (m, 4H), 2.86 − 2.68 (m, 7H), 2.66 − 2.52 (m, 1H), 2.02 − 1.87 (m, 3H), 1.78 (s, 6H).

+





224


embedded image


4-(2-((S)-1-(2- (pyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
418

1H NMR (300 MHz, MeOD) δ 8.65 (d, J = 4.4 Hz, 1H), 7.93 (t, J = 7.0 Hz, 1H), 7.65 (t, J = 8.5 Hz, 3H), 7.41 (t, J = 10.9 Hz, 3H), 4.29 (q, J = 7.5 Hz, 1H), 3.63 (d, J = 12.2 Hz, 1H), 3.48 (t, J = 7.2 Hz, 2H), 3.03 (d, J = 12.2 Hz, 1H), 2.78 (q, J = 15.4 Hz, 6H), 2.44 − 2.15 (m, 2H), 2.05 − 1.86 (m, 2H), 1.77 (s, 6H).

+





225


embedded image


(S)-4-(2-(3-(1H- imidazol-2-yl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile
386

1H NMR (300 MHz, MeOD) δ 8.65 (d, J = 3.7 Hz, 1H), 7.91 (t, J = 7.7 Hz, 1H), 7.59 (d, J = 8.0 Hz, 3H), 7.46 − 7.38 (m, 1H), 7.27 (d, J = 8.1 Hz, 2H), 7.15 (s, 2H), 3.73 (d, J = 11.0 Hz, 1H), 3.50 − 3.36 (m, 2H), 2.78 (q, J = 15.4 Hz, 5H), 2.68 − 2.55 (m, 1H), 2.52 − 2.32 (m, 2H), 2.27 − 2.11 (m, 3H), 1.64 (d, J = 13.7 Hz, 6H).

+





226


embedded image


(S)-4-(2-(1-(2-(5- fluoropyridin-2- yl)propan-2-yl)-3- (hydroxymethyl) pyrrolidin-3- yl)ethyl) benzonitrile
368

1H NMR (300 MHz, MeOD) δ 8.58 (s, 1H), 7.78 − 7.68 (m, 2H), 7.64 (d, J = 7.9 Hz, 2H), 7.41 (d, J = 7.9 Hz, 2H), 3.68 − 3.56 (m, 2H), 3.44 (t, J = 6.3 Hz, 2H), 3.10 (d, J = 11.5 Hz, 1H), 2.87 − 2.71 (m, 5H), 2.71 − 2.63 (m, 2H), 2.22 − 1.92 (m, 3H), 1.89 − 1.80 (m, 2H), 1.78 (d, J = 3.1 Hz, 6H).

+





227


embedded image


4-(2-((R)-1-((2,4- dimethylpyridin-3- yl)methyl)-3-((R or S)-2,2,2-trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
418

1H NMR (300 MHz, MeOD) δ 8.25 (d, J = 5.5 Hz, 1H), 7.62 (d, J = 7.7 Hz, 2H), 7.33 (d, J = 8.2 Hz, 2H), 7.27 (d, J = 5.1 Hz, 1H), 4.12 − 3.99 (m, 1H), 3.91 (s, 2H), 3.58 − 3.42 (m, 1H), 2.96 − 2.72 (m, 13H), 2.66 (s, 3H), 2.52 (s, 3H), 2.35 − 2.22 (m, 1H), 2.04 − 1.69 (m, 4H).

+





228


embedded image


4-(2-((R)-1-((2,4- dimethylpyridin-3- yl)methyl)-3-((R or S)-2,2,2-trifluoro- 1-hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
418

1H NMR (300 MHz, MeOD) δ 8.25 (d, J = 5.2 Hz, 1H), 7.62 (d, J = 7.6 Hz, 2H), 7.32 (d, J = 7.8 Hz, 2H), 7.26 (d, J = 5.2 Hz, 1H), 4.07 (dd, J = 16.2, 8.1 Hz, 1H), 3.91 (s, 2H), 3.49 (dd, J = 14.0, 7.0 Hz, 2H), 3.06 − 2.93 (m, 2H), 2.82 (dd, J = 30.3, 13.3 Hz, 7H), 2.75 − 2.70 (m, 2H), 2.66 (s, 3H), 2.51 (s, 3H), 2.15 − 2.00 (m, 1H), 1.95 − 1.74 (m, 3H).

+





229


embedded image


4-(2-((S)-1-(2-(5- fluoropyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
436

1H NMR (300 MHz, MeOD) δ 8.56 (s, 1H), 7.73 (d, J = 5.3 Hz, 2H), 7.66 (d, J = 7.9 Hz, 2H), 7.38 (d, J = 7.6 Hz, 2H), 4.25 (dd, J = 14.7, 8.3 Hz, 1H), 3.51 − 3.36 (m, 3H), 3.25 (s, 1H), 2.87 − 2.67 (m, 6H), 2.63- 2.45 (m, 1H), 1.98 − 1.86 (m, 3H), 1.77 (s, 6H).

+





230


embedded image


4-(2-((S)-1-(2-(5- fluoropyridin-2- yl)propan-2-yl)-3- ((R or S)-2,2,2- trifluoro-1- hydroxyethyl) pyrrolidin-3- yl)ethyl) benzonitrile
436

1H NMR (300 MHz, MeOD) δ 8.55 (s, 1H), 7.69 (dd, J = 15.6, 6.5 Hz, 4H), 7.38 (d, J = 8.0 Hz, 2H), 4.34- 4.21 (m, 1H), 3.59 (d, J = 12.1 Hz, 1H), 3.49 − 3.39 (m, 2H), 2.99 (d, J = 11.8 Hz, 1H), 2.78 (q, J = 15.4 Hz, 6H), 2.39 − 2.14 (m, 2H), 2.08 − 1.85 (m, 3H), 1.76 (s, 6H).

+





231


embedded image


4-(2-((R)-3-((R or S)-1- hydroxyethyl)-1-(2- (6- (trifluoromethyl) pyridin-3-yl)propan- 2-yl)pyrrolidin-3- yl)ethyl) benzonitrile
432

1H NMR (300 MHz, MeOD) δ 8.98 (s, 1H), 8.35 − 8.22 (m, 1H), 7.95 − 7.57 (m, 3H), 7.46 − 7.28 (m, 2H), 3.93 − 3.77 (m, 1H), 3.12 − 2.97 (m, 3H), 2.81 (dd, J = 31.9, 15.6 Hz, 6H), 2.72 − 2.61 (m, 2H), 2.58 (s, 1H), 2.09 − 1.96 (m, 1H), 1.88 − 1.65 (m, 9H), 1.16 (d, J = 6.5 Hz, 3H).

++





232


embedded image


5-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-3,3- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl) picolinonitrile








233


embedded image


6-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-3,3- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile








234


embedded image


6-(2-((R)-1-(2-(4- chlorophenyl) propan- 2-yl)-3-((R or S)- 3,3- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile








235


embedded image


(R)-1-(4- chlorobenzyl)-3- ((R or S)-3,3- dimethyloxetan-2- yl)-3-(4- (methylsulfonyl) phenethyl) pyrrolidine








236


embedded image


2-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-3,3- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








237


embedded image


5-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-3,3- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl)-2- (methylsulfonyl) pyridine








238


embedded image


2-(2-((R)-1-(2-(4- chlorophenyl) propan- 2-yl)-3-((R or S)- 3,3- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








239


embedded image


2-(2-((R)-1-(1-(4- chlorophenyl) cyclopropyl)- 3-((R or S)- 3,3- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








240


embedded image


4-(2-((R)-3-((R or S)-3,3- difluorooxetan-2- yl)-1-((5- (trifluoromethyl) thiazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








241


embedded image


4-(2-((R)-3-((R or S)-3,3- difluorooxetan-2- yl)-1-((5- fluorothiazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








242


embedded image


4-(2-((R)-3-((R or S)-3,3- difluorooxetan-2- yl)-1-((5- methoxythiazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








243


embedded image


4-(2-((R)-3-((R or S)-3,3- difluorooxetan-2- yl)-1-((4- isopropylthiazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








244


embedded image


4-(2-((R)-3-((R or S)-3,3- difluorooxetan-2- yl)-1 −((4- (trifluoromethyl) thiazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








245


embedded image


4-(2-((R)-1-((5- chloro-1,3,4- thiadiazol-2- yl)methyl)-3-((R or S)-3,3- difluorooxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile








246


embedded image


4-(2-((R)-3-((R or S)-3,3- difluorooxetan-2- yl)-1-((1-isopropyl- 1H-imidazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








247


embedded image


4-(2-((R)-3-((R or S)-3,3- difluorooxetan-2- yl)-1-(pyridazin-3- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile








248


embedded image


4-(2-((R)-3-((R or S)-3,3- difluorooxetan-2- yl)-1-((6- methylpyridazin-3- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








249


embedded image


4-(2-((R)-3-((R or S)-3,3- difluorooxetan-2- yl)-1-((6- (trifluoromethyl) pyridazin-3- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








250


embedded image


5-12 ((R)-1-(4) chlorobenzyl)-3 ((R or S): 3.3 difluorooxetan-2 yl)pyrrolidin-3- ylethyl) picolinonitrile








251


embedded image


6-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-3,3- difluorooxetan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile








252


embedded image


6-(2-((R)-1-(2-(4- chlorophenyl) propan- 2-yl)-3-((R or S)- 3,3-difluorooxetan- 2-yl)pyrrolidin-3- yl)ethyl) nicotinonitrile








253


embedded image


(R)-1-(4- chlorobenzyl)-3- ((R or S)-3,3- difluorooxetan-2- yl)-3-(4- (methylsulfonyl) phenethyl) pyrrolidine








254


embedded image


2-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-3,3- difluorooxetan-2- yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








255


embedded image


5-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-3,3- difluorooxetan-2- yl)pyrrolidin-3- yl)ethyl)-2- (methylsulfonyl) pyridine








256


embedded image


2-(2-((R)-1-(2-(4- chlorophenyl) propan- 2-yl)-3-((R or S)- 3,3-difluorooxetan- 2-yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








257


embedded image


2-(2-((R)-1-(1-(4- chlorophenyl) cyclopropyl)- 3-((R or S)- 3,3-difluorooxetan- 2-yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








258


embedded image


4-(2-((R)-1-((5- chlorothiazol-2- yl)methyl)-3-((R or S)-4,4- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile








259


embedded image


4-(2-((R)-3-((R or S)-4,4- dimethyloxetan-2- yl)-1-((5- (trifluoromethyl) thiazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








260


embedded image


4-(2-((R)-3-((R or S)-4,4- dimethyloxetan-2- yl)-1-((5- fluorothiazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








261


embedded image


4-(2-((R)-3-((R or S)-4,4- dimethyloxetan-2- yl)-1-((5- methoxythiazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








262


embedded image


4-(2-((R)-3-((R or S)-4,4- dimethyloxetan-2- yl)-1-((4- isopropylthiazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








263


embedded image


4-(2-((R)-3-((R or S)-4,4- dimethyloxetan-2- yl)-1-((4- (trifluoromethyl) thiazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








264


embedded image


4-(2-((R)-1-((5- chloro-1,3,4- thiadiazol-2- yl)methyl)-3-((R or S)-4,4- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile








265


embedded image


4-(2-((R)-3-((R or S)-4,4- dimethyloxetan-2- yl)-1-((1-isopropyl- 1H-imidazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








266


embedded image


4-(2-((R)-3-((R or S)-4,4- dimethyloxetan-2- yl)-1-(pyridazin-3- ylmethyl) pyrrolidin-3- yl)ethyl) benzonitrile








267


embedded image


4-(2-((R)-3-((R or S)-4,4- dimethyloxetan-2- yl)-1-((6- methylpyridazin-3- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








268


embedded image


4-(2-((R)-3-((R or S)-4,4- dimethyloxetan-2- yl)-1-((6- (trifluoromethyl) pyridazin-3- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








269


embedded image


5-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-4,4- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl) picolinonitrile








270


embedded image


6-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-4,4- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile








271


embedded image


6-(2-((R)-1-(2-(4- chlorophenyl)propa n-2-yl)-3-((R or S)- 4,4- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile








272


embedded image


(R)-1-(4- chlorobenzyl)-3- ((R or S)-4,4- dimethyloxetan-2- yl)-3-(4- (methylsulfonyl) phenethyl) pyrrolidine








273


embedded image


2-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-4,4- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








274


embedded image


5-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-4,4- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl)-2- (methylsulfonyl) pyridine








275


embedded image


2-(2-((R)-1-(2-(4- chlorophenyl) propan- 2-yl)-3-((R or S)- 4,4- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








276


embedded image


2-(2-((R)-1-(1-(4- chlorophenyl) cyclopropyl)- 3-((R or S)- 4,4- dimethyloxetan-2- yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








277


embedded image


4-(2-((R)-1- (pyridin-2- ylmethyl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile








278


embedded image


6-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile








279


embedded image


(R)-1-(4- chlorobenzyl)-3-(4- (methylsulfonyl) phenethyl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidine








280


embedded image


2-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








281


embedded image


4-(2-((R)-1-((5- chlorothiazol-2- yl)methyl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile








282


embedded image


4-(2-((R)-3-((R or S)-2- (trifluoromethyl) oxetan-2-yl)-1-((5- (trifluoromethyl) thiazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








283


embedded image


4-(2-((R)-1-((5- fluorothiazol-2- yl)methyl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile








284


embedded image


4-(2-((R)-1-((5- methoxythiazol-2- yl)methyl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile








285


embedded image


4-(2-((R)-1-((4- isopropylthiazol-2- yl)methyl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile








286


embedded image


4-(2-((R)-3-((R or S)-2- (trifluoromethyl) oxetan-2-yl)-1-((4- (trifluoromethyl) thiazol-2- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








287


embedded image


4-(2-((R)-1-((5- chloro-1,3,4- thiadiazol-2- yl)methyl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile








288


embedded image


4-(2-((R)-1-((1- isopropyl-1H- imidazol-2- yl)methyl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile








289


embedded image


4-(2-((R)-1- (pyridazin-3- ylmethyl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile








290


embedded image


4-(2-((R)-1-((6- methylpyridazin-3- yl)methyl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) benzonitrile








291


embedded image


4-(2-((R)-3-((R or S)-2- (trifluoromethyl) oxetan-2-yl)-1-((6- (trifluoromethyl) pyridazin-3- yl)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








292


embedded image


5-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) picolinonitrile








293


embedded image


6-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile








294


embedded image


6-(2-((R)-1-(2-(4- chlorophenyl) propan-2- yl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl) nicotinonitrile








295


embedded image


(R)-1-(4- chlorobenzyl)-3-(4- (methylsulfonyl) phenethyl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidine








296


embedded image


2-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








297


embedded image


5-(2-((R)-1-(4- chlorobenzyl)-3- ((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl)-2- (methylsulfonyl) pyridine








298


embedded image


2-(2-((R)-1-(2-(4- chlorophenyl) propan- 2-yl)-3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








299


embedded image


2-(2-((R)-1-(1-(4- chlorophenyl) cyclopropyl)- 3-((R or S)-2- (trifluoromethyl) oxetan-2- yl)pyrrolidin-3- yl)ethyl)-5- (methylsulfonyl) pyridine








300


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxamide








301


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (trifluoromethyl) pyrrolidine-3- carboxamide








302


embedded image


(R)-3-(4- cyanophenethyl)- N-(1,1- difluoroethyl)-1-(2- (pyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxamide








303


embedded image


(R)-N-(tert-butyl)- 3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxamide








304


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (1- (trifluoromethyl) cyclopropyl) pyrrolidine-3- carboxamide








305


embedded image


(R)-3-(4- cyanophenethyl)- N-(1- hydroxy- cyclopropyl)- 1-(2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxamide








306


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- carboxamide








307


embedded image


(R)-3-(4- cyanophenethyl)- N-(3-fluorooxetan- 3-yl)-1-(2-(pyridin- 2-yl)propan-2- yl)pyrrolidine-3- carboxamide








308


embedded image


(R)-3-(4- cyanophenethyl)- N-(pyridin-2-yl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- carboxamide








309


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (pyridin-3- yl)pyrrolidine-3- carboxamide








310


embedded image


(R)-3-(4- cyanophenethyl)- N-(6-fluoropyridin- 3-yl)-1-(2-(pyridin- 2-yl)propan-2- yl)pyrrolidine-3- carboxamide








311


embedded image


(R)-3-(4- cyanophenethyl)- N-(3-fluoropyridin- 2-yl)-1-(2-(pyridin- 2-yl)propan-2- yl)pyrrolidine-3- carboxamide








312


embedded image


(S)-4-(2-(1- (pyridin-2- ylmethyl)-3-(((1- (trifluoromethyl) cyclopropyl) amino)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








313


embedded image


(R)-N-(3- cyanooxetan-3-yl)- 3-(4- cyanophenethyl)-1- (pyridin-2- ylmethyl) pyrrolidine-3- carboxamide








314


embedded image


(R)-1-(4- chlorobenzyl)-N- (3-cyanooxetan-3- yl)-3-(4- cyanophenethyl) pyrrolidine-3- carboxamide








315


embedded image


(R)-3-(4- cyanophenethyl)-1- (pyridin-2- ylmethyl)-N-(3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- carboxamide








316


embedded image


(R)-1-((5- chloropyridin-2- yl)methyl)-3-(4- cyanophenethyl)- N-(3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- carboxamide








317


embedded image


(R)-3-(4- cyanophenethyl)-1- ((5-fluoropyridin-2- yl)methyl)-N-(3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- carboxamide








318


embedded image


(R)-3-(4- cyanophenethyl)-1- ((5- methoxypyridin-2- yl)methyl)-N-(3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- carboxamide








319


embedded image


(R)-3-(4- cyanophenethyl)-1- ((5-cyanopyridin-2- yl)methyl)-N-(3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- carboxamide








320


embedded image


(R)-3-(4- cyanophenethyl)-1- ((5- (difluoromethyl) pyridin-2-yl) methyl)- N-(3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- carboxamide








321


embedded image


(R)-3-(4- cyanophenethyl)- N-(3- (trifluoromethyl) oxetan-3-yl)-1-((5- (trifluoromethyl) pyridin-2- yl)methyl) pyrrolidine-3- carboxamide








322


embedded image


(R)-1-(4- chlorobenzyl)-N- (3-cyanooxetan-3- yl)-3-(4- cyanophenethyl) pyrrolidine-3- carboxamide








323


embedded image


(R)-N-(3- cyanooxetan-3-yl)- 3-(4- cyanophenethyl)-1- (pyridin-2- ylmethyl) pyrrolidine- 3-carboxamide








324


embedded image


(R)-N-(3- cyanooxetan-3-yl)- 3-(4- cyanophenethyl)-1- ((5-fluoropyridin-2- yl)methyl) pyrrolidine- 3-carboxamide








325


embedded image


(R)-N-(3- cyanooxetan-3-yl)- 3-(4- cyanophenethyl)-1- ((5- (trifluoromethyl) pyridin-2- yl)methyl) pyrrolidine-3- carboxamide








326


embedded image


(S)-4-(2-(1- (pyridin-2- ylmethyl)-3-(((1- (trifluoromethyl) cyclopropyl) amino)methyl) pyrrolidin-3- yl)ethyl) benzonitrile








327


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (6- (trifluoromethyl) pyridazin-3- yl)pyrrolidine-3- carboxamide








328


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (2- (trifluoromethyl) pyrimidin-5- yl)pyrrolidine-3- carboxamide








329


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (2- (trifluoromethyl) pyrimidin-5- yl)pyrrolidine-3- carboxamide








330


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- carboxamide








331


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- sulfonamide








332


embedded image


(R)-N-(3- cyanooxetan-3-yl)- 3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- sulfonamide








333


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- sulfonamide








334


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (6- (trifluoromethyl) pyridazin-3- yl)pyrrolidine-3- carboxamide








335


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (2- (trifluoromethyl) pyrimidin-5- yl)pyrrolidine-3- carboxamide








336


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (2- (trifluoromethyl) pyrimidin-5- yl)pyrrolidine-3- carboxamide








337


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- sulfonamide








338


embedded image


(R)-N-(3- cyanooxetan-3-yl)- 3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- sulfonamide








339


embedded image


(R)-3-(4-cyano-3- fluorophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (1- (trifluoromethyl) cyclopropyl) pyrrolidine- 3-carboxamide








340


embedded image


(R)-3-(4-cyano-3- fluorophenethyl)-1- (2-(pyridin-2- yl)propan-2-yl)-N- (3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- carboxamide








341


embedded image


(R)-3-(4- cyanophenethyl)-1- (2-(pyridin-2- yl)propan-2- yl)pyrrolidine-3- sulfonamide








342


embedded image


(R)-3-(2- (benzo[c][1,2,5] oxadiazol-5- yl)ethyl)- 1-(2-(pyridin-2- yl)propan-2-yl)-N- (1- (trifluoromethyl) cyclopropyl) pyrrolidine- 3-carboxamide








343


embedded image


(R)-3-(2- (benzo[c][1,2,5] oxadiazol- 5-yl)ethyl)- 1-(2-(pyridin-2- yl)propan-2-yl)-N- (3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- carboxamide








344


embedded image


(R)-3-(2- (benzofuran-6- yl)ethyl)-1-(2- (pyridin-2- yl)propan-2-yl)-N- (1- (trifluoromethyl) cyclopropyl) pyrrolidine- 3-carboxamide








345


embedded image


(R)-3-(2- (benzofuran-6- yl)ethyl)-1-(2- (pyridin-2- yl)propan-2-yl)-N- (3- (trifluoromethyl) oxetan-3- yl)pyrrolidine-3- carboxamide









The specific methods, processes, compounds and compositions described herein are representative of preferred and other embodiments, and are exemplary and not intended as limitations on the scope of the invention. Other objects, aspects, and embodiments will occur to those skilled in the art upon consideration of this specification, and are encompassed within the spirit of the invention as defined by the scope of the claims. It will be readily apparent to one skilled in the art that various substitutions and modifications may be made to the invention is closed herein without departing from the scope and spirit of the invention. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, or limitation or limitations, which is not specifically disclosed herein as essential. Thus, for example, in each instance herein, in embodiments or examples of the present invention, any of the terms “comprising”, “including”, containing”, “having” etc. are to be read expansively and without limitation. The methods and processes illustratively described herein suitably may be practiced in differing orders of steps, and that they are not necessarily restricted to the orders of steps indicated herein or in the claims. It is also noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference, and the plural include singular forms, unless the context clearly dictates otherwise. Under no circumstances may the patent be interpreted to be limited to the specific examples or embodiments or methods specifically disclosed herein. Under no circumstances may the patent be interpreted to be limited by any statement made by any Examiner or any other official or employee of the Patent and Trademark Office unless such statement is specifically and without qualification or reservation expressly adopted in a responsive writing by Applicants.


The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. The terms and expressions that have been employed are used as terms of description and not of limitation, and there is no intent in the use of such terms and expressions to exclude any equivalent of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention as claimed. Thus, it will be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

Claims
  • 1. A compound having one of the following formulae, or a pharmaceutically acceptable salt thereof:
  • 2. A compound selected from the group of the following compounds of claim 1, or a pharmaceutically acceptable salt thereof Compound numbers 1, 2, 5, 10, 27, 28, 29, 30, 35, 36, 38, 39, 43-58, 60-64, 67-69, 71, 72, 86-88, 91-101, 107, 111, 124, 128, 130, 134, 139, 141, 145-148, 151-156, 158-160, 168, 169, 175 and 220-223.
  • 3. A compound selected from the group of the following compounds of claim 1, or a pharmaceutically acceptable salt thereof Compound numbers 193-200; 202; 206-209; 212 and 233-346.
Provisional Applications (1)
Number Date Country
63046813 Jul 2020 US
Divisions (1)
Number Date Country
Parent 17363042 Jun 2021 US
Child 18092348 US
Continuation in Parts (1)
Number Date Country
Parent 18092348 Jan 2023 US
Child 18427489 US